Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2022-05-10
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## x
## 5_8S_rRNA 13.3743116
## 7SK 8.2273688
## A1BG 6.5686329
## A1BG-AS1 2.0364019
## A1CF -0.3353024
## A2M -19.6842209| Profile metrics | |
|---|---|
| num_genesets | 2512 |
| num_genes_in_profile | 26163 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8997 |
| num_profile_genes_not_in_sets | 17166 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt| Gene sets metrics | |
|---|---|
| num_genesets | 2512 |
| num_genesets_excluded | 1033 |
| num_genesets_included | 1479 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Results table
Top N= 50 gene sets| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 9.68e-07 | -0.853 | 6.07e-06 |
| Cohesin Loading onto Chromatin | 10 | 3.04e-06 | -0.852 | 1.63e-05 |
| Laminin interactions | 23 | 4.40e-11 | -0.793 | 5.87e-10 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
| Signaling by GSK3beta mutants | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
| Signaling by Hippo | 20 | 1.64e-09 | -0.779 | 1.78e-08 |
| Syndecan interactions | 20 | 1.76e-09 | -0.777 | 1.88e-08 |
| MET activates RAP1 and RAC1 | 11 | 8.89e-06 | -0.773 | 4.31e-05 |
| APC truncation mutants have impaired AXIN binding | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
| AXIN missense mutants destabilize the destruction complex | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
| Signaling by AMER1 mutants | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
| Signaling by APC mutants | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
| Signaling by AXIN mutants | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
| ERKs are inactivated | 13 | 1.68e-06 | -0.767 | 9.67e-06 |
| MET activates PTK2 signaling | 18 | 2.19e-08 | -0.762 | 2.01e-07 |
| Establishment of Sister Chromatid Cohesion | 11 | 1.50e-05 | -0.754 | 6.74e-05 |
| MET promotes cell motility | 29 | 5.60e-12 | -0.739 | 8.81e-11 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 4.77e-06 | -0.733 | 2.44e-05 |
| Defective EXT2 causes exostoses 2 | 13 | 4.77e-06 | -0.733 | 2.44e-05 |
| tRNA processing in the mitochondrion | 20 | 1.43e-08 | 0.732 | 1.35e-07 |
| Synthesis of PIPs at the early endosome membrane | 16 | 4.19e-07 | -0.730 | 2.92e-06 |
| Complex I biogenesis | 57 | 1.31e-21 | 0.730 | 5.88e-20 |
| Beta-catenin phosphorylation cascade | 17 | 1.86e-07 | -0.730 | 1.37e-06 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 1.41e-05 | -0.724 | 6.37e-05 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 1.41e-05 | -0.724 | 6.37e-05 |
| Non-integrin membrane-ECM interactions | 42 | 8.65e-16 | -0.717 | 2.00e-14 |
| Viral mRNA Translation | 87 | 6.88e-31 | 0.716 | 8.48e-29 |
| Peptide chain elongation | 87 | 7.93e-31 | 0.715 | 9.02e-29 |
| Signaling by PDGFR in disease | 19 | 8.02e-08 | -0.711 | 6.49e-07 |
| DCC mediated attractive signaling | 14 | 4.24e-06 | -0.710 | 2.22e-05 |
| Activation of RAC1 | 13 | 9.42e-06 | -0.709 | 4.53e-05 |
| FOXO-mediated transcription of cell cycle genes | 15 | 2.13e-06 | -0.707 | 1.19e-05 |
| HDMs demethylate histones | 22 | 1.56e-08 | -0.696 | 1.46e-07 |
| Adenylate cyclase inhibitory pathway | 12 | 3.89e-05 | -0.686 | 1.58e-04 |
| Eukaryotic Translation Termination | 91 | 1.29e-29 | 0.684 | 1.27e-27 |
| Synthesis of PIPs at the late endosome membrane | 11 | 8.49e-05 | -0.684 | 3.19e-04 |
| ERK/MAPK targets | 22 | 2.97e-08 | -0.682 | 2.66e-07 |
| Selenocysteine synthesis | 91 | 3.21e-29 | 0.680 | 2.97e-27 |
| Eukaryotic Translation Elongation | 92 | 5.39e-29 | 0.673 | 4.43e-27 |
| Platelet sensitization by LDL | 15 | 6.79e-06 | -0.671 | 3.36e-05 |
| rRNA processing in the mitochondrion | 24 | 1.27e-08 | 0.671 | 1.21e-07 |
| Signaling by FLT3 fusion proteins | 19 | 4.21e-07 | -0.670 | 2.92e-06 |
| Signaling by FGFR3 fusions in cancer | 10 | 2.58e-04 | -0.667 | 8.89e-04 |
| Defective B4GALT7 causes EDS, progeroid type | 18 | 1.16e-06 | -0.662 | 7.07e-06 |
| ALK mutants bind TKIs | 12 | 7.86e-05 | -0.658 | 2.99e-04 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 9.68e-07 | -0.853000 | 6.07e-06 |
| Cohesin Loading onto Chromatin | 10 | 3.04e-06 | -0.852000 | 1.63e-05 |
| Laminin interactions | 23 | 4.40e-11 | -0.793000 | 5.87e-10 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
| Signaling by GSK3beta mutants | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
| Signaling by Hippo | 20 | 1.64e-09 | -0.779000 | 1.78e-08 |
| Syndecan interactions | 20 | 1.76e-09 | -0.777000 | 1.88e-08 |
| MET activates RAP1 and RAC1 | 11 | 8.89e-06 | -0.773000 | 4.31e-05 |
| APC truncation mutants have impaired AXIN binding | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
| AXIN missense mutants destabilize the destruction complex | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
| Signaling by AMER1 mutants | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
| Signaling by APC mutants | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
| Signaling by AXIN mutants | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
| ERKs are inactivated | 13 | 1.68e-06 | -0.767000 | 9.67e-06 |
| MET activates PTK2 signaling | 18 | 2.19e-08 | -0.762000 | 2.01e-07 |
| Establishment of Sister Chromatid Cohesion | 11 | 1.50e-05 | -0.754000 | 6.74e-05 |
| MET promotes cell motility | 29 | 5.60e-12 | -0.739000 | 8.81e-11 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 4.77e-06 | -0.733000 | 2.44e-05 |
| Defective EXT2 causes exostoses 2 | 13 | 4.77e-06 | -0.733000 | 2.44e-05 |
| tRNA processing in the mitochondrion | 20 | 1.43e-08 | 0.732000 | 1.35e-07 |
| Synthesis of PIPs at the early endosome membrane | 16 | 4.19e-07 | -0.730000 | 2.92e-06 |
| Complex I biogenesis | 57 | 1.31e-21 | 0.730000 | 5.88e-20 |
| Beta-catenin phosphorylation cascade | 17 | 1.86e-07 | -0.730000 | 1.37e-06 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 1.41e-05 | -0.724000 | 6.37e-05 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 1.41e-05 | -0.724000 | 6.37e-05 |
| Non-integrin membrane-ECM interactions | 42 | 8.65e-16 | -0.717000 | 2.00e-14 |
| Viral mRNA Translation | 87 | 6.88e-31 | 0.716000 | 8.48e-29 |
| Peptide chain elongation | 87 | 7.93e-31 | 0.715000 | 9.02e-29 |
| Signaling by PDGFR in disease | 19 | 8.02e-08 | -0.711000 | 6.49e-07 |
| DCC mediated attractive signaling | 14 | 4.24e-06 | -0.710000 | 2.22e-05 |
| Activation of RAC1 | 13 | 9.42e-06 | -0.709000 | 4.53e-05 |
| FOXO-mediated transcription of cell cycle genes | 15 | 2.13e-06 | -0.707000 | 1.19e-05 |
| HDMs demethylate histones | 22 | 1.56e-08 | -0.696000 | 1.46e-07 |
| Adenylate cyclase inhibitory pathway | 12 | 3.89e-05 | -0.686000 | 1.58e-04 |
| Eukaryotic Translation Termination | 91 | 1.29e-29 | 0.684000 | 1.27e-27 |
| Synthesis of PIPs at the late endosome membrane | 11 | 8.49e-05 | -0.684000 | 3.19e-04 |
| ERK/MAPK targets | 22 | 2.97e-08 | -0.682000 | 2.66e-07 |
| Selenocysteine synthesis | 91 | 3.21e-29 | 0.680000 | 2.97e-27 |
| Eukaryotic Translation Elongation | 92 | 5.39e-29 | 0.673000 | 4.43e-27 |
| Platelet sensitization by LDL | 15 | 6.79e-06 | -0.671000 | 3.36e-05 |
| rRNA processing in the mitochondrion | 24 | 1.27e-08 | 0.671000 | 1.21e-07 |
| Signaling by FLT3 fusion proteins | 19 | 4.21e-07 | -0.670000 | 2.92e-06 |
| Signaling by FGFR3 fusions in cancer | 10 | 2.58e-04 | -0.667000 | 8.89e-04 |
| Defective B4GALT7 causes EDS, progeroid type | 18 | 1.16e-06 | -0.662000 | 7.07e-06 |
| ALK mutants bind TKIs | 12 | 7.86e-05 | -0.658000 | 2.99e-04 |
| Interleukin-6 signaling | 11 | 1.74e-04 | -0.654000 | 6.20e-04 |
| Cell-extracellular matrix interactions | 16 | 6.27e-06 | -0.652000 | 3.11e-05 |
| RORA activates gene expression | 18 | 1.70e-06 | -0.651000 | 9.74e-06 |
| Formation of a pool of free 40S subunits | 99 | 3.75e-29 | 0.651000 | 3.26e-27 |
| PKA-mediated phosphorylation of CREB | 18 | 1.74e-06 | -0.651000 | 9.94e-06 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 1.02e-04 | -0.648000 | 3.79e-04 |
| Caspase activation via Dependence Receptors in the absence of ligand | 10 | 4.06e-04 | -0.646000 | 1.34e-03 |
| PKA activation | 16 | 7.79e-06 | -0.645000 | 3.82e-05 |
| Synthesis of PIPs at the Golgi membrane | 15 | 1.95e-05 | -0.637000 | 8.56e-05 |
| Regulation of gene expression by Hypoxia-inducible Factor | 11 | 2.82e-04 | -0.632000 | 9.58e-04 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 8.04e-05 | -0.632000 | 3.05e-04 |
| Regulation of signaling by CBL | 18 | 3.88e-06 | -0.629000 | 2.06e-05 |
| RHOV GTPase cycle | 37 | 3.62e-11 | -0.628000 | 4.92e-10 |
| Interleukin-15 signaling | 14 | 5.26e-05 | -0.624000 | 2.08e-04 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 6.34e-27 | 0.624000 | 4.26e-25 |
| Formation of ATP by chemiosmotic coupling | 18 | 4.70e-06 | 0.623000 | 2.42e-05 |
| Downstream signal transduction | 29 | 7.03e-09 | -0.621000 | 6.93e-08 |
| VEGFR2 mediated cell proliferation | 19 | 2.97e-06 | -0.619000 | 1.60e-05 |
| RHOU GTPase cycle | 40 | 1.43e-11 | -0.617000 | 2.16e-10 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 1.07e-05 | -0.617000 | 5.02e-05 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 7.64e-25 | 0.617000 | 4.71e-23 |
| CTLA4 inhibitory signaling | 18 | 6.23e-06 | -0.615000 | 3.10e-05 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 7.61e-04 | -0.615000 | 2.31e-03 |
| Signaling by KIT in disease | 20 | 1.97e-06 | -0.614000 | 1.10e-05 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 1.97e-06 | -0.614000 | 1.10e-05 |
| Prolonged ERK activation events | 14 | 6.92e-05 | -0.614000 | 2.65e-04 |
| Nephrin family interactions | 20 | 2.46e-06 | -0.608000 | 1.35e-05 |
| Other semaphorin interactions | 15 | 4.86e-05 | -0.606000 | 1.93e-04 |
| RHOF GTPase cycle | 41 | 2.03e-11 | -0.605000 | 2.94e-10 |
| STAT5 activation downstream of FLT3 ITD mutants | 10 | 9.72e-04 | -0.602000 | 2.89e-03 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 125 | 3.41e-31 | 0.601000 | 5.04e-29 |
| Signal transduction by L1 | 21 | 2.24e-06 | -0.596000 | 1.23e-05 |
| Defective B3GAT3 causes JDSSDHD | 18 | 1.24e-05 | -0.595000 | 5.64e-05 |
| Miscellaneous transport and binding events | 24 | 5.25e-07 | -0.591000 | 3.57e-06 |
| Signaling by FLT3 ITD and TKD mutants | 16 | 4.68e-05 | -0.588000 | 1.86e-04 |
| Signaling by Leptin | 10 | 1.29e-03 | -0.588000 | 3.62e-03 |
| Respiratory electron transport | 103 | 6.97e-25 | 0.587000 | 4.48e-23 |
| Ephrin signaling | 19 | 9.78e-06 | -0.586000 | 4.63e-05 |
| RHOJ GTPase cycle | 54 | 9.18e-14 | -0.586000 | 1.81e-12 |
| MECP2 regulates neuronal receptors and channels | 17 | 2.93e-05 | -0.585000 | 1.23e-04 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 18 | 1.71e-05 | -0.585000 | 7.58e-05 |
| Frs2-mediated activation | 12 | 4.55e-04 | -0.584000 | 1.48e-03 |
| HS-GAG biosynthesis | 27 | 1.71e-07 | -0.581000 | 1.26e-06 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 25 | 5.03e-07 | -0.580000 | 3.46e-06 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 12 | 5.35e-04 | -0.577000 | 1.71e-03 |
| RAF-independent MAPK1/3 activation | 22 | 2.81e-06 | -0.577000 | 1.52e-05 |
| Insulin processing | 25 | 6.05e-07 | -0.576000 | 4.07e-06 |
| Signal regulatory protein family interactions | 11 | 9.87e-04 | -0.574000 | 2.93e-03 |
| Regulation of PTEN mRNA translation | 12 | 5.99e-04 | -0.572000 | 1.88e-03 |
| RHO GTPases activate KTN1 | 11 | 1.02e-03 | -0.572000 | 2.98e-03 |
| RHOH GTPase cycle | 36 | 3.18e-09 | -0.570000 | 3.33e-08 |
| RHO GTPases Activate WASPs and WAVEs | 36 | 3.45e-09 | -0.569000 | 3.55e-08 |
| Netrin-1 signaling | 45 | 4.65e-11 | -0.567000 | 6.14e-10 |
| RHOQ GTPase cycle | 58 | 9.01e-14 | -0.565000 | 1.80e-12 |
| Mitotic Telophase/Cytokinesis | 13 | 4.35e-04 | -0.563000 | 1.42e-03 |
| Regulation of RUNX1 Expression and Activity | 18 | 3.60e-05 | -0.562000 | 1.48e-04 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 6.92e-08 | -0.559000 | 5.81e-07 |
| Signaling by WNT in cancer | 33 | 2.94e-08 | -0.557000 | 2.66e-07 |
| Regulation of localization of FOXO transcription factors | 12 | 8.36e-04 | -0.557000 | 2.50e-03 |
| Heme signaling | 43 | 2.62e-10 | -0.557000 | 3.07e-09 |
| Growth hormone receptor signaling | 20 | 1.63e-05 | -0.557000 | 7.30e-05 |
| RAC2 GTPase cycle | 86 | 5.34e-19 | -0.555000 | 1.61e-17 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 2.45e-03 | -0.553000 | 6.38e-03 |
| RAC3 GTPase cycle | 90 | 1.13e-19 | -0.553000 | 3.72e-18 |
| Recycling pathway of L1 | 27 | 6.63e-07 | -0.553000 | 4.28e-06 |
| RHOC GTPase cycle | 72 | 4.88e-16 | -0.553000 | 1.16e-14 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 1.51e-03 | -0.552000 | 4.17e-03 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 1.79e-11 | -0.549000 | 2.63e-10 |
| Mitochondrial translation elongation | 90 | 2.79e-19 | 0.547000 | 8.77e-18 |
| Apoptotic cleavage of cellular proteins | 34 | 3.90e-08 | -0.544000 | 3.43e-07 |
| STAT3 nuclear events downstream of ALK signaling | 10 | 2.88e-03 | -0.544000 | 7.34e-03 |
| RUNX3 regulates NOTCH signaling | 14 | 4.24e-04 | -0.544000 | 1.39e-03 |
| Mitochondrial translation initiation | 90 | 4.60e-19 | 0.543000 | 1.42e-17 |
| FCGR3A-mediated phagocytosis | 56 | 1.99e-12 | -0.543000 | 3.43e-11 |
| Leishmania phagocytosis | 56 | 1.99e-12 | -0.543000 | 3.43e-11 |
| Parasite infection | 56 | 1.99e-12 | -0.543000 | 3.43e-11 |
| Deadenylation of mRNA | 22 | 1.09e-05 | -0.542000 | 5.07e-05 |
| Mitochondrial translation termination | 90 | 2.10e-18 | 0.533000 | 6.09e-17 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 9.28e-05 | -0.532000 | 3.48e-04 |
| Uptake and function of anthrax toxins | 11 | 2.25e-03 | -0.532000 | 5.94e-03 |
| G-protein mediated events | 48 | 1.87e-10 | -0.531000 | 2.25e-09 |
| SRP-dependent cotranslational protein targeting to membrane | 110 | 5.68e-22 | 0.531000 | 2.71e-20 |
| MET receptor recycling | 10 | 3.64e-03 | -0.531000 | 9.11e-03 |
| Formation of the ternary complex, and subsequently, the 43S complex | 50 | 8.27e-11 | 0.531000 | 1.05e-09 |
| RHOG GTPase cycle | 74 | 2.98e-15 | -0.530000 | 6.55e-14 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 28 | 1.20e-06 | -0.530000 | 7.29e-06 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 5.30e-07 | -0.529000 | 3.60e-06 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 1.00e-21 | 0.528000 | 4.62e-20 |
| RND1 GTPase cycle | 42 | 3.35e-09 | -0.527000 | 3.49e-08 |
| FCGR3A-mediated IL10 synthesis | 32 | 2.49e-07 | -0.527000 | 1.78e-06 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 3.49e-21 | 0.523000 | 1.26e-19 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 26 | 4.00e-06 | -0.522000 | 2.11e-05 |
| DAG and IP3 signaling | 37 | 3.87e-08 | -0.522000 | 3.43e-07 |
| Ca-dependent events | 33 | 2.09e-07 | -0.522000 | 1.52e-06 |
| Synthesis of PIPs at the plasma membrane | 50 | 1.68e-10 | -0.522000 | 2.03e-09 |
| Signaling by ALK fusions and activated point mutants | 55 | 2.20e-11 | -0.521000 | 3.10e-10 |
| Signaling by ALK in cancer | 55 | 2.20e-11 | -0.521000 | 3.10e-10 |
| CD209 (DC-SIGN) signaling | 20 | 5.67e-05 | -0.520000 | 2.22e-04 |
| PLC beta mediated events | 44 | 2.46e-09 | -0.519000 | 2.62e-08 |
| FCERI mediated Ca+2 mobilization | 28 | 2.08e-06 | -0.518000 | 1.16e-05 |
| PKA activation in glucagon signalling | 15 | 5.35e-04 | -0.516000 | 1.71e-03 |
| Reduction of cytosolic Ca++ levels | 12 | 2.03e-03 | -0.514000 | 5.44e-03 |
| Selenoamino acid metabolism | 115 | 1.53e-21 | 0.514000 | 6.67e-20 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 4.23e-11 | -0.514000 | 5.68e-10 |
| VEGFA-VEGFR2 Pathway | 92 | 1.61e-17 | -0.513000 | 4.19e-16 |
| Mitochondrial translation | 96 | 3.34e-18 | 0.513000 | 9.31e-17 |
| Circadian Clock | 67 | 4.34e-13 | -0.511000 | 8.13e-12 |
| Activated NTRK2 signals through FRS2 and FRS3 | 11 | 3.49e-03 | -0.508000 | 8.79e-03 |
| Aflatoxin activation and detoxification | 15 | 6.75e-04 | 0.507000 | 2.08e-03 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 3.61e-03 | -0.507000 | 9.04e-03 |
| Cap-dependent Translation Initiation | 117 | 2.75e-21 | 0.506000 | 1.04e-19 |
| Eukaryotic Translation Initiation | 117 | 2.75e-21 | 0.506000 | 1.04e-19 |
| Signaling by VEGF | 101 | 1.64e-18 | -0.505000 | 4.86e-17 |
| Signaling by FGFR4 in disease | 11 | 3.77e-03 | -0.504000 | 9.39e-03 |
| Interleukin-27 signaling | 10 | 5.81e-03 | -0.504000 | 1.35e-02 |
| RHOB GTPase cycle | 69 | 4.94e-13 | -0.503000 | 9.13e-12 |
| MET activates RAS signaling | 11 | 3.94e-03 | -0.502000 | 9.77e-03 |
| Cargo concentration in the ER | 31 | 1.38e-06 | -0.501000 | 8.29e-06 |
| RHOD GTPase cycle | 52 | 4.36e-10 | -0.500000 | 4.94e-09 |
| Signaling by BMP | 23 | 3.61e-05 | -0.498000 | 1.48e-04 |
| Diseases associated with glycosaminoglycan metabolism | 35 | 3.53e-07 | -0.497000 | 2.48e-06 |
| Signaling by Erythropoietin | 25 | 1.69e-05 | -0.497000 | 7.49e-05 |
| CaM pathway | 31 | 1.66e-06 | -0.497000 | 9.61e-06 |
| Calmodulin induced events | 31 | 1.66e-06 | -0.497000 | 9.61e-06 |
| Signaling by MET | 66 | 3.00e-12 | -0.496000 | 5.04e-11 |
| RAF activation | 33 | 8.43e-07 | -0.495000 | 5.35e-06 |
| Signaling by SCF-KIT | 42 | 2.78e-08 | -0.495000 | 2.52e-07 |
| Regulated proteolysis of p75NTR | 11 | 4.52e-03 | -0.494000 | 1.09e-02 |
| Tie2 Signaling | 17 | 4.23e-04 | -0.494000 | 1.39e-03 |
| VEGFR2 mediated vascular permeability | 27 | 9.78e-06 | -0.492000 | 4.63e-05 |
| PI Metabolism | 77 | 8.57e-14 | -0.491000 | 1.74e-12 |
| RND3 GTPase cycle | 41 | 5.54e-08 | -0.490000 | 4.74e-07 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 7.44e-03 | -0.489000 | 1.69e-02 |
| Sema3A PAK dependent Axon repulsion | 16 | 7.40e-04 | -0.487000 | 2.26e-03 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 3.52e-03 | -0.487000 | 8.83e-03 |
| Zinc transporters | 15 | 1.13e-03 | -0.486000 | 3.24e-03 |
| Response to metal ions | 10 | 7.88e-03 | 0.485000 | 1.76e-02 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 24 | 3.92e-05 | -0.485000 | 1.59e-04 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 2.79e-05 | -0.484000 | 1.18e-04 |
| MAPK3 (ERK1) activation | 10 | 8.13e-03 | -0.483000 | 1.81e-02 |
| Erythropoietin activates RAS | 14 | 1.81e-03 | -0.482000 | 4.87e-03 |
| L1CAM interactions | 93 | 1.10e-15 | -0.480000 | 2.51e-14 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 4.78e-05 | 0.479000 | 1.90e-04 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 1.89e-06 | -0.479000 | 1.06e-05 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 38 | 3.30e-07 | -0.478000 | 2.34e-06 |
| PECAM1 interactions | 12 | 4.20e-03 | -0.477000 | 1.03e-02 |
| The activation of arylsulfatases | 10 | 9.05e-03 | -0.477000 | 1.98e-02 |
| Regulation of actin dynamics for phagocytic cup formation | 58 | 3.36e-10 | -0.477000 | 3.91e-09 |
| Keratan sulfate biosynthesis | 24 | 5.58e-05 | -0.475000 | 2.19e-04 |
| COPI-mediated anterograde transport | 79 | 2.88e-13 | -0.475000 | 5.47e-12 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 82 | 1.10e-13 | -0.474000 | 2.15e-12 |
| RAC1 GTPase cycle | 177 | 1.18e-27 | -0.474000 | 9.15e-26 |
| Unwinding of DNA | 12 | 4.50e-03 | 0.474000 | 1.08e-02 |
| Signaling by PDGF | 52 | 3.62e-09 | -0.473000 | 3.69e-08 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 11 | 6.66e-03 | -0.472000 | 1.53e-02 |
| Interleukin receptor SHC signaling | 21 | 1.84e-04 | -0.471000 | 6.52e-04 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 2.45e-03 | -0.468000 | 6.38e-03 |
| Activation of gene expression by SREBF (SREBP) | 42 | 1.58e-07 | -0.467000 | 1.19e-06 |
| RUNX2 regulates osteoblast differentiation | 23 | 1.06e-04 | -0.467000 | 3.94e-04 |
| Cristae formation | 31 | 6.98e-06 | 0.466000 | 3.44e-05 |
| Molecules associated with elastic fibres | 26 | 3.85e-05 | -0.466000 | 1.57e-04 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 1.05e-06 | -0.464000 | 6.48e-06 |
| RHO GTPases activate IQGAPs | 11 | 7.75e-03 | -0.464000 | 1.74e-02 |
| VxPx cargo-targeting to cilium | 19 | 4.77e-04 | -0.463000 | 1.54e-03 |
| CDC42 GTPase cycle | 153 | 5.00e-23 | -0.462000 | 2.64e-21 |
| Elastic fibre formation | 36 | 1.58e-06 | -0.462000 | 9.33e-06 |
| Regulation of KIT signaling | 16 | 1.39e-03 | -0.462000 | 3.87e-03 |
| Signaling by NTRK3 (TRKC) | 16 | 1.42e-03 | -0.461000 | 3.94e-03 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 2.83e-17 | 0.460000 | 6.98e-16 |
| Nonsense-Mediated Decay (NMD) | 113 | 2.83e-17 | 0.460000 | 6.98e-16 |
| Signaling by ALK | 26 | 5.03e-05 | -0.459000 | 1.99e-04 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 4.21e-03 | 0.458000 | 1.03e-02 |
| NOTCH2 intracellular domain regulates transcription | 11 | 8.66e-03 | -0.457000 | 1.91e-02 |
| HS-GAG degradation | 19 | 5.71e-04 | -0.456000 | 1.80e-03 |
| Interleukin-7 signaling | 23 | 1.52e-04 | -0.456000 | 5.50e-04 |
| GAB1 signalosome | 17 | 1.15e-03 | -0.455000 | 3.28e-03 |
| CD28 co-stimulation | 30 | 1.61e-05 | -0.455000 | 7.23e-05 |
| Oncogenic MAPK signaling | 77 | 5.03e-12 | -0.455000 | 8.09e-11 |
| RHOA GTPase cycle | 146 | 3.46e-21 | -0.452000 | 1.26e-19 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 24 | 1.30e-04 | -0.451000 | 4.74e-04 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 17 | 1.31e-03 | -0.450000 | 3.67e-03 |
| Keratan sulfate/keratin metabolism | 29 | 2.70e-05 | -0.450000 | 1.16e-04 |
| RET signaling | 37 | 2.18e-06 | -0.450000 | 1.21e-05 |
| NOTCH3 Intracellular Domain Regulates Transcription | 22 | 2.60e-04 | -0.450000 | 8.94e-04 |
| Myogenesis | 25 | 1.11e-04 | -0.446000 | 4.09e-04 |
| Extra-nuclear estrogen signaling | 68 | 1.93e-10 | -0.446000 | 2.31e-09 |
| Integrin signaling | 26 | 8.32e-05 | -0.446000 | 3.13e-04 |
| Activation of BAD and translocation to mitochondria | 15 | 2.82e-03 | -0.445000 | 7.24e-03 |
| Chondroitin sulfate biosynthesis | 19 | 7.97e-04 | -0.444000 | 2.39e-03 |
| Dermatan sulfate biosynthesis | 10 | 1.50e-02 | -0.444000 | 3.12e-02 |
| Post NMDA receptor activation events | 56 | 8.91e-09 | -0.444000 | 8.67e-08 |
| N-Glycan antennae elongation | 14 | 4.09e-03 | -0.443000 | 1.01e-02 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 14 | 4.11e-03 | -0.443000 | 1.01e-02 |
| Platelet calcium homeostasis | 25 | 1.34e-04 | -0.441000 | 4.85e-04 |
| VLDLR internalisation and degradation | 11 | 1.13e-02 | -0.441000 | 2.41e-02 |
| Regulation of expression of SLITs and ROBOs | 166 | 1.06e-22 | 0.440000 | 5.42e-21 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 28 | 5.54e-05 | -0.440000 | 2.18e-04 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 1.01e-07 | -0.440000 | 8.05e-07 |
| Cell-Cell communication | 108 | 3.01e-15 | -0.439000 | 6.55e-14 |
| Notch-HLH transcription pathway | 28 | 5.99e-05 | -0.438000 | 2.34e-04 |
| ER to Golgi Anterograde Transport | 131 | 5.69e-18 | -0.437000 | 1.56e-16 |
| Metal ion SLC transporters | 23 | 3.06e-04 | -0.435000 | 1.03e-03 |
| Transport to the Golgi and subsequent modification | 161 | 2.05e-21 | -0.433000 | 8.53e-20 |
| RUNX2 regulates bone development | 30 | 4.03e-05 | -0.433000 | 1.63e-04 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 1.67e-23 | -0.432000 | 9.15e-22 |
| DARPP-32 events | 23 | 3.40e-04 | -0.431000 | 1.14e-03 |
| MAP kinase activation | 62 | 4.35e-09 | -0.431000 | 4.38e-08 |
| Signaling by ERBB2 ECD mutants | 16 | 2.88e-03 | -0.430000 | 7.34e-03 |
| rRNA processing | 214 | 1.94e-27 | 0.430000 | 1.37e-25 |
| Constitutive Signaling by EGFRvIII | 15 | 4.03e-03 | -0.429000 | 9.96e-03 |
| Signaling by EGFRvIII in Cancer | 15 | 4.03e-03 | -0.429000 | 9.96e-03 |
| Signalling to ERKs | 33 | 2.12e-05 | -0.428000 | 9.26e-05 |
| Intra-Golgi traffic | 43 | 1.25e-06 | -0.427000 | 7.52e-06 |
| Activation of NMDA receptors and postsynaptic events | 69 | 8.31e-10 | -0.427000 | 9.18e-09 |
| Glutathione conjugation | 29 | 6.85e-05 | 0.427000 | 2.62e-04 |
| Signaling by Activin | 15 | 4.19e-03 | -0.427000 | 1.03e-02 |
| RHO GTPase cycle | 435 | 8.83e-53 | -0.426000 | 3.27e-50 |
| RND2 GTPase cycle | 41 | 2.53e-06 | -0.425000 | 1.38e-05 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 26 | 1.83e-04 | -0.424000 | 6.52e-04 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 6.06e-03 | -0.424000 | 1.40e-02 |
| Opioid Signalling | 78 | 9.71e-11 | -0.424000 | 1.22e-09 |
| Ca2+ pathway | 56 | 4.24e-08 | -0.423000 | 3.69e-07 |
| Interleukin-2 signaling | 10 | 2.11e-02 | -0.421000 | 4.17e-02 |
| Golgi Associated Vesicle Biogenesis | 55 | 7.07e-08 | -0.420000 | 5.90e-07 |
| Gap junction degradation | 10 | 2.20e-02 | -0.418000 | 4.33e-02 |
| GPVI-mediated activation cascade | 31 | 6.12e-05 | -0.416000 | 2.37e-04 |
| Signaling by EGFR | 50 | 3.71e-07 | -0.415000 | 2.60e-06 |
| Gap junction trafficking and regulation | 21 | 1.00e-03 | -0.415000 | 2.94e-03 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 48 | 6.81e-07 | -0.414000 | 4.38e-06 |
| EPHB-mediated forward signaling | 34 | 2.93e-05 | -0.414000 | 1.23e-04 |
| Interleukin-35 Signalling | 12 | 1.30e-02 | -0.414000 | 2.73e-02 |
| Regulation of MECP2 expression and activity | 29 | 1.15e-04 | -0.414000 | 4.22e-04 |
| p130Cas linkage to MAPK signaling for integrins | 14 | 7.66e-03 | -0.412000 | 1.73e-02 |
| Signaling by NODAL | 19 | 1.89e-03 | -0.412000 | 5.10e-03 |
| Glycosaminoglycan metabolism | 109 | 1.16e-13 | -0.411000 | 2.23e-12 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 2.08e-21 | 0.410000 | 8.53e-20 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 1.05e-02 | -0.410000 | 2.26e-02 |
| Glutamate and glutamine metabolism | 13 | 1.05e-02 | -0.410000 | 2.26e-02 |
| Sodium/Calcium exchangers | 10 | 2.48e-02 | -0.410000 | 4.76e-02 |
| CRMPs in Sema3A signaling | 16 | 4.56e-03 | -0.410000 | 1.09e-02 |
| Signaling by TGF-beta Receptor Complex | 74 | 1.66e-09 | -0.405000 | 1.79e-08 |
| Glycolysis | 67 | 9.95e-09 | -0.405000 | 9.62e-08 |
| Signaling by BRAF and RAF1 fusions | 60 | 6.37e-08 | -0.403000 | 5.38e-07 |
| FLT3 signaling in disease | 28 | 2.34e-04 | -0.402000 | 8.16e-04 |
| G alpha (z) signalling events | 40 | 1.12e-05 | -0.401000 | 5.19e-05 |
| Membrane Trafficking | 581 | 9.61e-62 | -0.401000 | 7.11e-59 |
| Cellular response to starvation | 150 | 2.52e-17 | 0.400000 | 6.43e-16 |
| COPII-mediated vesicle transport | 66 | 1.94e-08 | -0.400000 | 1.81e-07 |
| Regulation of IFNA signaling | 12 | 1.66e-02 | -0.399000 | 3.38e-02 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 4.23e-04 | -0.399000 | 1.39e-03 |
| rRNA processing in the nucleus and cytosol | 190 | 2.56e-21 | 0.398000 | 1.02e-19 |
| Receptor-type tyrosine-protein phosphatases | 18 | 3.46e-03 | -0.398000 | 8.72e-03 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 94 | 2.72e-11 | -0.397000 | 3.80e-10 |
| Negative regulation of the PI3K/AKT network | 101 | 5.32e-12 | -0.397000 | 8.47e-11 |
| Signaling by NTRK2 (TRKB) | 24 | 7.68e-04 | -0.397000 | 2.32e-03 |
| Role of phospholipids in phagocytosis | 22 | 1.28e-03 | -0.397000 | 3.61e-03 |
| EPHA-mediated growth cone collapse | 15 | 7.88e-03 | -0.396000 | 1.76e-02 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 45 | 4.36e-06 | -0.396000 | 2.27e-05 |
| Influenza Viral RNA Transcription and Replication | 134 | 2.70e-15 | 0.395000 | 6.05e-14 |
| FGFR1 mutant receptor activation | 29 | 2.34e-04 | -0.395000 | 8.16e-04 |
| ECM proteoglycans | 45 | 4.85e-06 | -0.394000 | 2.46e-05 |
| Sphingolipid de novo biosynthesis | 42 | 1.16e-05 | -0.391000 | 5.34e-05 |
| FCERI mediated MAPK activation | 29 | 2.71e-04 | -0.391000 | 9.25e-04 |
| Interleukin-2 family signaling | 35 | 6.45e-05 | -0.390000 | 2.48e-04 |
| IRE1alpha activates chaperones | 50 | 1.82e-06 | -0.390000 | 1.03e-05 |
| Signal amplification | 28 | 3.54e-04 | -0.390000 | 1.18e-03 |
| Prolactin receptor signaling | 11 | 2.52e-02 | -0.390000 | 4.81e-02 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 13 | 1.53e-02 | -0.388000 | 3.16e-02 |
| Signaling by NOTCH1 | 72 | 1.25e-08 | -0.388000 | 1.20e-07 |
| Transcriptional activation of mitochondrial biogenesis | 53 | 1.09e-06 | -0.387000 | 6.72e-06 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 6.16e-05 | -0.386000 | 2.38e-04 |
| Signaling by FGFR1 in disease | 36 | 6.20e-05 | -0.386000 | 2.39e-04 |
| DAP12 interactions | 34 | 9.97e-05 | -0.386000 | 3.72e-04 |
| AKT phosphorylates targets in the cytosol | 14 | 1.26e-02 | -0.385000 | 2.67e-02 |
| SUMOylation of intracellular receptors | 27 | 5.39e-04 | -0.385000 | 1.72e-03 |
| Apoptotic execution phase | 47 | 5.08e-06 | -0.384000 | 2.58e-05 |
| Carnitine metabolism | 11 | 2.73e-02 | -0.384000 | 5.15e-02 |
| Gap junction assembly | 10 | 3.54e-02 | -0.384000 | 6.44e-02 |
| The citric acid (TCA) cycle and respiratory electron transport | 173 | 2.57e-18 | 0.384000 | 7.31e-17 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 2.76e-02 | -0.384000 | 5.19e-02 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.74e-04 | -0.383000 | 6.21e-04 |
| Signaling by TGFB family members | 98 | 5.31e-11 | -0.383000 | 6.83e-10 |
| Cell junction organization | 78 | 5.27e-09 | -0.382000 | 5.23e-08 |
| Golgi-to-ER retrograde transport | 111 | 3.55e-12 | -0.382000 | 5.90e-11 |
| FLT3 Signaling | 37 | 6.07e-05 | -0.381000 | 2.36e-04 |
| Vesicle-mediated transport | 612 | 1.01e-58 | -0.381000 | 4.99e-56 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 5.93e-07 | 0.379000 | 4.01e-06 |
| SHC1 events in ERBB2 signaling | 21 | 2.67e-03 | -0.379000 | 6.89e-03 |
| XBP1(S) activates chaperone genes | 48 | 5.81e-06 | -0.378000 | 2.93e-05 |
| EPH-ephrin mediated repulsion of cells | 48 | 5.97e-06 | -0.378000 | 2.98e-05 |
| Interleukin-17 signaling | 67 | 9.22e-08 | -0.377000 | 7.41e-07 |
| Signaling by NTRKs | 133 | 5.83e-14 | -0.377000 | 1.23e-12 |
| Negative regulation of MAPK pathway | 42 | 2.38e-05 | -0.377000 | 1.03e-04 |
| Dissolution of Fibrin Clot | 12 | 2.40e-02 | -0.376000 | 4.63e-02 |
| Fatty acyl-CoA biosynthesis | 35 | 1.18e-04 | -0.376000 | 4.31e-04 |
| activated TAK1 mediates p38 MAPK activation | 18 | 5.92e-03 | -0.375000 | 1.37e-02 |
| Elevation of cytosolic Ca2+ levels | 13 | 1.98e-02 | -0.373000 | 3.94e-02 |
| NOTCH1 Intracellular Domain Regulates Transcription | 47 | 9.66e-06 | -0.373000 | 4.62e-05 |
| Chondroitin sulfate/dermatan sulfate metabolism | 48 | 8.15e-06 | -0.372000 | 3.98e-05 |
| WNT ligand biogenesis and trafficking | 24 | 1.61e-03 | -0.372000 | 4.42e-03 |
| Signaling by NTRK1 (TRKA) | 115 | 6.18e-12 | -0.371000 | 9.53e-11 |
| Gap junction trafficking | 19 | 5.15e-03 | -0.371000 | 1.22e-02 |
| Ribosomal scanning and start codon recognition | 57 | 1.28e-06 | 0.371000 | 7.71e-06 |
| EPH-Ephrin signaling | 91 | 9.82e-10 | -0.370000 | 1.08e-08 |
| Effects of PIP2 hydrolysis | 24 | 1.71e-03 | -0.370000 | 4.63e-03 |
| Translation initiation complex formation | 57 | 1.40e-06 | 0.369000 | 8.33e-06 |
| mRNA decay by 3’ to 5’ exoribonuclease | 16 | 1.07e-02 | 0.368000 | 2.31e-02 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 4.42e-02 | -0.368000 | 7.82e-02 |
| CD28 dependent PI3K/Akt signaling | 19 | 5.59e-03 | -0.367000 | 1.31e-02 |
| TBC/RABGAPs | 43 | 3.20e-05 | -0.366000 | 1.34e-04 |
| Spry regulation of FGF signaling | 16 | 1.13e-02 | -0.366000 | 2.42e-02 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 1.26e-03 | 0.365000 | 3.58e-03 |
| Semaphorin interactions | 60 | 9.93e-07 | -0.365000 | 6.17e-06 |
| DAP12 signaling | 27 | 1.04e-03 | -0.365000 | 3.03e-03 |
| Disorders of Developmental Biology | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
| Disorders of Nervous System Development | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
| Loss of function of MECP2 in Rett syndrome | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
| Pervasive developmental disorders | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
| Phosphorylation of the APC/C | 20 | 5.05e-03 | 0.362000 | 1.20e-02 |
| AKT phosphorylates targets in the nucleus | 10 | 4.77e-02 | -0.362000 | 8.39e-02 |
| WNT5A-dependent internalization of FZD4 | 15 | 1.54e-02 | -0.361000 | 3.16e-02 |
| N-glycan antennae elongation in the medial/trans-Golgi | 25 | 1.77e-03 | -0.361000 | 4.79e-03 |
| NRAGE signals death through JNK | 59 | 1.60e-06 | -0.361000 | 9.36e-06 |
| trans-Golgi Network Vesicle Budding | 71 | 1.66e-07 | -0.359000 | 1.24e-06 |
| DNA strand elongation | 32 | 4.65e-04 | 0.357000 | 1.51e-03 |
| Asparagine N-linked glycosylation | 278 | 9.61e-25 | -0.357000 | 5.68e-23 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 15 | 1.69e-02 | -0.356000 | 3.44e-02 |
| Downregulation of TGF-beta receptor signaling | 26 | 1.67e-03 | -0.356000 | 4.56e-03 |
| Transport of the SLBP independent Mature mRNA | 35 | 2.75e-04 | -0.355000 | 9.36e-04 |
| Interactions of Vpr with host cellular proteins | 37 | 1.85e-04 | -0.355000 | 6.55e-04 |
| TRAF3-dependent IRF activation pathway | 14 | 2.15e-02 | -0.355000 | 4.25e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 2.19e-02 | -0.354000 | 4.31e-02 |
| PPARA activates gene expression | 110 | 1.65e-10 | -0.352000 | 2.02e-09 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 18 | 9.81e-03 | -0.352000 | 2.13e-02 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 5.86e-04 | -0.351000 | 1.85e-03 |
| Vpr-mediated nuclear import of PICs | 34 | 3.96e-04 | -0.351000 | 1.31e-03 |
| Insulin receptor signalling cascade | 50 | 1.78e-05 | -0.351000 | 7.84e-05 |
| PI3K/AKT Signaling in Cancer | 94 | 4.15e-09 | -0.351000 | 4.20e-08 |
| Lewis blood group biosynthesis | 15 | 1.89e-02 | -0.350000 | 3.78e-02 |
| Retrograde neurotrophin signalling | 14 | 2.36e-02 | -0.349000 | 4.58e-02 |
| Adherens junctions interactions | 29 | 1.14e-03 | -0.349000 | 3.26e-03 |
| RAB GEFs exchange GTP for GDP on RABs | 88 | 1.49e-08 | -0.349000 | 1.41e-07 |
| NOTCH4 Intracellular Domain Regulates Transcription | 19 | 8.55e-03 | -0.348000 | 1.88e-02 |
| Signaling by RAF1 mutants | 37 | 2.48e-04 | -0.348000 | 8.58e-04 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 3.04e-04 | -0.348000 | 1.03e-03 |
| MyD88 cascade initiated on plasma membrane | 80 | 7.51e-08 | -0.348000 | 6.17e-07 |
| Toll Like Receptor 10 (TLR10) Cascade | 80 | 7.51e-08 | -0.348000 | 6.17e-07 |
| Toll Like Receptor 5 (TLR5) Cascade | 80 | 7.51e-08 | -0.348000 | 6.17e-07 |
| Regulation of lipid metabolism by PPARalpha | 112 | 2.21e-10 | -0.347000 | 2.62e-09 |
| Ovarian tumor domain proteases | 37 | 2.69e-04 | -0.346000 | 9.22e-04 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 5.87e-04 | -0.346000 | 1.85e-03 |
| Platelet Aggregation (Plug Formation) | 32 | 7.13e-04 | -0.346000 | 2.19e-03 |
| Synaptic adhesion-like molecules | 21 | 6.16e-03 | -0.345000 | 1.42e-02 |
| Cytosolic iron-sulfur cluster assembly | 13 | 3.12e-02 | 0.345000 | 5.81e-02 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 5.11e-03 | -0.345000 | 1.21e-02 |
| Endosomal/Vacuolar pathway | 12 | 3.89e-02 | -0.344000 | 6.97e-02 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 11 | 4.87e-02 | -0.343000 | 8.54e-02 |
| Attenuation phase | 23 | 4.44e-03 | -0.343000 | 1.07e-02 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 2.52e-03 | 0.342000 | 6.56e-03 |
| APC/C:Cdc20 mediated degradation of Securin | 66 | 1.56e-06 | 0.342000 | 9.25e-06 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 35 | 4.73e-04 | -0.341000 | 1.54e-03 |
| Toll Like Receptor 3 (TLR3) Cascade | 89 | 2.71e-08 | -0.341000 | 2.47e-07 |
| LDL clearance | 16 | 1.84e-02 | -0.340000 | 3.69e-02 |
| COPI-dependent Golgi-to-ER retrograde traffic | 78 | 2.14e-07 | -0.339000 | 1.55e-06 |
| Nucleotide biosynthesis | 12 | 4.24e-02 | -0.338000 | 7.56e-02 |
| Citric acid cycle (TCA cycle) | 22 | 6.13e-03 | -0.338000 | 1.41e-02 |
| G alpha (12/13) signalling events | 75 | 4.33e-07 | -0.337000 | 2.99e-06 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 1.00e-03 | -0.336000 | 2.94e-03 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 1.00e-03 | -0.336000 | 2.94e-03 |
| Translocation of ZAP-70 to Immunological synapse | 15 | 2.43e-02 | 0.336000 | 4.68e-02 |
| SARS-CoV-2 Infection | 71 | 9.85e-07 | -0.336000 | 6.15e-06 |
| RNA Polymerase I Promoter Opening | 25 | 3.68e-03 | 0.336000 | 9.18e-03 |
| Pre-NOTCH Processing in Golgi | 18 | 1.38e-02 | -0.335000 | 2.87e-02 |
| Signaling by Receptor Tyrosine Kinases | 480 | 1.62e-36 | -0.335000 | 2.66e-34 |
| Toll Like Receptor 9 (TLR9) Cascade | 90 | 4.31e-08 | -0.334000 | 3.70e-07 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 3.87e-03 | -0.334000 | 9.61e-03 |
| Signaling by Rho GTPases | 629 | 1.15e-46 | -0.334000 | 2.43e-44 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 4.18e-06 | 0.332000 | 2.20e-05 |
| Diseases of signal transduction by growth factor receptors and second messengers | 411 | 4.46e-31 | -0.332000 | 5.99e-29 |
| RHOBTB GTPase Cycle | 35 | 6.65e-04 | -0.332000 | 2.06e-03 |
| Deactivation of the beta-catenin transactivating complex | 41 | 2.34e-04 | -0.332000 | 8.16e-04 |
| Glucagon signaling in metabolic regulation | 26 | 3.41e-03 | -0.332000 | 8.61e-03 |
| Transcriptional Regulation by MECP2 | 55 | 2.10e-05 | -0.331000 | 9.18e-05 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 645 | 3.62e-47 | -0.331000 | 8.93e-45 |
| Extracellular matrix organization | 256 | 7.37e-20 | -0.331000 | 2.48e-18 |
| HSF1-dependent transactivation | 31 | 1.48e-03 | -0.330000 | 4.10e-03 |
| DNA methylation | 27 | 3.01e-03 | 0.330000 | 7.67e-03 |
| Interleukin-20 family signaling | 19 | 1.29e-02 | -0.330000 | 2.70e-02 |
| Rab regulation of trafficking | 120 | 4.34e-10 | -0.330000 | 4.94e-09 |
| Integrin cell surface interactions | 60 | 1.03e-05 | -0.329000 | 4.84e-05 |
| Clathrin-mediated endocytosis | 138 | 2.98e-11 | -0.327000 | 4.11e-10 |
| Initial triggering of complement | 15 | 2.81e-02 | 0.327000 | 5.29e-02 |
| Glycogen breakdown (glycogenolysis) | 15 | 2.83e-02 | -0.327000 | 5.32e-02 |
| IGF1R signaling cascade | 49 | 7.55e-05 | -0.327000 | 2.88e-04 |
| Platelet activation, signaling and aggregation | 230 | 1.57e-17 | -0.326000 | 4.15e-16 |
| Rap1 signalling | 15 | 2.93e-02 | -0.325000 | 5.49e-02 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 67 | 4.37e-06 | -0.324000 | 2.27e-05 |
| Platelet homeostasis | 73 | 1.65e-06 | -0.324000 | 9.61e-06 |
| Translesion synthesis by POLI | 17 | 2.07e-02 | 0.324000 | 4.09e-02 |
| Diseases associated with visual transduction | 10 | 7.60e-02 | 0.324000 | 1.26e-01 |
| Diseases of the neuronal system | 10 | 7.60e-02 | 0.324000 | 1.26e-01 |
| Retinoid cycle disease events | 10 | 7.60e-02 | 0.324000 | 1.26e-01 |
| RAB geranylgeranylation | 62 | 1.07e-05 | -0.323000 | 5.04e-05 |
| MyD88-independent TLR4 cascade | 93 | 7.63e-08 | -0.322000 | 6.20e-07 |
| TRIF(TICAM1)-mediated TLR4 signaling | 93 | 7.63e-08 | -0.322000 | 6.20e-07 |
| Processing and activation of SUMO | 10 | 7.80e-02 | -0.322000 | 1.29e-01 |
| p75 NTR receptor-mediated signalling | 95 | 5.94e-08 | -0.322000 | 5.05e-07 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 61 | 1.40e-05 | -0.321000 | 6.36e-05 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 85 | 3.01e-07 | -0.321000 | 2.14e-06 |
| TGF-beta receptor signaling activates SMADs | 32 | 1.67e-03 | -0.321000 | 4.56e-03 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 2.59e-06 | 0.320000 | 1.41e-05 |
| SUMOylation of SUMOylation proteins | 35 | 1.04e-03 | -0.320000 | 3.03e-03 |
| Translation | 293 | 4.91e-21 | 0.319000 | 1.73e-19 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 1.16e-02 | -0.318000 | 2.47e-02 |
| Sialic acid metabolism | 31 | 2.18e-03 | -0.318000 | 5.78e-03 |
| Mitochondrial protein import | 64 | 1.09e-05 | 0.318000 | 5.09e-05 |
| Cargo recognition for clathrin-mediated endocytosis | 100 | 4.03e-08 | -0.317000 | 3.53e-07 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 4.31e-03 | -0.317000 | 1.05e-02 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 1.08e-04 | 0.316000 | 3.98e-04 |
| p53-Independent DNA Damage Response | 50 | 1.08e-04 | 0.316000 | 3.98e-04 |
| p53-Independent G1/S DNA damage checkpoint | 50 | 1.08e-04 | 0.316000 | 3.98e-04 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
| Signaling by NOTCH1 in Cancer | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
| CDT1 association with the CDC6:ORC:origin complex | 57 | 3.62e-05 | 0.316000 | 1.48e-04 |
| Influenza Infection | 153 | 1.44e-11 | 0.316000 | 2.16e-10 |
| Nuclear Receptor transcription pathway | 46 | 2.08e-04 | -0.316000 | 7.29e-04 |
| SUMOylation of ubiquitinylation proteins | 39 | 6.42e-04 | -0.316000 | 1.99e-03 |
| IRS-related events triggered by IGF1R | 48 | 1.55e-04 | -0.316000 | 5.57e-04 |
| Signaling by ERBB2 in Cancer | 25 | 6.33e-03 | -0.315000 | 1.46e-02 |
| mRNA Splicing - Minor Pathway | 52 | 8.30e-05 | 0.315000 | 3.13e-04 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 24 | 7.48e-03 | -0.315000 | 1.70e-02 |
| Fanconi Anemia Pathway | 36 | 1.10e-03 | 0.314000 | 3.16e-03 |
| Transcriptional regulation of white adipocyte differentiation | 81 | 1.13e-06 | -0.313000 | 6.93e-06 |
| Repression of WNT target genes | 14 | 4.34e-02 | -0.312000 | 7.70e-02 |
| Integration of energy metabolism | 93 | 2.04e-07 | -0.312000 | 1.50e-06 |
| PI3K events in ERBB2 signaling | 15 | 3.75e-02 | -0.310000 | 6.78e-02 |
| MyD88 dependent cascade initiated on endosome | 86 | 6.62e-07 | -0.310000 | 4.28e-06 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 86 | 6.62e-07 | -0.310000 | 4.28e-06 |
| Assembly and cell surface presentation of NMDA receptors | 23 | 1.02e-02 | -0.310000 | 2.20e-02 |
| Vif-mediated degradation of APOBEC3G | 52 | 1.15e-04 | 0.309000 | 4.23e-04 |
| Blood group systems biosynthesis | 19 | 1.98e-02 | -0.309000 | 3.95e-02 |
| Cellular response to heat stress | 94 | 2.34e-07 | -0.308000 | 1.68e-06 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 50 | 1.64e-04 | -0.308000 | 5.90e-04 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 4.62e-06 | 0.308000 | 2.39e-05 |
| SHC1 events in EGFR signaling | 14 | 4.62e-02 | -0.308000 | 8.16e-02 |
| Metabolism of carbohydrates | 263 | 8.01e-18 | -0.307000 | 2.15e-16 |
| NR1H2 and NR1H3-mediated signaling | 43 | 4.88e-04 | -0.307000 | 1.58e-03 |
| Regulation of TP53 Activity through Acetylation | 29 | 4.38e-03 | -0.306000 | 1.06e-02 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 35 | 1.78e-03 | -0.305000 | 4.82e-03 |
| Signaling by high-kinase activity BRAF mutants | 33 | 2.42e-03 | -0.305000 | 6.35e-03 |
| Biotin transport and metabolism | 11 | 8.03e-02 | -0.304000 | 1.33e-01 |
| SARS-CoV Infections | 151 | 1.03e-10 | -0.304000 | 1.28e-09 |
| Sphingolipid metabolism | 84 | 1.44e-06 | -0.304000 | 8.55e-06 |
| Cell surface interactions at the vascular wall | 100 | 1.56e-07 | -0.303000 | 1.17e-06 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 2.42e-04 | 0.303000 | 8.40e-04 |
| PI-3K cascade:FGFR3 | 16 | 3.59e-02 | -0.303000 | 6.52e-02 |
| Translesion synthesis by REV1 | 16 | 3.62e-02 | 0.303000 | 6.55e-02 |
| Sensory processing of sound by outer hair cells of the cochlea | 44 | 5.20e-04 | -0.302000 | 1.67e-03 |
| Signaling by FGFR3 | 38 | 1.26e-03 | -0.302000 | 3.58e-03 |
| NS1 Mediated Effects on Host Pathways | 40 | 9.45e-04 | -0.302000 | 2.82e-03 |
| Costimulation by the CD28 family | 59 | 6.24e-05 | -0.301000 | 2.40e-04 |
| Nuclear Events (kinase and transcription factor activation) | 62 | 4.24e-05 | -0.301000 | 1.70e-04 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 19 | 2.34e-02 | -0.300000 | 4.57e-02 |
| Ras activation upon Ca2+ influx through NMDA receptor | 18 | 2.75e-02 | -0.300000 | 5.19e-02 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 8.50e-02 | -0.300000 | 1.38e-01 |
| Nuclear Envelope Breakdown | 53 | 1.62e-04 | -0.299000 | 5.82e-04 |
| Leishmania infection | 189 | 1.23e-12 | -0.299000 | 2.20e-11 |
| DSCAM interactions | 10 | 1.02e-01 | -0.299000 | 1.61e-01 |
| Signaling by FGFR1 | 47 | 3.94e-04 | -0.299000 | 1.30e-03 |
| Digestion and absorption | 11 | 8.69e-02 | 0.298000 | 1.41e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 76 | 7.25e-06 | -0.297000 | 3.56e-05 |
| IRS-mediated signalling | 45 | 5.59e-04 | -0.297000 | 1.77e-03 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
| Signaling by RAS mutants | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
| Signaling by moderate kinase activity BRAF mutants | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
| Signaling downstream of RAS mutants | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
| Protein-protein interactions at synapses | 78 | 5.93e-06 | -0.296000 | 2.98e-05 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 1.05e-01 | 0.296000 | 1.65e-01 |
| Assembly of active LPL and LIPC lipase complexes | 13 | 6.45e-02 | -0.296000 | 1.09e-01 |
| Hemostasis | 495 | 1.11e-29 | -0.296000 | 1.17e-27 |
| Negative regulation of MET activity | 21 | 1.88e-02 | -0.296000 | 3.77e-02 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 34 | 2.82e-03 | -0.296000 | 7.24e-03 |
| PI-3K cascade:FGFR1 | 19 | 2.56e-02 | -0.296000 | 4.90e-02 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 9.42e-06 | 0.296000 | 4.53e-05 |
| TNFR1-induced proapoptotic signaling | 13 | 6.50e-02 | -0.296000 | 1.10e-01 |
| Synthesis of DNA | 118 | 3.07e-08 | 0.295000 | 2.73e-07 |
| Inositol phosphate metabolism | 45 | 6.37e-04 | -0.294000 | 1.98e-03 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 27 | 8.32e-03 | -0.293000 | 1.85e-02 |
| Trafficking of AMPA receptors | 27 | 8.32e-03 | -0.293000 | 1.85e-02 |
| ISG15 antiviral mechanism | 72 | 1.67e-05 | -0.293000 | 7.45e-05 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 2.32e-02 | 0.293000 | 4.55e-02 |
| Class I peroxisomal membrane protein import | 19 | 2.71e-02 | -0.293000 | 5.13e-02 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 3.15e-02 | -0.293000 | 5.83e-02 |
| Long-term potentiation | 20 | 2.34e-02 | -0.293000 | 4.57e-02 |
| Death Receptor Signalling | 138 | 2.91e-09 | -0.292000 | 3.07e-08 |
| SHC1 events in ERBB4 signaling | 13 | 6.86e-02 | -0.292000 | 1.15e-01 |
| Downstream signaling of activated FGFR3 | 23 | 1.55e-02 | -0.292000 | 3.18e-02 |
| DNA Replication | 151 | 6.63e-10 | 0.291000 | 7.37e-09 |
| Signaling by ERBB2 KD Mutants | 24 | 1.37e-02 | -0.291000 | 2.86e-02 |
| Listeria monocytogenes entry into host cells | 20 | 2.45e-02 | -0.290000 | 4.72e-02 |
| Physiological factors | 10 | 1.12e-01 | -0.290000 | 1.75e-01 |
| Glucose metabolism | 84 | 4.31e-06 | -0.290000 | 2.25e-05 |
| Assembly of the pre-replicative complex | 91 | 1.76e-06 | 0.290000 | 1.00e-05 |
| TRAF6 mediated IRF7 activation | 16 | 4.50e-02 | -0.290000 | 7.95e-02 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 45 | 7.88e-04 | 0.289000 | 2.37e-03 |
| Nucleosome assembly | 45 | 7.88e-04 | 0.289000 | 2.37e-03 |
| FOXO-mediated transcription | 59 | 1.22e-04 | -0.289000 | 4.45e-04 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 2.21e-05 | 0.289000 | 9.63e-05 |
| CDK-mediated phosphorylation and removal of Cdc6 | 71 | 2.58e-05 | 0.289000 | 1.11e-04 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 2.79e-03 | -0.288000 | 7.18e-03 |
| DNA Replication Pre-Initiation | 108 | 2.32e-07 | 0.288000 | 1.67e-06 |
| Lagging Strand Synthesis | 20 | 2.61e-02 | 0.287000 | 4.97e-02 |
| EGFR downregulation | 31 | 5.65e-03 | -0.287000 | 1.32e-02 |
| ESR-mediated signaling | 174 | 6.10e-11 | -0.287000 | 7.78e-10 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.92e-04 | 0.287000 | 1.86e-03 |
| Antiviral mechanism by IFN-stimulated genes | 80 | 9.39e-06 | -0.286000 | 4.53e-05 |
| PI3K Cascade | 41 | 1.52e-03 | -0.286000 | 4.17e-03 |
| Formation of the cornified envelope | 22 | 2.02e-02 | -0.286000 | 4.00e-02 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 3.39e-03 | -0.286000 | 8.58e-03 |
| Activation of the pre-replicative complex | 33 | 4.49e-03 | 0.286000 | 1.08e-02 |
| Lysosphingolipid and LPA receptors | 11 | 1.01e-01 | -0.286000 | 1.60e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 1.35e-03 | -0.286000 | 3.78e-03 |
| CDC6 association with the ORC:origin complex | 11 | 1.01e-01 | 0.286000 | 1.60e-01 |
| Negative regulation of NOTCH4 signaling | 54 | 2.80e-04 | 0.286000 | 9.53e-04 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 3.18e-05 | 0.285000 | 1.33e-04 |
| Depolymerisation of the Nuclear Lamina | 15 | 5.57e-02 | -0.285000 | 9.63e-02 |
| Cargo trafficking to the periciliary membrane | 47 | 7.15e-04 | -0.285000 | 2.19e-03 |
| Stabilization of p53 | 53 | 3.29e-04 | 0.285000 | 1.11e-03 |
| Nuclear import of Rev protein | 34 | 4.03e-03 | -0.285000 | 9.96e-03 |
| Interleukin-6 family signaling | 23 | 1.83e-02 | -0.284000 | 3.68e-02 |
| SUMOylation of transcription cofactors | 44 | 1.11e-03 | -0.284000 | 3.21e-03 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 4.27e-02 | 0.284000 | 7.60e-02 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 8.95e-02 | -0.283000 | 1.44e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 8.95e-02 | -0.283000 | 1.44e-01 |
| Cell-cell junction organization | 53 | 3.70e-04 | -0.283000 | 1.23e-03 |
| Neurexins and neuroligins | 49 | 6.33e-04 | -0.282000 | 1.98e-03 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 30 | 7.62e-03 | -0.281000 | 1.72e-02 |
| PKMTs methylate histone lysines | 45 | 1.09e-03 | -0.281000 | 3.14e-03 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 1.42e-03 | -0.281000 | 3.96e-03 |
| Phospholipid metabolism | 192 | 1.80e-11 | -0.281000 | 2.63e-10 |
| Amine ligand-binding receptors | 23 | 1.99e-02 | -0.280000 | 3.95e-02 |
| Rev-mediated nuclear export of HIV RNA | 35 | 4.09e-03 | -0.280000 | 1.01e-02 |
| RHO GTPases activate PAKs | 21 | 2.65e-02 | -0.280000 | 5.04e-02 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.66e-02 | 0.279000 | 5.05e-02 |
| Leading Strand Synthesis | 14 | 7.02e-02 | 0.279000 | 1.18e-01 |
| Polymerase switching | 14 | 7.02e-02 | 0.279000 | 1.18e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 37 | 3.27e-03 | -0.279000 | 8.32e-03 |
| Potential therapeutics for SARS | 82 | 1.23e-05 | -0.279000 | 5.62e-05 |
| Signal Transduction | 2189 | 0.00e+00 | -0.279000 | 0.00e+00 |
| Downstream signaling of activated FGFR1 | 29 | 9.57e-03 | -0.278000 | 2.09e-02 |
| Signaling by ERBB2 | 49 | 7.72e-04 | -0.278000 | 2.33e-03 |
| Processive synthesis on the lagging strand | 15 | 6.28e-02 | 0.277000 | 1.07e-01 |
| Aquaporin-mediated transport | 39 | 2.72e-03 | -0.277000 | 7.01e-03 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 1.27e-02 | -0.277000 | 2.67e-02 |
| FOXO-mediated transcription of cell death genes | 15 | 6.32e-02 | -0.277000 | 1.07e-01 |
| Receptor Mediated Mitophagy | 11 | 1.13e-01 | -0.276000 | 1.76e-01 |
| Uptake and actions of bacterial toxins | 29 | 1.02e-02 | -0.276000 | 2.20e-02 |
| Metabolism of fat-soluble vitamins | 36 | 4.26e-03 | -0.275000 | 1.04e-02 |
| Defective pyroptosis | 35 | 4.86e-03 | 0.275000 | 1.16e-02 |
| Intracellular signaling by second messengers | 292 | 6.05e-16 | -0.275000 | 1.42e-14 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 6.64e-02 | -0.274000 | 1.12e-01 |
| HSF1 activation | 26 | 1.59e-02 | -0.273000 | 3.26e-02 |
| Ion homeostasis | 45 | 1.53e-03 | -0.273000 | 4.21e-03 |
| RHO GTPases activate CIT | 19 | 3.96e-02 | -0.273000 | 7.09e-02 |
| Condensation of Prometaphase Chromosomes | 11 | 1.17e-01 | 0.273000 | 1.81e-01 |
| O-linked glycosylation of mucins | 52 | 6.75e-04 | -0.272000 | 2.08e-03 |
| RHOBTB1 GTPase cycle | 23 | 2.38e-02 | -0.272000 | 4.60e-02 |
| Defects in vitamin and cofactor metabolism | 21 | 3.12e-02 | -0.271000 | 5.81e-02 |
| Mucopolysaccharidoses | 11 | 1.20e-01 | -0.271000 | 1.83e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 3.72e-04 | 0.270000 | 1.23e-03 |
| GRB2 events in ERBB2 signaling | 15 | 7.04e-02 | -0.270000 | 1.18e-01 |
| Regulation of HSF1-mediated heat shock response | 78 | 3.98e-05 | -0.269000 | 1.61e-04 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 1.24e-01 | -0.268000 | 1.89e-01 |
| G-protein beta:gamma signalling | 27 | 1.59e-02 | -0.268000 | 3.25e-02 |
| Ion transport by P-type ATPases | 47 | 1.50e-03 | -0.268000 | 4.13e-03 |
| Switching of origins to a post-replicative state | 89 | 1.27e-05 | 0.268000 | 5.77e-05 |
| Signaling by Non-Receptor Tyrosine Kinases | 53 | 7.49e-04 | -0.268000 | 2.28e-03 |
| Signaling by PTK6 | 53 | 7.49e-04 | -0.268000 | 2.28e-03 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 3.83e-02 | 0.267000 | 6.91e-02 |
| Vpu mediated degradation of CD4 | 50 | 1.08e-03 | 0.267000 | 3.12e-03 |
| Regulation of insulin secretion | 65 | 1.99e-04 | -0.267000 | 7.01e-04 |
| Synthesis of IP2, IP, and Ins in the cytosol | 14 | 8.41e-02 | -0.267000 | 1.37e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 3.47e-02 | 0.266000 | 6.35e-02 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 3.47e-02 | 0.266000 | 6.35e-02 |
| Defective GALNT12 causes CRCS1 | 12 | 1.11e-01 | 0.265000 | 1.74e-01 |
| ER Quality Control Compartment (ERQC) | 21 | 3.52e-02 | -0.265000 | 6.43e-02 |
| GRB2 events in EGFR signaling | 13 | 9.79e-02 | -0.265000 | 1.56e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 50 | 1.20e-03 | 0.265000 | 3.42e-03 |
| Interactions of Rev with host cellular proteins | 37 | 5.41e-03 | -0.264000 | 1.27e-02 |
| SUMOylation of chromatin organization proteins | 57 | 5.59e-04 | -0.264000 | 1.77e-03 |
| Lysosome Vesicle Biogenesis | 34 | 7.70e-03 | -0.264000 | 1.73e-02 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 2.27e-02 | 0.263000 | 4.46e-02 |
| Thromboxane signalling through TP receptor | 20 | 4.20e-02 | -0.263000 | 7.51e-02 |
| eNOS activation | 11 | 1.33e-01 | -0.262000 | 2.01e-01 |
| Factors involved in megakaryocyte development and platelet production | 116 | 1.10e-06 | -0.262000 | 6.78e-06 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 1.33e-01 | 0.262000 | 2.01e-01 |
| SUMOylation of transcription factors | 19 | 4.85e-02 | -0.261000 | 8.52e-02 |
| Neurotransmitter receptors and postsynaptic signal transmission | 155 | 2.06e-08 | -0.261000 | 1.91e-07 |
| Autophagy | 125 | 5.14e-07 | -0.260000 | 3.52e-06 |
| MHC class II antigen presentation | 98 | 8.80e-06 | -0.260000 | 4.28e-05 |
| Toll Like Receptor 4 (TLR4) Cascade | 122 | 7.93e-07 | -0.259000 | 5.08e-06 |
| Toll-like Receptor Cascades | 140 | 1.26e-07 | -0.259000 | 9.91e-07 |
| Regulation of TP53 Expression and Degradation | 36 | 7.41e-03 | -0.258000 | 1.69e-02 |
| The NLRP3 inflammasome | 15 | 8.48e-02 | -0.257000 | 1.38e-01 |
| Interleukin-4 and Interleukin-13 signaling | 97 | 1.21e-05 | -0.257000 | 5.55e-05 |
| Regulation of beta-cell development | 31 | 1.34e-02 | -0.256000 | 2.82e-02 |
| Activation of the AP-1 family of transcription factors | 10 | 1.60e-01 | -0.256000 | 2.35e-01 |
| Glutathione synthesis and recycling | 12 | 1.24e-01 | 0.256000 | 1.90e-01 |
| Collagen degradation | 35 | 8.75e-03 | -0.256000 | 1.92e-02 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 1.32e-03 | 0.255000 | 3.70e-03 |
| Retinoid metabolism and transport | 32 | 1.27e-02 | -0.254000 | 2.68e-02 |
| CS/DS degradation | 13 | 1.12e-01 | -0.254000 | 1.75e-01 |
| Endogenous sterols | 22 | 3.91e-02 | -0.254000 | 7.01e-02 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 1.49e-02 | -0.253000 | 3.10e-02 |
| Response to elevated platelet cytosolic Ca2+ | 117 | 2.35e-06 | -0.252000 | 1.29e-05 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 1.49e-03 | 0.252000 | 4.12e-03 |
| Regulation of TLR by endogenous ligand | 15 | 9.18e-02 | 0.251000 | 1.47e-01 |
| MAPK family signaling cascades | 299 | 7.30e-14 | -0.251000 | 1.52e-12 |
| Macroautophagy | 111 | 4.80e-06 | -0.251000 | 2.45e-05 |
| Trafficking of GluR2-containing AMPA receptors | 16 | 8.35e-02 | -0.250000 | 1.37e-01 |
| SUMOylation of DNA damage response and repair proteins | 76 | 1.65e-04 | -0.250000 | 5.90e-04 |
| Activation of BH3-only proteins | 29 | 1.99e-02 | -0.250000 | 3.95e-02 |
| Synthesis of IP3 and IP4 in the cytosol | 24 | 3.43e-02 | -0.250000 | 6.29e-02 |
| Signaling by FGFR4 | 38 | 7.75e-03 | -0.250000 | 1.74e-02 |
| Signalling to RAS | 20 | 5.35e-02 | -0.249000 | 9.31e-02 |
| SCF-beta-TrCP mediated degradation of Emi1 | 53 | 1.69e-03 | 0.249000 | 4.61e-03 |
| Calnexin/calreticulin cycle | 26 | 2.79e-02 | -0.249000 | 5.24e-02 |
| Regulation of Apoptosis | 51 | 2.08e-03 | 0.249000 | 5.55e-03 |
| Sulfur amino acid metabolism | 25 | 3.13e-02 | 0.249000 | 5.81e-02 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
| Toll Like Receptor 2 (TLR2) Cascade | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
| Toll Like Receptor TLR1:TLR2 Cascade | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
| Toll Like Receptor TLR6:TLR2 Cascade | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
| Post-translational protein modification | 1270 | 6.69e-51 | -0.249000 | 1.98e-48 |
| Orc1 removal from chromatin | 69 | 3.62e-04 | 0.248000 | 1.20e-03 |
| O-linked glycosylation | 99 | 1.97e-05 | -0.248000 | 8.65e-05 |
| NCAM signaling for neurite out-growth | 55 | 1.46e-03 | -0.248000 | 4.06e-03 |
| Glycogen synthesis | 15 | 9.67e-02 | -0.248000 | 1.54e-01 |
| Platelet degranulation | 112 | 5.95e-06 | -0.248000 | 2.98e-05 |
| SARS-CoV-1 Infection | 50 | 2.62e-03 | -0.246000 | 6.79e-03 |
| RHO GTPases Activate ROCKs | 19 | 6.38e-02 | -0.246000 | 1.08e-01 |
| IRAK1 recruits IKK complex | 10 | 1.79e-01 | -0.245000 | 2.59e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 1.79e-01 | -0.245000 | 2.59e-01 |
| Platelet Adhesion to exposed collagen | 11 | 1.59e-01 | -0.245000 | 2.34e-01 |
| Synthesis of substrates in N-glycan biosythesis | 61 | 9.40e-04 | -0.245000 | 2.81e-03 |
| Signaling by NOTCH2 | 32 | 1.65e-02 | -0.245000 | 3.37e-02 |
| G beta:gamma signalling through PI3Kgamma | 21 | 5.25e-02 | -0.244000 | 9.15e-02 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 45 | 4.55e-03 | 0.244000 | 1.09e-02 |
| ERBB2 Regulates Cell Motility | 14 | 1.14e-01 | -0.244000 | 1.76e-01 |
| Degradation of the extracellular matrix | 94 | 4.30e-05 | -0.244000 | 1.72e-04 |
| Mitochondrial Fatty Acid Beta-Oxidation | 34 | 1.39e-02 | 0.244000 | 2.90e-02 |
| Signaling by ERBB4 | 52 | 2.45e-03 | -0.243000 | 6.38e-03 |
| Unblocking of NMDA receptors, glutamate binding and activation | 18 | 7.48e-02 | -0.243000 | 1.25e-01 |
| Translesion synthesis by POLK | 17 | 8.34e-02 | 0.242000 | 1.37e-01 |
| Resolution of D-Loop Structures | 33 | 1.61e-02 | 0.242000 | 3.30e-02 |
| MAP2K and MAPK activation | 37 | 1.12e-02 | -0.241000 | 2.40e-02 |
| Signaling by FGFR3 in disease | 20 | 6.26e-02 | -0.240000 | 1.07e-01 |
| Signaling by FGFR3 point mutants in cancer | 20 | 6.26e-02 | -0.240000 | 1.07e-01 |
| PIP3 activates AKT signaling | 256 | 3.63e-11 | -0.240000 | 4.92e-10 |
| FGFRL1 modulation of FGFR1 signaling | 12 | 1.51e-01 | -0.239000 | 2.23e-01 |
| G beta:gamma signalling through CDC42 | 16 | 9.74e-02 | -0.239000 | 1.55e-01 |
| ADP signalling through P2Y purinoceptor 12 | 17 | 8.80e-02 | -0.239000 | 1.42e-01 |
| Negative regulation of FGFR1 signaling | 30 | 2.35e-02 | -0.239000 | 4.57e-02 |
| Regulation of TP53 Degradation | 35 | 1.47e-02 | -0.238000 | 3.05e-02 |
| Negative regulators of DDX58/IFIH1 signaling | 35 | 1.52e-02 | -0.237000 | 3.15e-02 |
| Negative regulation of FGFR3 signaling | 27 | 3.32e-02 | -0.237000 | 6.09e-02 |
| Signaling by NOTCH3 | 46 | 5.52e-03 | -0.236000 | 1.29e-02 |
| Hh mutants are degraded by ERAD | 54 | 2.66e-03 | 0.236000 | 6.87e-03 |
| Downstream signaling of activated FGFR2 | 27 | 3.41e-02 | -0.236000 | 6.25e-02 |
| Signaling by WNT | 277 | 1.44e-11 | -0.235000 | 2.16e-10 |
| FRS-mediated FGFR1 signaling | 21 | 6.24e-02 | -0.235000 | 1.07e-01 |
| Kinesins | 39 | 1.15e-02 | -0.234000 | 2.44e-02 |
| Anti-inflammatory response favouring Leishmania parasite infection | 108 | 2.71e-05 | -0.234000 | 1.16e-04 |
| Leishmania parasite growth and survival | 108 | 2.71e-05 | -0.234000 | 1.16e-04 |
| Signaling by Nuclear Receptors | 240 | 4.50e-10 | -0.233000 | 5.04e-09 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 13 | 1.46e-01 | -0.233000 | 2.17e-01 |
| Phase 4 - resting membrane potential | 16 | 1.07e-01 | -0.233000 | 1.69e-01 |
| SUMOylation | 170 | 1.63e-07 | -0.233000 | 1.22e-06 |
| APC/C-mediated degradation of cell cycle proteins | 86 | 1.99e-04 | 0.232000 | 7.01e-04 |
| Regulation of mitotic cell cycle | 86 | 1.99e-04 | 0.232000 | 7.01e-04 |
| PRC2 methylates histones and DNA | 35 | 1.76e-02 | 0.232000 | 3.55e-02 |
| RNA Polymerase II Transcription Termination | 65 | 1.24e-03 | 0.232000 | 3.52e-03 |
| Removal of the Flap Intermediate | 14 | 1.34e-01 | 0.231000 | 2.02e-01 |
| Adaptive Immune System | 649 | 6.04e-24 | -0.231000 | 3.44e-22 |
| Condensation of Prophase Chromosomes | 35 | 1.79e-02 | 0.231000 | 3.61e-02 |
| FRS-mediated FGFR3 signaling | 18 | 8.97e-02 | -0.231000 | 1.44e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 49 | 5.23e-03 | -0.231000 | 1.23e-02 |
| Nuclear events stimulated by ALK signaling in cancer | 19 | 8.27e-02 | -0.230000 | 1.36e-01 |
| NOD1/2 Signaling Pathway | 31 | 2.71e-02 | -0.229000 | 5.14e-02 |
| Peptide hormone metabolism | 69 | 1.07e-03 | -0.228000 | 3.10e-03 |
| Downstream signaling of activated FGFR4 | 24 | 5.52e-02 | -0.226000 | 9.56e-02 |
| Degradation of DVL | 55 | 3.73e-03 | 0.226000 | 9.31e-03 |
| p53-Dependent G1 DNA Damage Response | 62 | 2.17e-03 | 0.225000 | 5.74e-03 |
| p53-Dependent G1/S DNA damage checkpoint | 62 | 2.17e-03 | 0.225000 | 5.74e-03 |
| PI-3K cascade:FGFR2 | 20 | 8.15e-02 | -0.225000 | 1.34e-01 |
| SIRT1 negatively regulates rRNA expression | 30 | 3.31e-02 | 0.225000 | 6.09e-02 |
| Metabolism of amino acids and derivatives | 341 | 9.19e-13 | 0.225000 | 1.68e-11 |
| Transport of vitamins, nucleosides, and related molecules | 35 | 2.15e-02 | -0.225000 | 4.24e-02 |
| SUMOylation of DNA replication proteins | 46 | 8.50e-03 | -0.224000 | 1.88e-02 |
| Glycogen metabolism | 26 | 4.80e-02 | -0.224000 | 8.43e-02 |
| RHOBTB2 GTPase cycle | 23 | 6.32e-02 | -0.224000 | 1.07e-01 |
| Diseases of glycosylation | 131 | 9.71e-06 | -0.224000 | 4.63e-05 |
| RAS processing | 19 | 9.27e-02 | -0.223000 | 1.49e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 79 | 6.18e-04 | 0.223000 | 1.93e-03 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 1.03e-01 | 0.222000 | 1.62e-01 |
| Protein ubiquitination | 73 | 1.05e-03 | -0.222000 | 3.04e-03 |
| Regulation of ornithine decarboxylase (ODC) | 49 | 7.28e-03 | 0.222000 | 1.66e-02 |
| SUMO E3 ligases SUMOylate target proteins | 164 | 9.64e-07 | -0.222000 | 6.07e-06 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 3.02e-02 | 0.221000 | 5.63e-02 |
| G1/S DNA Damage Checkpoints | 64 | 2.20e-03 | 0.221000 | 5.80e-03 |
| MTOR signalling | 40 | 1.55e-02 | -0.221000 | 3.19e-02 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 4.32e-02 | -0.221000 | 7.67e-02 |
| RNA Polymerase I Promoter Escape | 53 | 5.49e-03 | 0.220000 | 1.29e-02 |
| Neuronal System | 331 | 5.79e-12 | -0.220000 | 9.01e-11 |
| ROS sensing by NFE2L2 | 55 | 4.91e-03 | 0.219000 | 1.17e-02 |
| Signaling by CSF3 (G-CSF) | 30 | 3.85e-02 | -0.218000 | 6.93e-02 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 1.31e-01 | -0.218000 | 1.98e-01 |
| STING mediated induction of host immune responses | 15 | 1.43e-01 | -0.218000 | 2.15e-01 |
| Signaling by Insulin receptor | 73 | 1.27e-03 | -0.218000 | 3.58e-03 |
| SLC transporter disorders | 84 | 5.48e-04 | -0.218000 | 1.74e-03 |
| Regulation of PTEN gene transcription | 61 | 3.38e-03 | -0.217000 | 8.56e-03 |
| Metabolism of steroids | 138 | 1.09e-05 | -0.217000 | 5.07e-05 |
| Polo-like kinase mediated events | 16 | 1.33e-01 | 0.217000 | 2.02e-01 |
| Glycosphingolipid metabolism | 42 | 1.53e-02 | -0.216000 | 3.16e-02 |
| Selective autophagy | 58 | 4.55e-03 | -0.215000 | 1.09e-02 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 1.50e-01 | -0.215000 | 2.22e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 58 | 4.68e-03 | -0.215000 | 1.12e-02 |
| TNFR1-induced NFkappaB signaling pathway | 26 | 5.82e-02 | -0.215000 | 1.00e-01 |
| G alpha (q) signalling events | 157 | 3.53e-06 | -0.214000 | 1.88e-05 |
| Class I MHC mediated antigen processing & presentation | 354 | 4.00e-12 | -0.214000 | 6.58e-11 |
| Inflammasomes | 19 | 1.07e-01 | -0.214000 | 1.68e-01 |
| SUMOylation of RNA binding proteins | 47 | 1.12e-02 | -0.214000 | 2.40e-02 |
| Translation of Structural Proteins | 29 | 4.71e-02 | -0.213000 | 8.28e-02 |
| Signaling by ERBB2 TMD/JMD mutants | 21 | 9.13e-02 | -0.213000 | 1.47e-01 |
| Signaling by ROBO receptors | 210 | 1.13e-07 | 0.212000 | 8.98e-07 |
| Antigen processing: Ubiquitination & Proteasome degradation | 292 | 4.38e-10 | -0.212000 | 4.94e-09 |
| MAPK1/MAPK3 signaling | 260 | 5.09e-09 | -0.210000 | 5.08e-08 |
| Activation of ATR in response to replication stress | 37 | 2.73e-02 | 0.210000 | 5.15e-02 |
| PI-3K cascade:FGFR4 | 17 | 1.35e-01 | -0.210000 | 2.03e-01 |
| RAF/MAP kinase cascade | 254 | 8.86e-09 | -0.209000 | 8.67e-08 |
| Reactions specific to the complex N-glycan synthesis pathway | 10 | 2.53e-01 | -0.209000 | 3.48e-01 |
| Transmission across Chemical Synapses | 216 | 1.23e-07 | -0.209000 | 9.74e-07 |
| SCF(Skp2)-mediated degradation of p27/p21 | 60 | 5.41e-03 | 0.208000 | 1.27e-02 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 1.08e-01 | -0.207000 | 1.70e-01 |
| RHOBTB3 ATPase cycle | 10 | 2.57e-01 | -0.207000 | 3.53e-01 |
| Hh mutants abrogate ligand secretion | 57 | 6.87e-03 | 0.207000 | 1.57e-02 |
| SHC-mediated cascade:FGFR1 | 19 | 1.21e-01 | -0.206000 | 1.85e-01 |
| Immune System | 1645 | 1.70e-44 | -0.205000 | 3.15e-42 |
| Cytochrome c-mediated apoptotic response | 13 | 2.00e-01 | -0.205000 | 2.87e-01 |
| Purine salvage | 12 | 2.18e-01 | -0.205000 | 3.07e-01 |
| Degradation of cysteine and homocysteine | 11 | 2.39e-01 | 0.205000 | 3.32e-01 |
| Metabolism of lipids | 661 | 2.49e-19 | -0.204000 | 8.02e-18 |
| NIK–>noncanonical NF-kB signaling | 57 | 7.77e-03 | 0.204000 | 1.74e-02 |
| Meiotic recombination | 46 | 1.72e-02 | 0.203000 | 3.49e-02 |
| IRAK2 mediated activation of TAK1 complex | 10 | 2.67e-01 | -0.203000 | 3.62e-01 |
| Signaling by FGFR in disease | 60 | 6.69e-03 | -0.202000 | 1.53e-02 |
| Chromosome Maintenance | 110 | 2.56e-04 | 0.202000 | 8.84e-04 |
| Synthesis of PA | 33 | 4.51e-02 | -0.202000 | 7.96e-02 |
| CASP8 activity is inhibited | 10 | 2.70e-01 | -0.202000 | 3.63e-01 |
| Dimerization of procaspase-8 | 10 | 2.70e-01 | -0.202000 | 3.63e-01 |
| Regulation by c-FLIP | 10 | 2.70e-01 | -0.202000 | 3.63e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 1.19e-01 | -0.201000 | 1.82e-01 |
| Neurodegenerative Diseases | 20 | 1.19e-01 | -0.201000 | 1.82e-01 |
| MyD88 deficiency (TLR2/4) | 15 | 1.77e-01 | 0.201000 | 2.57e-01 |
| Degradation of AXIN | 53 | 1.12e-02 | 0.201000 | 2.40e-02 |
| SLC-mediated transmembrane transport | 200 | 9.28e-07 | -0.201000 | 5.86e-06 |
| Phospholipase C-mediated cascade; FGFR4 | 12 | 2.28e-01 | 0.201000 | 3.20e-01 |
| Signaling by GPCR | 486 | 2.99e-14 | -0.201000 | 6.42e-13 |
| Triglyceride catabolism | 18 | 1.40e-01 | -0.201000 | 2.11e-01 |
| Sensory processing of sound | 63 | 5.89e-03 | -0.201000 | 1.37e-02 |
| PERK regulates gene expression | 31 | 5.41e-02 | 0.200000 | 9.39e-02 |
| GPCR downstream signalling | 431 | 1.03e-12 | -0.200000 | 1.86e-11 |
| Activation of GABAB receptors | 36 | 3.81e-02 | -0.200000 | 6.88e-02 |
| GABA B receptor activation | 36 | 3.81e-02 | -0.200000 | 6.88e-02 |
| Interaction between L1 and Ankyrins | 26 | 7.87e-02 | -0.199000 | 1.30e-01 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 2.53e-01 | -0.199000 | 3.48e-01 |
| Degradation of GLI2 by the proteasome | 57 | 9.49e-03 | 0.199000 | 2.07e-02 |
| RHO GTPases Activate NADPH Oxidases | 21 | 1.15e-01 | -0.198000 | 1.78e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 15 | 1.84e-01 | -0.198000 | 2.65e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 89 | 1.24e-03 | 0.198000 | 3.53e-03 |
| Pyrimidine salvage | 10 | 2.80e-01 | 0.197000 | 3.75e-01 |
| Pexophagy | 11 | 2.57e-01 | -0.197000 | 3.53e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 82 | 2.02e-03 | -0.197000 | 5.42e-03 |
| mRNA 3’-end processing | 56 | 1.09e-02 | 0.197000 | 2.35e-02 |
| G-protein activation | 18 | 1.49e-01 | -0.196000 | 2.21e-01 |
| Degradation of GLI1 by the proteasome | 57 | 1.04e-02 | 0.196000 | 2.24e-02 |
| SHC-mediated cascade:FGFR3 | 16 | 1.75e-01 | -0.196000 | 2.54e-01 |
| Antimicrobial peptides | 26 | 8.43e-02 | 0.196000 | 1.38e-01 |
| HCMV Infection | 106 | 5.13e-04 | -0.195000 | 1.65e-03 |
| Negative regulation of FGFR2 signaling | 31 | 6.01e-02 | -0.195000 | 1.03e-01 |
| Methylation | 14 | 2.07e-01 | 0.195000 | 2.95e-01 |
| Chemokine receptors bind chemokines | 25 | 9.22e-02 | 0.195000 | 1.48e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.54e-02 | -0.194000 | 3.16e-02 |
| mTORC1-mediated signalling | 24 | 1.00e-01 | -0.194000 | 1.59e-01 |
| Detoxification of Reactive Oxygen Species | 31 | 6.26e-02 | 0.193000 | 1.07e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 1.45e-01 | -0.193000 | 2.17e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 1.45e-01 | -0.193000 | 2.17e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 1.55e-02 | -0.192000 | 3.19e-02 |
| BBSome-mediated cargo-targeting to cilium | 21 | 1.28e-01 | -0.192000 | 1.94e-01 |
| Regulation of IFNG signaling | 13 | 2.31e-01 | -0.192000 | 3.23e-01 |
| Nuclear signaling by ERBB4 | 27 | 8.49e-02 | -0.192000 | 1.38e-01 |
| HDR through Homologous Recombination (HRR) | 66 | 7.28e-03 | 0.191000 | 1.66e-02 |
| Basigin interactions | 23 | 1.14e-01 | -0.190000 | 1.76e-01 |
| G1/S-Specific Transcription | 29 | 7.62e-02 | 0.190000 | 1.26e-01 |
| RHO GTPase Effectors | 257 | 1.55e-07 | -0.190000 | 1.17e-06 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 13 | 2.36e-01 | 0.190000 | 3.29e-01 |
| Cell recruitment (pro-inflammatory response) | 23 | 1.15e-01 | -0.190000 | 1.78e-01 |
| Purinergic signaling in leishmaniasis infection | 23 | 1.15e-01 | -0.190000 | 1.78e-01 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 11 | 2.76e-01 | -0.190000 | 3.71e-01 |
| Protein methylation | 15 | 2.04e-01 | -0.190000 | 2.92e-01 |
| p38MAPK events | 13 | 2.38e-01 | -0.189000 | 3.31e-01 |
| Defective GALNT3 causes HFTC | 12 | 2.58e-01 | 0.188000 | 3.53e-01 |
| Peroxisomal protein import | 59 | 1.24e-02 | -0.188000 | 2.63e-02 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 33 | 6.15e-02 | -0.188000 | 1.06e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 59 | 1.27e-02 | 0.188000 | 2.67e-02 |
| HCMV Early Events | 82 | 3.35e-03 | -0.187000 | 8.50e-03 |
| Telomere Maintenance | 85 | 2.87e-03 | 0.187000 | 7.34e-03 |
| Metabolism of cofactors | 19 | 1.60e-01 | 0.186000 | 2.35e-01 |
| mRNA Splicing | 187 | 1.11e-05 | 0.186000 | 5.15e-05 |
| Innate Immune System | 861 | 2.29e-20 | -0.185000 | 7.88e-19 |
| O-glycosylation of TSR domain-containing proteins | 37 | 5.18e-02 | -0.185000 | 9.04e-02 |
| Neutrophil degranulation | 415 | 1.07e-10 | -0.184000 | 1.32e-09 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 76 | 5.44e-03 | -0.184000 | 1.28e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 1.12e-01 | 0.184000 | 1.74e-01 |
| Neurotransmitter release cycle | 47 | 3.00e-02 | -0.183000 | 5.59e-02 |
| Negative regulation of FGFR4 signaling | 28 | 9.45e-02 | -0.183000 | 1.51e-01 |
| NoRC negatively regulates rRNA expression | 68 | 9.31e-03 | 0.182000 | 2.03e-02 |
| Response of Mtb to phagocytosis | 22 | 1.39e-01 | -0.182000 | 2.10e-01 |
| GABA receptor activation | 48 | 2.92e-02 | -0.182000 | 5.47e-02 |
| Sema4D in semaphorin signaling | 24 | 1.23e-01 | -0.182000 | 1.88e-01 |
| Activation of Matrix Metalloproteinases | 26 | 1.09e-01 | -0.181000 | 1.71e-01 |
| G1/S Transition | 131 | 3.41e-04 | 0.181000 | 1.14e-03 |
| G alpha (s) signalling events | 93 | 2.57e-03 | -0.181000 | 6.66e-03 |
| Resolution of Abasic Sites (AP sites) | 38 | 5.39e-02 | 0.181000 | 9.36e-02 |
| Adrenaline,noradrenaline inhibits insulin secretion | 23 | 1.34e-01 | -0.181000 | 2.02e-01 |
| Assembly of the ORC complex at the origin of replication | 31 | 8.18e-02 | 0.181000 | 1.35e-01 |
| Estrogen-dependent gene expression | 109 | 1.14e-03 | -0.180000 | 3.26e-03 |
| p75NTR signals via NF-kB | 16 | 2.12e-01 | -0.180000 | 3.00e-01 |
| Acetylcholine binding and downstream events | 10 | 3.24e-01 | 0.180000 | 4.24e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 10 | 3.24e-01 | 0.180000 | 4.24e-01 |
| Chromatin modifying enzymes | 224 | 3.39e-06 | -0.180000 | 1.81e-05 |
| Chromatin organization | 224 | 3.39e-06 | -0.180000 | 1.81e-05 |
| Termination of translesion DNA synthesis | 32 | 7.86e-02 | 0.180000 | 1.30e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 8.85e-02 | -0.180000 | 1.43e-01 |
| Metabolism of amine-derived hormones | 12 | 2.82e-01 | 0.179000 | 3.77e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 4.28e-02 | 0.179000 | 7.62e-02 |
| Biosynthesis of DHA-derived SPMs | 14 | 2.48e-01 | 0.178000 | 3.43e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 8.69e-02 | -0.178000 | 1.41e-01 |
| Branched-chain amino acid catabolism | 21 | 1.59e-01 | -0.178000 | 2.34e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 1.27e-02 | -0.177000 | 2.67e-02 |
| Amino acid transport across the plasma membrane | 31 | 8.76e-02 | -0.177000 | 1.42e-01 |
| Deubiquitination | 248 | 1.63e-06 | -0.177000 | 9.51e-06 |
| mRNA Splicing - Major Pathway | 179 | 4.61e-05 | 0.176000 | 1.84e-04 |
| Interleukin-37 signaling | 21 | 1.63e-01 | -0.176000 | 2.39e-01 |
| Neurotoxicity of clostridium toxins | 10 | 3.36e-01 | 0.176000 | 4.34e-01 |
| Defective B3GALTL causes PpS | 36 | 6.83e-02 | -0.176000 | 1.15e-01 |
| Regulation of RUNX3 expression and activity | 54 | 2.61e-02 | 0.175000 | 4.97e-02 |
| G2/M Checkpoints | 140 | 3.57e-04 | 0.175000 | 1.19e-03 |
| Signaling by Interleukins | 388 | 3.45e-09 | -0.174000 | 3.55e-08 |
| Mitochondrial tRNA aminoacylation | 21 | 1.66e-01 | -0.174000 | 2.43e-01 |
| Mitotic Prophase | 104 | 2.13e-03 | -0.174000 | 5.66e-03 |
| GLI3 is processed to GLI3R by the proteasome | 57 | 2.34e-02 | 0.174000 | 4.57e-02 |
| Transcriptional regulation of testis differentiation | 11 | 3.19e-01 | -0.174000 | 4.17e-01 |
| Cholesterol biosynthesis | 24 | 1.42e-01 | -0.173000 | 2.12e-01 |
| FRS-mediated FGFR2 signaling | 22 | 1.59e-01 | -0.173000 | 2.35e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 3.44e-01 | -0.173000 | 4.41e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 1.61e-01 | -0.173000 | 2.36e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 53 | 2.98e-02 | -0.173000 | 5.57e-02 |
| Nonhomologous End-Joining (NHEJ) | 43 | 5.04e-02 | -0.172000 | 8.81e-02 |
| Metabolism of polyamines | 57 | 2.47e-02 | 0.172000 | 4.74e-02 |
| Infection with Mycobacterium tuberculosis | 24 | 1.45e-01 | -0.172000 | 2.17e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 12 | 3.05e-01 | 0.171000 | 4.01e-01 |
| Budding and maturation of HIV virion | 28 | 1.19e-01 | -0.170000 | 1.82e-01 |
| Vitamin D (calciferol) metabolism | 10 | 3.51e-01 | -0.170000 | 4.50e-01 |
| tRNA Aminoacylation | 42 | 5.82e-02 | -0.169000 | 1.00e-01 |
| Disease | 1461 | 1.66e-27 | -0.169000 | 1.22e-25 |
| Beta-catenin independent WNT signaling | 138 | 6.38e-04 | -0.168000 | 1.98e-03 |
| ZBP1(DAI) mediated induction of type I IFNs | 19 | 2.04e-01 | -0.168000 | 2.92e-01 |
| Cardiac conduction | 109 | 2.41e-03 | -0.168000 | 6.34e-03 |
| Response of EIF2AK1 (HRI) to heme deficiency | 15 | 2.62e-01 | 0.167000 | 3.55e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 97 | 4.49e-03 | -0.167000 | 1.08e-02 |
| Class B/2 (Secretin family receptors) | 71 | 1.53e-02 | -0.166000 | 3.16e-02 |
| RIP-mediated NFkB activation via ZBP1 | 16 | 2.51e-01 | -0.166000 | 3.47e-01 |
| Cytosolic tRNA aminoacylation | 24 | 1.61e-01 | -0.165000 | 2.36e-01 |
| Developmental Biology | 851 | 2.55e-16 | -0.165000 | 6.19e-15 |
| PD-1 signaling | 18 | 2.29e-01 | 0.164000 | 3.21e-01 |
| tRNA processing | 124 | 1.64e-03 | 0.164000 | 4.49e-03 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 10 | 3.71e-01 | -0.164000 | 4.69e-01 |
| Diseases of hemostasis | 10 | 3.71e-01 | -0.164000 | 4.69e-01 |
| Pentose phosphate pathway | 13 | 3.07e-01 | -0.163000 | 4.03e-01 |
| Post-chaperonin tubulin folding pathway | 20 | 2.07e-01 | 0.163000 | 2.94e-01 |
| Defective CFTR causes cystic fibrosis | 58 | 3.21e-02 | 0.163000 | 5.93e-02 |
| Post-translational protein phosphorylation | 87 | 8.83e-03 | -0.162000 | 1.93e-02 |
| Collagen formation | 83 | 1.10e-02 | -0.161000 | 2.36e-02 |
| Negative epigenetic regulation of rRNA expression | 71 | 1.88e-02 | 0.161000 | 3.77e-02 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 92 | 7.56e-03 | -0.161000 | 1.71e-02 |
| Unfolded Protein Response (UPR) | 90 | 8.54e-03 | -0.160000 | 1.88e-02 |
| Signaling by EGFR in Cancer | 25 | 1.66e-01 | -0.160000 | 2.42e-01 |
| Nuclear Envelope (NE) Reassembly | 73 | 1.83e-02 | -0.160000 | 3.68e-02 |
| Nervous system development | 524 | 3.70e-10 | -0.160000 | 4.27e-09 |
| Oncogene Induced Senescence | 31 | 1.25e-01 | -0.159000 | 1.91e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 16 | 2.70e-01 | -0.159000 | 3.64e-01 |
| Cytokine Signaling in Immune system | 605 | 2.12e-11 | -0.159000 | 3.05e-10 |
| Inhibition of DNA recombination at telomere | 40 | 8.32e-02 | 0.158000 | 1.37e-01 |
| Voltage gated Potassium channels | 33 | 1.16e-01 | -0.158000 | 1.79e-01 |
| Purine catabolism | 17 | 2.60e-01 | 0.158000 | 3.53e-01 |
| Defective C1GALT1C1 causes TNPS | 13 | 3.26e-01 | 0.157000 | 4.25e-01 |
| Regulation of TP53 Activity | 155 | 7.20e-04 | -0.157000 | 2.20e-03 |
| Fc epsilon receptor (FCERI) signaling | 128 | 2.12e-03 | -0.157000 | 5.65e-03 |
| Viral Messenger RNA Synthesis | 44 | 7.15e-02 | -0.157000 | 1.20e-01 |
| The phototransduction cascade | 27 | 1.59e-01 | -0.156000 | 2.35e-01 |
| Transcriptional regulation by RUNX3 | 94 | 8.71e-03 | -0.156000 | 1.91e-02 |
| Telomere C-strand synthesis initiation | 13 | 3.29e-01 | -0.156000 | 4.28e-01 |
| Hedgehog ligand biogenesis | 63 | 3.18e-02 | 0.156000 | 5.88e-02 |
| Metabolism of RNA | 677 | 4.23e-12 | 0.156000 | 6.88e-11 |
| Phosphorylation of CD3 and TCR zeta chains | 17 | 2.66e-01 | 0.156000 | 3.61e-01 |
| Transport of small molecules | 608 | 4.96e-11 | -0.156000 | 6.49e-10 |
| Removal of the Flap Intermediate from the C-strand | 17 | 2.68e-01 | -0.155000 | 3.62e-01 |
| Base Excision Repair | 64 | 3.22e-02 | 0.155000 | 5.93e-02 |
| Diseases of metabolism | 218 | 8.06e-05 | -0.155000 | 3.05e-04 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 27 | 1.64e-01 | 0.155000 | 2.40e-01 |
| TCF dependent signaling in response to WNT | 187 | 2.61e-04 | -0.155000 | 8.96e-04 |
| Phase II - Conjugation of compounds | 76 | 2.00e-02 | 0.154000 | 3.97e-02 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 2.88e-01 | -0.153000 | 3.83e-01 |
| IRAK4 deficiency (TLR2/4) | 16 | 2.90e-01 | 0.153000 | 3.85e-01 |
| Heme degradation | 12 | 3.62e-01 | 0.152000 | 4.60e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 36 | 1.15e-01 | -0.152000 | 1.78e-01 |
| rRNA modification in the nucleus and cytosol | 60 | 4.21e-02 | 0.152000 | 7.52e-02 |
| Plasma lipoprotein assembly | 13 | 3.44e-01 | 0.152000 | 4.41e-01 |
| FRS-mediated FGFR4 signaling | 19 | 2.53e-01 | -0.151000 | 3.48e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 26 | 1.83e-01 | -0.151000 | 2.65e-01 |
| UCH proteinases | 92 | 1.26e-02 | 0.150000 | 2.67e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 38 | 1.10e-01 | 0.150000 | 1.73e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 3.87e-02 | 0.149000 | 6.95e-02 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 3.06e-01 | -0.148000 | 4.02e-01 |
| FGFR2 alternative splicing | 25 | 2.03e-01 | 0.147000 | 2.91e-01 |
| Visual phototransduction | 73 | 2.99e-02 | -0.147000 | 5.58e-02 |
| Deadenylation-dependent mRNA decay | 53 | 6.55e-02 | -0.146000 | 1.11e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 25 | 2.06e-01 | -0.146000 | 2.94e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 3.28e-01 | -0.146000 | 4.27e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 3.28e-01 | -0.146000 | 4.27e-01 |
| Scavenging by Class A Receptors | 17 | 2.98e-01 | 0.146000 | 3.94e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 1.99e-01 | 0.145000 | 2.86e-01 |
| Signaling by FGFR | 80 | 2.46e-02 | -0.145000 | 4.72e-02 |
| Regulation of TP53 Activity through Methylation | 19 | 2.75e-01 | 0.145000 | 3.70e-01 |
| FGFR4 ligand binding and activation | 11 | 4.06e-01 | 0.145000 | 5.03e-01 |
| TNFR2 non-canonical NF-kB pathway | 91 | 1.73e-02 | 0.144000 | 3.51e-02 |
| Activation of kainate receptors upon glutamate binding | 24 | 2.22e-01 | -0.144000 | 3.11e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 2.90e-01 | -0.144000 | 3.86e-01 |
| Glycerophospholipid biosynthesis | 116 | 7.46e-03 | -0.144000 | 1.69e-02 |
| Transcriptional regulation of pluripotent stem cells | 30 | 1.74e-01 | -0.143000 | 2.53e-01 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 4.33e-01 | 0.143000 | 5.28e-01 |
| Phenylalanine and tyrosine metabolism | 10 | 4.33e-01 | 0.143000 | 5.28e-01 |
| RNA Polymerase I Promoter Clearance | 72 | 3.57e-02 | 0.143000 | 6.49e-02 |
| RNA Polymerase I Transcription | 72 | 3.57e-02 | 0.143000 | 6.49e-02 |
| Formation of the beta-catenin:TCF transactivating complex | 53 | 7.15e-02 | -0.143000 | 1.20e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 34 | 1.49e-01 | -0.143000 | 2.21e-01 |
| Sema4D induced cell migration and growth-cone collapse | 20 | 2.69e-01 | -0.143000 | 3.63e-01 |
| G alpha (i) signalling events | 199 | 5.22e-04 | -0.143000 | 1.67e-03 |
| Axon guidance | 502 | 4.28e-08 | -0.143000 | 3.70e-07 |
| Late Phase of HIV Life Cycle | 135 | 4.27e-03 | -0.142000 | 1.04e-02 |
| Tight junction interactions | 22 | 2.48e-01 | -0.142000 | 3.43e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 12 | 3.99e-01 | -0.141000 | 4.97e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 2.53e-01 | -0.141000 | 3.48e-01 |
| IRF3-mediated induction of type I IFN | 12 | 4.00e-01 | -0.140000 | 4.97e-01 |
| HCMV Late Events | 78 | 3.23e-02 | -0.140000 | 5.95e-02 |
| Programmed Cell Death | 195 | 7.38e-04 | -0.140000 | 2.25e-03 |
| Regulation of FZD by ubiquitination | 21 | 2.68e-01 | -0.140000 | 3.63e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 18 | 3.06e-01 | 0.139000 | 4.02e-01 |
| SHC-mediated cascade:FGFR2 | 20 | 2.81e-01 | -0.139000 | 3.76e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 3.84e-01 | -0.139000 | 4.84e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 13 | 3.88e-01 | 0.138000 | 4.86e-01 |
| Metabolism of proteins | 1745 | 4.58e-22 | -0.138000 | 2.26e-20 |
| Synthesis of bile acids and bile salts | 30 | 1.93e-01 | -0.137000 | 2.77e-01 |
| Metabolism of non-coding RNA | 53 | 8.37e-02 | -0.137000 | 1.37e-01 |
| snRNP Assembly | 53 | 8.37e-02 | -0.137000 | 1.37e-01 |
| Regulation of RUNX2 expression and activity | 70 | 4.71e-02 | 0.137000 | 8.28e-02 |
| IL-6-type cytokine receptor ligand interactions | 16 | 3.43e-01 | -0.137000 | 4.41e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 18 | 3.20e-01 | -0.135000 | 4.18e-01 |
| HIV Life Cycle | 147 | 4.65e-03 | -0.135000 | 1.11e-02 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 6.18e-02 | 0.135000 | 1.06e-01 |
| Cleavage of the damaged purine | 29 | 2.10e-01 | 0.135000 | 2.97e-01 |
| Depurination | 29 | 2.10e-01 | 0.135000 | 2.97e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 29 | 2.10e-01 | 0.135000 | 2.97e-01 |
| Pyruvate metabolism | 28 | 2.18e-01 | -0.134000 | 3.07e-01 |
| Dual incision in TC-NER | 65 | 6.25e-02 | 0.134000 | 1.07e-01 |
| RNA Polymerase I Transcription Termination | 30 | 2.06e-01 | 0.133000 | 2.94e-01 |
| Interferon Signaling | 174 | 2.49e-03 | -0.133000 | 6.49e-03 |
| Peroxisomal lipid metabolism | 27 | 2.32e-01 | -0.133000 | 3.25e-01 |
| Mitotic G1 phase and G1/S transition | 147 | 5.67e-03 | 0.132000 | 1.32e-02 |
| Activation of SMO | 18 | 3.35e-01 | -0.131000 | 4.34e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 26 | 2.47e-01 | -0.131000 | 3.42e-01 |
| S Phase | 160 | 4.57e-03 | 0.130000 | 1.09e-02 |
| cGMP effects | 14 | 4.02e-01 | -0.129000 | 4.99e-01 |
| Pre-NOTCH Expression and Processing | 71 | 5.93e-02 | -0.129000 | 1.02e-01 |
| Presynaptic depolarization and calcium channel opening | 11 | 4.58e-01 | 0.129000 | 5.52e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 3.57e-01 | -0.129000 | 4.55e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 3.57e-01 | -0.129000 | 4.55e-01 |
| Processing of Intronless Pre-mRNAs | 19 | 3.30e-01 | -0.129000 | 4.28e-01 |
| Cytosolic sensors of pathogen-associated DNA | 61 | 8.24e-02 | -0.129000 | 1.36e-01 |
| Hyaluronan metabolism | 14 | 4.05e-01 | -0.128000 | 5.02e-01 |
| Assembly of collagen fibrils and other multimeric structures | 52 | 1.10e-01 | -0.128000 | 1.72e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 105 | 2.35e-02 | 0.128000 | 4.57e-02 |
| Apoptosis | 169 | 4.13e-03 | -0.128000 | 1.01e-02 |
| Signaling by FGFR2 IIIa TM | 19 | 3.35e-01 | 0.128000 | 4.34e-01 |
| Regulation of HMOX1 expression and activity | 63 | 8.05e-02 | 0.127000 | 1.33e-01 |
| Gluconeogenesis | 29 | 2.36e-01 | -0.127000 | 3.29e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 4.12e-01 | -0.127000 | 5.09e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 3.97e-01 | -0.126000 | 4.96e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 15 | 4.00e-01 | -0.125000 | 4.98e-01 |
| ABC transporter disorders | 73 | 6.45e-02 | 0.125000 | 1.09e-01 |
| Cyclin D associated events in G1 | 45 | 1.47e-01 | -0.125000 | 2.19e-01 |
| G1 Phase | 45 | 1.47e-01 | -0.125000 | 2.19e-01 |
| Dual Incision in GG-NER | 41 | 1.67e-01 | 0.125000 | 2.44e-01 |
| Muscle contraction | 164 | 5.87e-03 | -0.125000 | 1.36e-02 |
| Base-Excision Repair, AP Site Formation | 36 | 1.98e-01 | 0.124000 | 2.84e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 25 | 2.83e-01 | 0.124000 | 3.78e-01 |
| Triglyceride metabolism | 28 | 2.58e-01 | -0.123000 | 3.53e-01 |
| Arachidonic acid metabolism | 44 | 1.58e-01 | 0.123000 | 2.34e-01 |
| Generic Transcription Pathway | 1126 | 2.84e-12 | -0.123000 | 4.82e-11 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 2.44e-01 | 0.123000 | 3.39e-01 |
| Chaperonin-mediated protein folding | 83 | 5.34e-02 | -0.123000 | 9.30e-02 |
| Ion channel transport | 152 | 9.72e-03 | -0.121000 | 2.11e-02 |
| Neddylation | 222 | 1.83e-03 | -0.121000 | 4.93e-03 |
| Cyclin E associated events during G1/S transition | 83 | 5.73e-02 | 0.121000 | 9.91e-02 |
| Asymmetric localization of PCP proteins | 62 | 1.01e-01 | 0.121000 | 1.60e-01 |
| Common Pathway of Fibrin Clot Formation | 15 | 4.23e-01 | -0.120000 | 5.19e-01 |
| Regulation of gene expression in beta cells | 14 | 4.38e-01 | -0.120000 | 5.32e-01 |
| TNF signaling | 44 | 1.71e-01 | -0.119000 | 2.49e-01 |
| ER-Phagosome pathway | 87 | 5.45e-02 | 0.119000 | 9.45e-02 |
| Gene expression (Transcription) | 1379 | 8.57e-14 | -0.119000 | 1.74e-12 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 15 | 4.28e-01 | 0.118000 | 5.25e-01 |
| Homology Directed Repair | 111 | 3.16e-02 | 0.118000 | 5.84e-02 |
| Nitric oxide stimulates guanylate cyclase | 18 | 3.87e-01 | -0.118000 | 4.86e-01 |
| PTEN Regulation | 140 | 1.69e-02 | -0.117000 | 3.44e-02 |
| Extension of Telomeres | 51 | 1.50e-01 | 0.117000 | 2.22e-01 |
| Sensory Perception | 181 | 7.27e-03 | -0.116000 | 1.66e-02 |
| DNA Damage Recognition in GG-NER | 38 | 2.18e-01 | 0.115000 | 3.07e-01 |
| Ub-specific processing proteases | 177 | 8.15e-03 | -0.115000 | 1.81e-02 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 4.42e-01 | -0.115000 | 5.35e-01 |
| Synthesis of PC | 27 | 3.04e-01 | -0.114000 | 4.01e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 238 | 2.42e-03 | 0.114000 | 6.35e-03 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 3.07e-01 | 0.114000 | 4.02e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 3.07e-01 | 0.114000 | 4.02e-01 |
| Signaling by the B Cell Receptor (BCR) | 106 | 4.32e-02 | -0.114000 | 7.67e-02 |
| FGFR2 mutant receptor activation | 30 | 2.82e-01 | 0.113000 | 3.77e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 13 | 4.79e-01 | -0.113000 | 5.75e-01 |
| E2F mediated regulation of DNA replication | 22 | 3.60e-01 | 0.113000 | 4.59e-01 |
| Dopamine Neurotransmitter Release Cycle | 22 | 3.60e-01 | -0.113000 | 4.59e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 4.36e-01 | 0.113000 | 5.31e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 20 | 3.84e-01 | -0.112000 | 4.84e-01 |
| Cell Cycle Checkpoints | 260 | 1.94e-03 | 0.112000 | 5.20e-03 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 2.47e-01 | 0.111000 | 3.42e-01 |
| Signaling by NOTCH | 194 | 7.72e-03 | -0.111000 | 1.74e-02 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 5.27e-01 | -0.110000 | 6.15e-01 |
| RNA Polymerase II Transcription | 1244 | 5.24e-11 | -0.110000 | 6.80e-10 |
| Surfactant metabolism | 20 | 3.96e-01 | -0.110000 | 4.95e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 5.11e-01 | -0.110000 | 6.01e-01 |
| SHC-mediated cascade:FGFR4 | 17 | 4.37e-01 | -0.109000 | 5.31e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 4.39e-01 | 0.109000 | 5.32e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 85 | 8.49e-02 | 0.108000 | 1.38e-01 |
| Diseases associated with O-glycosylation of proteins | 62 | 1.42e-01 | -0.108000 | 2.13e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 1.01e-01 | 0.107000 | 1.60e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 3.35e-01 | 0.107000 | 4.34e-01 |
| Defective Intrinsic Pathway for Apoptosis | 22 | 3.86e-01 | -0.107000 | 4.85e-01 |
| Apoptosis induced DNA fragmentation | 12 | 5.23e-01 | 0.107000 | 6.11e-01 |
| Tryptophan catabolism | 13 | 5.07e-01 | 0.106000 | 5.99e-01 |
| Homologous DNA Pairing and Strand Exchange | 42 | 2.33e-01 | 0.106000 | 3.26e-01 |
| Infectious disease | 740 | 8.00e-07 | -0.106000 | 5.10e-06 |
| Diseases of programmed cell death | 62 | 1.48e-01 | 0.106000 | 2.21e-01 |
| Activation of NF-kappaB in B cells | 65 | 1.41e-01 | 0.106000 | 2.11e-01 |
| Packaging Of Telomere Ends | 25 | 3.61e-01 | 0.105000 | 4.60e-01 |
| Biological oxidations | 157 | 2.26e-02 | 0.105000 | 4.44e-02 |
| Stimuli-sensing channels | 84 | 9.56e-02 | -0.105000 | 1.53e-01 |
| RHO GTPases Activate Formins | 118 | 4.96e-02 | -0.105000 | 8.68e-02 |
| Metabolism of vitamins and cofactors | 171 | 1.86e-02 | -0.104000 | 3.73e-02 |
| Formation of apoptosome | 11 | 5.50e-01 | -0.104000 | 6.37e-01 |
| Regulation of the apoptosome activity | 11 | 5.50e-01 | -0.104000 | 6.37e-01 |
| Smooth Muscle Contraction | 34 | 2.94e-01 | -0.104000 | 3.90e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 13 | 5.17e-01 | -0.104000 | 6.07e-01 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 11 | 5.52e-01 | 0.103000 | 6.39e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 15 | 4.88e-01 | -0.103000 | 5.83e-01 |
| Phospholipase C-mediated cascade; FGFR3 | 11 | 5.56e-01 | 0.103000 | 6.41e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 29 | 3.39e-01 | -0.103000 | 4.38e-01 |
| Cleavage of the damaged pyrimidine | 34 | 3.05e-01 | 0.102000 | 4.01e-01 |
| Depyrimidination | 34 | 3.05e-01 | 0.102000 | 4.01e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 34 | 3.05e-01 | 0.102000 | 4.01e-01 |
| Glutamate Neurotransmitter Release Cycle | 23 | 4.00e-01 | -0.101000 | 4.97e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 1.02e-01 | 0.101000 | 1.61e-01 |
| Hedgehog ‘on’ state | 84 | 1.11e-01 | 0.100000 | 1.74e-01 |
| Pyroptosis | 24 | 3.98e-01 | -0.099700 | 4.97e-01 |
| G beta:gamma signalling through BTK | 14 | 5.19e-01 | -0.099500 | 6.08e-01 |
| Regulated Necrosis | 51 | 2.21e-01 | -0.099100 | 3.10e-01 |
| Cellular response to chemical stress | 150 | 3.65e-02 | 0.098900 | 6.60e-02 |
| Mitochondrial calcium ion transport | 22 | 4.22e-01 | -0.098900 | 5.19e-01 |
| RIPK1-mediated regulated necrosis | 27 | 3.76e-01 | -0.098500 | 4.74e-01 |
| Regulation of necroptotic cell death | 27 | 3.76e-01 | -0.098500 | 4.74e-01 |
| Phospholipase C-mediated cascade; FGFR2 | 15 | 5.09e-01 | 0.098400 | 6.00e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 48 | 2.39e-01 | -0.098200 | 3.32e-01 |
| B-WICH complex positively regulates rRNA expression | 53 | 2.17e-01 | 0.097900 | 3.07e-01 |
| Aggrephagy | 21 | 4.37e-01 | 0.097900 | 5.31e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 23 | 4.23e-01 | -0.096400 | 5.20e-01 |
| Fertilization | 16 | 5.05e-01 | 0.096300 | 5.97e-01 |
| FGFR2 ligand binding and activation | 15 | 5.21e-01 | 0.095700 | 6.10e-01 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 12 | 5.67e-01 | 0.095400 | 6.52e-01 |
| RHO GTPases activate PKNs | 53 | 2.30e-01 | -0.095300 | 3.22e-01 |
| Formation of the Early Elongation Complex | 33 | 3.44e-01 | 0.095200 | 4.41e-01 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 3.44e-01 | 0.095200 | 4.41e-01 |
| Dectin-2 family | 18 | 4.85e-01 | 0.095100 | 5.80e-01 |
| HIV Transcription Initiation | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
| RNA Polymerase II HIV Promoter Escape | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
| RNA Polymerase II Promoter Escape | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
| RNA Polymerase II Transcription Initiation | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
| Separation of Sister Chromatids | 168 | 3.51e-02 | 0.094200 | 6.41e-02 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 1.36e-01 | 0.094000 | 2.05e-01 |
| Mitochondrial biogenesis | 91 | 1.21e-01 | -0.093900 | 1.86e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 5.09e-01 | 0.092600 | 6.00e-01 |
| GABA synthesis, release, reuptake and degradation | 18 | 4.97e-01 | -0.092500 | 5.91e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 72 | 1.77e-01 | 0.092000 | 2.57e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 30 | 3.83e-01 | 0.092000 | 4.83e-01 |
| Collagen biosynthesis and modifying enzymes | 61 | 2.14e-01 | -0.091900 | 3.03e-01 |
| Pre-NOTCH Transcription and Translation | 55 | 2.40e-01 | -0.091500 | 3.33e-01 |
| Inactivation of CSF3 (G-CSF) signaling | 25 | 4.29e-01 | -0.091400 | 5.25e-01 |
| RNA polymerase II transcribes snRNA genes | 71 | 1.84e-01 | -0.091200 | 2.65e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 3.62e-01 | 0.090300 | 4.60e-01 |
| TRAF6 mediated NF-kB activation | 23 | 4.55e-01 | -0.090000 | 5.50e-01 |
| Maturation of nucleoprotein | 11 | 6.06e-01 | -0.089800 | 6.86e-01 |
| Metabolism of porphyrins | 23 | 4.57e-01 | 0.089700 | 5.51e-01 |
| Translesion Synthesis by POLH | 18 | 5.11e-01 | 0.089500 | 6.01e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 6.07e-01 | -0.089500 | 6.87e-01 |
| Metabolism of water-soluble vitamins and cofactors | 117 | 9.51e-02 | -0.089300 | 1.52e-01 |
| Signaling by FGFR2 | 67 | 2.07e-01 | -0.089000 | 2.95e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 5.02e-01 | 0.089000 | 5.95e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 6.11e-01 | 0.088600 | 6.89e-01 |
| ROS and RNS production in phagocytes | 32 | 3.86e-01 | 0.088500 | 4.85e-01 |
| Complement cascade | 37 | 3.52e-01 | 0.088400 | 4.50e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.41e-01 | 0.088100 | 4.40e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 56 | 2.54e-01 | -0.088000 | 3.49e-01 |
| Cytosolic sulfonation of small molecules | 21 | 4.88e-01 | -0.087500 | 5.82e-01 |
| Formation of TC-NER Pre-Incision Complex | 53 | 2.73e-01 | 0.087000 | 3.67e-01 |
| HIV Infection | 223 | 2.58e-02 | -0.086600 | 4.92e-02 |
| Late endosomal microautophagy | 30 | 4.12e-01 | -0.086500 | 5.09e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 5.18e-01 | -0.085700 | 6.07e-01 |
| Cellular Senescence | 153 | 6.85e-02 | -0.085300 | 1.15e-01 |
| Transcriptional regulation of granulopoiesis | 52 | 2.93e-01 | -0.084300 | 3.89e-01 |
| Nucleotide Excision Repair | 110 | 1.27e-01 | 0.084200 | 1.93e-01 |
| Interconversion of nucleotide di- and triphosphates | 29 | 4.32e-01 | 0.084200 | 5.28e-01 |
| Potassium Channels | 83 | 1.86e-01 | -0.084000 | 2.67e-01 |
| Acyl chain remodelling of PI | 13 | 6.05e-01 | -0.083000 | 6.86e-01 |
| Negative regulation of FLT3 | 14 | 5.93e-01 | -0.082600 | 6.76e-01 |
| NGF-stimulated transcription | 40 | 3.69e-01 | -0.082100 | 4.68e-01 |
| Processing of DNA double-strand break ends | 72 | 2.29e-01 | 0.082000 | 3.21e-01 |
| Intraflagellar transport | 39 | 3.77e-01 | 0.081800 | 4.75e-01 |
| G0 and Early G1 | 27 | 4.63e-01 | 0.081700 | 5.56e-01 |
| IKK complex recruitment mediated by RIP1 | 22 | 5.08e-01 | -0.081500 | 6.00e-01 |
| G beta:gamma signalling through PLC beta | 15 | 5.85e-01 | -0.081400 | 6.69e-01 |
| Presynaptic function of Kainate receptors | 15 | 5.85e-01 | -0.081400 | 6.69e-01 |
| Regulation of Complement cascade | 29 | 4.51e-01 | 0.080900 | 5.45e-01 |
| Aspartate and asparagine metabolism | 10 | 6.59e-01 | 0.080500 | 7.33e-01 |
| Cytoprotection by HMOX1 | 120 | 1.29e-01 | 0.080300 | 1.95e-01 |
| TRP channels | 18 | 5.56e-01 | -0.080200 | 6.41e-01 |
| Formation of RNA Pol II elongation complex | 57 | 2.96e-01 | -0.080000 | 3.92e-01 |
| RNA Polymerase II Transcription Elongation | 57 | 2.96e-01 | -0.080000 | 3.92e-01 |
| Plasma lipoprotein clearance | 29 | 4.58e-01 | -0.079700 | 5.52e-01 |
| Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
| Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
| Diseases of DNA Double-Strand Break Repair | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 51 | 3.29e-01 | -0.079000 | 4.28e-01 |
| Antigen processing-Cross presentation | 98 | 1.78e-01 | 0.078700 | 2.58e-01 |
| Downregulation of ERBB2 signaling | 28 | 4.72e-01 | -0.078600 | 5.67e-01 |
| RA biosynthesis pathway | 17 | 5.78e-01 | 0.077900 | 6.64e-01 |
| Interleukin-12 family signaling | 51 | 3.40e-01 | -0.077200 | 4.39e-01 |
| Diseases of mitotic cell cycle | 38 | 4.24e-01 | 0.074900 | 5.20e-01 |
| NF-kB is activated and signals survival | 13 | 6.40e-01 | -0.074800 | 7.17e-01 |
| Cellular hexose transport | 17 | 5.94e-01 | 0.074700 | 6.77e-01 |
| Termination of O-glycan biosynthesis | 19 | 5.74e-01 | -0.074500 | 6.60e-01 |
| Gene Silencing by RNA | 97 | 2.06e-01 | -0.074300 | 2.94e-01 |
| Killing mechanisms | 11 | 6.70e-01 | -0.074100 | 7.41e-01 |
| WNT5:FZD7-mediated leishmania damping | 11 | 6.70e-01 | -0.074100 | 7.41e-01 |
| Regulation of RAS by GAPs | 64 | 3.05e-01 | 0.074100 | 4.01e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 5.22e-01 | -0.073900 | 6.11e-01 |
| Transcriptional Regulation by TP53 | 356 | 1.74e-02 | -0.073300 | 3.51e-02 |
| Acetylcholine Neurotransmitter Release Cycle | 15 | 6.23e-01 | -0.073300 | 7.01e-01 |
| Collagen chain trimerization | 39 | 4.29e-01 | -0.073200 | 5.25e-01 |
| Butyrophilin (BTN) family interactions | 10 | 6.91e-01 | 0.072700 | 7.60e-01 |
| Apoptotic factor-mediated response | 19 | 5.88e-01 | -0.071800 | 6.72e-01 |
| Striated Muscle Contraction | 27 | 5.20e-01 | 0.071500 | 6.09e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 6.98e-01 | -0.070800 | 7.64e-01 |
| p75NTR recruits signalling complexes | 13 | 6.61e-01 | -0.070300 | 7.33e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.16e-01 | 0.070300 | 6.94e-01 |
| RNA Polymerase II Pre-transcription Events | 80 | 2.78e-01 | -0.070100 | 3.73e-01 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | 20 | 5.89e-01 | -0.069800 | 6.73e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 4.59e-01 | 0.069400 | 5.53e-01 |
| C-type lectin receptors (CLRs) | 128 | 1.76e-01 | -0.069300 | 2.55e-01 |
| Mitotic G2-G2/M phases | 183 | 1.12e-01 | 0.068100 | 1.74e-01 |
| Advanced glycosylation endproduct receptor signaling | 11 | 6.96e-01 | -0.068100 | 7.63e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 5.42e-01 | -0.067800 | 6.30e-01 |
| NCAM1 interactions | 35 | 4.88e-01 | -0.067700 | 5.82e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 16 | 6.40e-01 | -0.067500 | 7.17e-01 |
| Transcriptional regulation by RUNX1 | 187 | 1.12e-01 | -0.067300 | 1.75e-01 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 5.81e-01 | 0.066500 | 6.66e-01 |
| HDR through Single Strand Annealing (SSA) | 37 | 4.85e-01 | 0.066300 | 5.80e-01 |
| Mismatch Repair | 15 | 6.57e-01 | -0.066200 | 7.32e-01 |
| Glycogen storage diseases | 14 | 6.69e-01 | 0.066000 | 7.41e-01 |
| mRNA Capping | 29 | 5.39e-01 | 0.065900 | 6.27e-01 |
| ERBB2 Activates PTK6 Signaling | 12 | 6.93e-01 | -0.065800 | 7.62e-01 |
| Protein folding | 89 | 2.85e-01 | -0.065500 | 3.80e-01 |
| G2/M Transition | 181 | 1.28e-01 | 0.065500 | 1.95e-01 |
| Acyl chain remodelling of PC | 22 | 5.95e-01 | 0.065400 | 6.78e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 7.20e-01 | 0.065400 | 7.82e-01 |
| Organelle biogenesis and maintenance | 272 | 6.94e-02 | -0.063900 | 1.17e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 18 | 6.40e-01 | -0.063700 | 7.17e-01 |
| TNFs bind their physiological receptors | 21 | 6.17e-01 | 0.063100 | 6.95e-01 |
| GPCR ligand binding | 273 | 7.36e-02 | -0.062800 | 1.23e-01 |
| Prostacyclin signalling through prostacyclin receptor | 15 | 6.74e-01 | -0.062700 | 7.44e-01 |
| Acyl chain remodelling of PE | 23 | 6.04e-01 | 0.062400 | 6.86e-01 |
| DNA Double Strand Break Response | 52 | 4.37e-01 | -0.062300 | 5.31e-01 |
| Interferon gamma signaling | 80 | 3.37e-01 | -0.062100 | 4.35e-01 |
| HATs acetylate histones | 101 | 2.83e-01 | -0.061800 | 3.78e-01 |
| Serotonin Neurotransmitter Release Cycle | 17 | 6.60e-01 | -0.061600 | 7.33e-01 |
| Nucleotide catabolism | 31 | 5.54e-01 | 0.061400 | 6.40e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 43 | 4.93e-01 | -0.060500 | 5.87e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 5.44e-01 | 0.060200 | 6.31e-01 |
| Na+/Cl- dependent neurotransmitter transporters | 13 | 7.13e-01 | -0.059000 | 7.75e-01 |
| Disorders of transmembrane transporters | 157 | 2.05e-01 | -0.058600 | 2.92e-01 |
| tRNA processing in the nucleus | 59 | 4.36e-01 | -0.058600 | 5.31e-01 |
| Signaling by NOTCH4 | 81 | 3.64e-01 | 0.058300 | 4.63e-01 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 15 | 6.98e-01 | 0.057900 | 7.64e-01 |
| Fatty acid metabolism | 153 | 2.18e-01 | -0.057700 | 3.07e-01 |
| RNA Polymerase I Transcription Initiation | 47 | 4.97e-01 | 0.057300 | 5.91e-01 |
| HDR through MMEJ (alt-NHEJ) | 10 | 7.54e-01 | -0.057200 | 8.10e-01 |
| ABC-family proteins mediated transport | 97 | 3.32e-01 | 0.057000 | 4.31e-01 |
| Recycling of bile acids and salts | 13 | 7.22e-01 | 0.056900 | 7.84e-01 |
| Activation of HOX genes during differentiation | 82 | 3.74e-01 | -0.056800 | 4.73e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 82 | 3.74e-01 | -0.056800 | 4.73e-01 |
| Glyoxylate metabolism and glycine degradation | 25 | 6.24e-01 | -0.056600 | 7.02e-01 |
| Processing of Capped Intronless Pre-mRNA | 28 | 6.05e-01 | 0.056400 | 6.86e-01 |
| Regulation of PTEN stability and activity | 67 | 4.27e-01 | 0.056100 | 5.24e-01 |
| Mitophagy | 28 | 6.08e-01 | -0.055900 | 6.87e-01 |
| Positive epigenetic regulation of rRNA expression | 68 | 4.30e-01 | 0.055400 | 5.25e-01 |
| Diseases of DNA repair | 34 | 5.83e-01 | 0.054500 | 6.68e-01 |
| Phase 2 - plateau phase | 14 | 7.28e-01 | 0.053700 | 7.89e-01 |
| Incretin synthesis, secretion, and inactivation | 18 | 6.94e-01 | -0.053600 | 7.62e-01 |
| Chaperone Mediated Autophagy | 18 | 6.96e-01 | -0.053300 | 7.63e-01 |
| MAPK6/MAPK4 signaling | 87 | 3.97e-01 | -0.052600 | 4.96e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 52 | 5.16e-01 | -0.052100 | 6.06e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 33 | 6.05e-01 | 0.052100 | 6.86e-01 |
| Trafficking and processing of endosomal TLR | 11 | 7.66e-01 | -0.051900 | 8.18e-01 |
| Bile acid and bile salt metabolism | 37 | 5.85e-01 | -0.051800 | 6.69e-01 |
| Plasma lipoprotein remodeling | 23 | 6.69e-01 | -0.051400 | 7.41e-01 |
| Degradation of beta-catenin by the destruction complex | 83 | 4.18e-01 | -0.051400 | 5.16e-01 |
| Mitotic Spindle Checkpoint | 109 | 3.56e-01 | 0.051100 | 4.55e-01 |
| Downstream TCR signaling | 90 | 4.07e-01 | 0.050500 | 5.04e-01 |
| ABC transporters in lipid homeostasis | 15 | 7.37e-01 | 0.050100 | 7.97e-01 |
| CLEC7A (Dectin-1) signaling | 97 | 4.05e-01 | -0.048900 | 5.02e-01 |
| Hedgehog ‘off’ state | 95 | 4.14e-01 | 0.048500 | 5.11e-01 |
| Metabolic disorders of biological oxidation enzymes | 30 | 6.46e-01 | 0.048400 | 7.21e-01 |
| Cilium Assembly | 181 | 2.62e-01 | -0.048300 | 3.55e-01 |
| Cellular response to hypoxia | 73 | 4.78e-01 | 0.048000 | 5.74e-01 |
| Interferon alpha/beta signaling | 57 | 5.33e-01 | 0.047700 | 6.21e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 27 | 6.68e-01 | -0.047700 | 7.41e-01 |
| Amyloid fiber formation | 60 | 5.25e-01 | 0.047400 | 6.12e-01 |
| Inwardly rectifying K+ channels | 29 | 6.60e-01 | 0.047300 | 7.33e-01 |
| LGI-ADAM interactions | 12 | 7.77e-01 | -0.047200 | 8.28e-01 |
| Diseases associated with N-glycosylation of proteins | 17 | 7.38e-01 | -0.046900 | 7.97e-01 |
| Xenobiotics | 15 | 7.53e-01 | -0.046800 | 8.10e-01 |
| Activated point mutants of FGFR2 | 14 | 7.62e-01 | 0.046800 | 8.16e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 6.88e-01 | 0.046300 | 7.58e-01 |
| Insulin receptor recycling | 24 | 6.95e-01 | 0.046200 | 7.63e-01 |
| Signaling by Retinoic Acid | 37 | 6.31e-01 | -0.045600 | 7.10e-01 |
| FGFR2c ligand binding and activation | 10 | 8.03e-01 | 0.045500 | 8.48e-01 |
| PCP/CE pathway | 90 | 4.59e-01 | -0.045100 | 5.53e-01 |
| RNA Polymerase III Chain Elongation | 18 | 7.41e-01 | 0.045000 | 7.99e-01 |
| TP53 Regulates Metabolic Genes | 85 | 4.80e-01 | -0.044300 | 5.75e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 7.39e-01 | -0.044200 | 7.98e-01 |
| Activation of G protein gated Potassium channels | 24 | 7.11e-01 | 0.043700 | 7.74e-01 |
| G protein gated Potassium channels | 24 | 7.11e-01 | 0.043700 | 7.74e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 24 | 7.11e-01 | 0.043700 | 7.74e-01 |
| Membrane binding and targetting of GAG proteins | 14 | 7.80e-01 | -0.043000 | 8.30e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 7.80e-01 | -0.043000 | 8.30e-01 |
| Signaling by FGFR2 in disease | 40 | 6.39e-01 | -0.042900 | 7.17e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 64 | 5.57e-01 | -0.042400 | 6.42e-01 |
| FCERI mediated NF-kB activation | 76 | 5.38e-01 | 0.040900 | 6.26e-01 |
| Cytochrome P450 - arranged by substrate type | 46 | 6.34e-01 | -0.040600 | 7.12e-01 |
| Glucagon-type ligand receptors | 23 | 7.42e-01 | -0.039700 | 8.00e-01 |
| Phase I - Functionalization of compounds | 76 | 5.53e-01 | 0.039400 | 6.39e-01 |
| Carboxyterminal post-translational modifications of tubulin | 37 | 6.79e-01 | -0.039300 | 7.49e-01 |
| Diseases of carbohydrate metabolism | 30 | 7.13e-01 | -0.038800 | 7.75e-01 |
| Lysine catabolism | 12 | 8.17e-01 | -0.038700 | 8.58e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 16 | 7.89e-01 | -0.038600 | 8.37e-01 |
| Regulation of BACH1 activity | 11 | 8.25e-01 | 0.038600 | 8.65e-01 |
| Suppression of phagosomal maturation | 13 | 8.11e-01 | 0.038300 | 8.53e-01 |
| Assembly Of The HIV Virion | 16 | 7.93e-01 | -0.037900 | 8.40e-01 |
| SUMOylation of DNA methylation proteins | 16 | 7.94e-01 | 0.037700 | 8.40e-01 |
| Transcriptional Regulation by E2F6 | 34 | 7.05e-01 | -0.037500 | 7.70e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 7.96e-01 | 0.037400 | 8.41e-01 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 8.39e-01 | 0.037100 | 8.78e-01 |
| FGFR3 ligand binding and activation | 11 | 8.32e-01 | -0.037000 | 8.71e-01 |
| FGFR3c ligand binding and activation | 11 | 8.32e-01 | -0.037000 | 8.71e-01 |
| Amino acids regulate mTORC1 | 51 | 6.49e-01 | -0.036900 | 7.23e-01 |
| Resolution of Sister Chromatid Cohesion | 105 | 5.14e-01 | -0.036900 | 6.04e-01 |
| Olfactory Signaling Pathway | 24 | 7.55e-01 | 0.036700 | 8.11e-01 |
| Regulation of TP53 Activity through Phosphorylation | 91 | 5.45e-01 | -0.036700 | 6.32e-01 |
| Epigenetic regulation of gene expression | 110 | 5.07e-01 | 0.036600 | 5.99e-01 |
| Metabolism | 1881 | 8.46e-03 | -0.036400 | 1.87e-02 |
| Polymerase switching on the C-strand of the telomere | 26 | 7.49e-01 | 0.036200 | 8.07e-01 |
| Host Interactions of HIV factors | 125 | 4.86e-01 | -0.036100 | 5.81e-01 |
| Nicotinamide salvaging | 18 | 7.91e-01 | -0.036000 | 8.39e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 8.16e-01 | 0.035800 | 8.58e-01 |
| Peptide ligand-binding receptors | 106 | 5.24e-01 | 0.035800 | 6.12e-01 |
| FGFR1 ligand binding and activation | 13 | 8.24e-01 | -0.035700 | 8.65e-01 |
| Beta-oxidation of very long chain fatty acids | 10 | 8.46e-01 | 0.035500 | 8.83e-01 |
| Metabolism of folate and pterines | 16 | 8.06e-01 | -0.035500 | 8.50e-01 |
| Reproduction | 92 | 5.60e-01 | 0.035100 | 6.45e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 6.06e-01 | 0.035100 | 6.86e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 7.04e-01 | -0.034300 | 7.70e-01 |
| RNA Polymerase III Transcription | 41 | 7.04e-01 | -0.034300 | 7.70e-01 |
| EML4 and NUDC in mitotic spindle formation | 96 | 5.64e-01 | -0.034000 | 6.50e-01 |
| Metabolism of steroid hormones | 30 | 7.50e-01 | -0.033600 | 8.08e-01 |
| Regulation of TNFR1 signaling | 35 | 7.31e-01 | -0.033600 | 7.92e-01 |
| Class A/1 (Rhodopsin-like receptors) | 187 | 4.41e-01 | -0.032700 | 5.34e-01 |
| Transcription of the HIV genome | 69 | 6.49e-01 | -0.031700 | 7.23e-01 |
| Mitotic Metaphase and Anaphase | 229 | 4.12e-01 | 0.031500 | 5.09e-01 |
| Telomere Extension By Telomerase | 23 | 7.94e-01 | -0.031500 | 8.40e-01 |
| Defects in cobalamin (B12) metabolism | 13 | 8.45e-01 | -0.031300 | 8.82e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 8.47e-01 | -0.031000 | 8.83e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 7.77e-01 | -0.030900 | 8.28e-01 |
| Mitotic Anaphase | 228 | 4.21e-01 | 0.030900 | 5.18e-01 |
| FGFR3 mutant receptor activation | 10 | 8.66e-01 | 0.030800 | 8.95e-01 |
| Signaling by activated point mutants of FGFR3 | 10 | 8.66e-01 | 0.030800 | 8.95e-01 |
| Folding of actin by CCT/TriC | 10 | 8.71e-01 | -0.029800 | 8.97e-01 |
| Oxidative Stress Induced Senescence | 83 | 6.43e-01 | -0.029400 | 7.20e-01 |
| SUMOylation of immune response proteins | 11 | 8.66e-01 | -0.029300 | 8.95e-01 |
| Iron uptake and transport | 56 | 7.08e-01 | -0.028900 | 7.73e-01 |
| Heme biosynthesis | 13 | 8.57e-01 | 0.028900 | 8.91e-01 |
| DNA Repair | 298 | 4.02e-01 | 0.028200 | 4.99e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 8.33e-01 | -0.028000 | 8.72e-01 |
| PINK1-PRKN Mediated Mitophagy | 21 | 8.25e-01 | 0.027900 | 8.65e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 79 | 6.73e-01 | 0.027500 | 7.44e-01 |
| Interleukin-1 family signaling | 126 | 5.96e-01 | -0.027300 | 6.78e-01 |
| Early Phase of HIV Life Cycle | 13 | 8.65e-01 | 0.027200 | 8.95e-01 |
| Acyl chain remodelling of PG | 13 | 8.66e-01 | -0.027000 | 8.95e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 6.83e-01 | 0.026200 | 7.53e-01 |
| Generation of second messenger molecules | 29 | 8.07e-01 | 0.026100 | 8.51e-01 |
| Interleukin-12 signaling | 43 | 7.68e-01 | -0.026000 | 8.20e-01 |
| RMTs methylate histone arginines | 44 | 7.65e-01 | 0.026000 | 8.18e-01 |
| Signaling by Hedgehog | 132 | 6.08e-01 | -0.025800 | 6.87e-01 |
| DNA Double-Strand Break Repair | 140 | 5.98e-01 | 0.025800 | 6.80e-01 |
| Phospholipase C-mediated cascade: FGFR1 | 14 | 8.69e-01 | 0.025400 | 8.97e-01 |
| Transcriptional regulation by small RNAs | 69 | 7.19e-01 | -0.025000 | 7.81e-01 |
| Transcriptional regulation by RUNX2 | 116 | 6.46e-01 | -0.024700 | 7.21e-01 |
| Anchoring of the basal body to the plasma membrane | 97 | 6.74e-01 | 0.024700 | 7.44e-01 |
| Protein localization | 158 | 5.95e-01 | 0.024500 | 6.78e-01 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 7.85e-01 | 0.024300 | 8.33e-01 |
| HIV Transcription Elongation | 42 | 7.85e-01 | 0.024300 | 8.33e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 7.85e-01 | 0.024300 | 8.33e-01 |
| NRIF signals cell death from the nucleus | 16 | 8.70e-01 | 0.023700 | 8.97e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 57 | 7.62e-01 | -0.023200 | 8.16e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 8.81e-01 | -0.023100 | 9.08e-01 |
| Meiosis | 76 | 7.38e-01 | 0.022200 | 7.97e-01 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.04e-01 | 0.022100 | 9.26e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 81 | 7.32e-01 | -0.022000 | 7.92e-01 |
| Cell Cycle, Mitotic | 513 | 3.96e-01 | 0.021800 | 4.96e-01 |
| Cell Cycle | 637 | 3.52e-01 | 0.021600 | 4.50e-01 |
| Other interleukin signaling | 22 | 8.65e-01 | -0.020900 | 8.95e-01 |
| AURKA Activation by TPX2 | 72 | 7.65e-01 | 0.020400 | 8.18e-01 |
| G2/M DNA damage checkpoint | 69 | 7.70e-01 | 0.020400 | 8.21e-01 |
| Meiotic synapsis | 50 | 8.04e-01 | -0.020300 | 8.49e-01 |
| Centrosome maturation | 81 | 7.59e-01 | 0.019800 | 8.14e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 81 | 7.59e-01 | 0.019800 | 8.14e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 8.58e-01 | 0.018900 | 8.91e-01 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 8.58e-01 | 0.018900 | 8.91e-01 |
| Synthesis of PE | 13 | 9.11e-01 | 0.017800 | 9.32e-01 |
| RNA Polymerase III Transcription Initiation | 36 | 8.60e-01 | -0.017000 | 8.93e-01 |
| Eicosanoid ligand-binding receptors | 12 | 9.21e-01 | -0.016600 | 9.40e-01 |
| Vitamin B5 (pantothenate) metabolism | 17 | 9.08e-01 | 0.016200 | 9.29e-01 |
| Triglyceride biosynthesis | 10 | 9.31e-01 | 0.015700 | 9.49e-01 |
| Transferrin endocytosis and recycling | 30 | 8.82e-01 | 0.015600 | 9.08e-01 |
| HDACs deacetylate histones | 54 | 8.43e-01 | 0.015500 | 8.82e-01 |
| Metabolism of nucleotides | 90 | 8.07e-01 | 0.014900 | 8.50e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 8.65e-01 | 0.014800 | 8.95e-01 |
| Interleukin-10 signaling | 33 | 8.88e-01 | -0.014200 | 9.12e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 9.04e-01 | -0.013200 | 9.26e-01 |
| Formation of Incision Complex in GG-NER | 43 | 8.82e-01 | -0.013000 | 9.08e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 9.34e-01 | -0.012800 | 9.51e-01 |
| Nucleotide salvage | 21 | 9.26e-01 | 0.011700 | 9.45e-01 |
| Cellular responses to stress | 677 | 6.45e-01 | -0.010400 | 7.21e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 8.91e-01 | 0.010100 | 9.15e-01 |
| TCR signaling | 110 | 8.55e-01 | -0.010100 | 8.91e-01 |
| Nicotinate metabolism | 29 | 9.27e-01 | -0.009790 | 9.46e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 14 | 9.58e-01 | -0.008170 | 9.70e-01 |
| Interleukin-1 signaling | 96 | 8.94e-01 | -0.007870 | 9.17e-01 |
| Mitotic Prometaphase | 186 | 8.56e-01 | -0.007690 | 8.91e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 87 | 9.12e-01 | -0.006820 | 9.33e-01 |
| Hyaluronan uptake and degradation | 10 | 9.71e-01 | 0.006580 | 9.82e-01 |
| MicroRNA (miRNA) biogenesis | 24 | 9.57e-01 | 0.006350 | 9.70e-01 |
| Diseases associated with the TLR signaling cascade | 28 | 9.55e-01 | 0.006170 | 9.69e-01 |
| Diseases of Immune System | 28 | 9.55e-01 | 0.006170 | 9.69e-01 |
| HIV elongation arrest and recovery | 32 | 9.52e-01 | 0.006160 | 9.67e-01 |
| Pausing and recovery of HIV elongation | 32 | 9.52e-01 | 0.006160 | 9.67e-01 |
| M Phase | 371 | 8.65e-01 | 0.005140 | 8.95e-01 |
| Phase 0 - rapid depolarisation | 29 | 9.64e-01 | 0.004900 | 9.75e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 92 | 9.41e-01 | -0.004450 | 9.57e-01 |
| Amplification of signal from the kinetochores | 92 | 9.41e-01 | -0.004450 | 9.57e-01 |
| Metalloprotease DUBs | 26 | 9.70e-01 | 0.004320 | 9.81e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 9.83e-01 | 0.003460 | 9.89e-01 |
| Acyl chain remodelling of PS | 18 | 9.81e-01 | -0.003310 | 9.87e-01 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 13 | 9.84e-01 | -0.003190 | 9.89e-01 |
| Cellular responses to stimuli | 687 | 8.94e-01 | -0.002980 | 9.17e-01 |
| Transcriptional Regulation by VENTX | 38 | 9.76e-01 | -0.002800 | 9.84e-01 |
| DNA Damage Bypass | 47 | 9.74e-01 | -0.002720 | 9.84e-01 |
| Keratinization | 47 | 9.77e-01 | 0.002400 | 9.85e-01 |
| Nucleotide-like (purinergic) receptors | 12 | 9.89e-01 | -0.002400 | 9.93e-01 |
| Sensory perception of taste | 25 | 9.84e-01 | 0.002380 | 9.89e-01 |
| Loss of Nlp from mitotic centrosomes | 69 | 9.76e-01 | 0.002060 | 9.84e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 9.76e-01 | 0.002060 | 9.84e-01 |
| Processing of SMDT1 | 15 | 9.95e-01 | 0.000943 | 9.98e-01 |
| RNA Polymerase III Transcription Termination | 23 | 9.95e-01 | 0.000788 | 9.98e-01 |
| Pregnenolone biosynthesis | 11 | 9.97e-01 | 0.000640 | 9.98e-01 |
| Crosslinking of collagen fibrils | 10 | 9.98e-01 | -0.000505 | 9.98e-01 |
| Recruitment of NuMA to mitotic centrosomes | 80 | 9.96e-01 | 0.000344 | 9.98e-01 |
| Josephin domain DUBs | 10 | 9.99e-01 | -0.000291 | 9.99e-01 |
Detailed Gene set reports
CLEC7A (Dectin-1) induces NFAT activation
| 134 | |
|---|---|
| set | CLEC7A (Dectin-1) induces NFAT activation |
| setSize | 11 |
| pANOVA | 9.68e-07 |
| s.dist | -0.853 |
| p.adjustANOVA | 6.07e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITPR1 | -11377 |
| ITPR3 | -10980 |
| AHCYL1 | -10915 |
| PPP3CA | -10754 |
| ITPR2 | -10484 |
| PPP3R1 | -10098 |
| NFATC3 | -9413 |
| NFATC1 | -9330 |
| PPP3CB | -7240 |
| CALM1 | -7050 |
| NFATC2 | -6401 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITPR1 | -11377 |
| ITPR3 | -10980 |
| AHCYL1 | -10915 |
| PPP3CA | -10754 |
| ITPR2 | -10484 |
| PPP3R1 | -10098 |
| NFATC3 | -9413 |
| NFATC1 | -9330 |
| PPP3CB | -7240 |
| CALM1 | -7050 |
| NFATC2 | -6401 |
Cohesin Loading onto Chromatin
| 203 | |
|---|---|
| set | Cohesin Loading onto Chromatin |
| setSize | 10 |
| pANOVA | 3.04e-06 |
| s.dist | -0.852 |
| p.adjustANOVA | 1.63e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| WAPL | -10914 |
| NIPBL | -10299 |
| RAD21 | -10290 |
| PDS5A | -10246 |
| STAG2 | -10214 |
| SMC1A | -9265 |
| PDS5B | -9064 |
| STAG1 | -8365 |
| MAU2 | -8358 |
| SMC3 | -7530 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| WAPL | -10914 |
| NIPBL | -10299 |
| RAD21 | -10290 |
| PDS5A | -10246 |
| STAG2 | -10214 |
| SMC1A | -9265 |
| PDS5B | -9064 |
| STAG1 | -8365 |
| MAU2 | -8358 |
| SMC3 | -7530 |
Laminin interactions
| 630 | |
|---|---|
| set | Laminin interactions |
| setSize | 23 |
| pANOVA | 4.4e-11 |
| s.dist | -0.793 |
| p.adjustANOVA | 5.87e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| ITGA6 | -11286 |
| NID1 | -11180 |
| ITGAV | -11113 |
| LAMB2 | -10934 |
| ITGA1 | -10654 |
| LAMA5 | -10549 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| LAMA1 | -10193 |
| HSPG2 | -9870 |
| ITGA3 | -9698 |
| ITGB4 | -8554 |
| ITGA7 | -7619 |
| NID2 | -7129 |
| LAMC2 | -6635 |
| COL18A1 | -6473 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| ITGA6 | -11286 |
| NID1 | -11180 |
| ITGAV | -11113 |
| LAMB2 | -10934 |
| ITGA1 | -10654 |
| LAMA5 | -10549 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| LAMA1 | -10193 |
| HSPG2 | -9870 |
| ITGA3 | -9698 |
| ITGB4 | -8554 |
| ITGA7 | -7619 |
| NID2 | -7129 |
| LAMC2 | -6635 |
| COL18A1 | -6473 |
| LAMA2 | -4267 |
| LAMC3 | -2462 |
| LAMA3 | 5212 |
S33 mutants of beta-catenin aren’t phosphorylated
| 1103 | |
|---|---|
| set | S33 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.53e-07 |
| s.dist | -0.783 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
S37 mutants of beta-catenin aren’t phosphorylated
| 1104 | |
|---|---|
| set | S37 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.53e-07 |
| s.dist | -0.783 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
S45 mutants of beta-catenin aren’t phosphorylated
| 1105 | |
|---|---|
| set | S45 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.53e-07 |
| s.dist | -0.783 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Signaling by CTNNB1 phospho-site mutants
| 1175 | |
|---|---|
| set | Signaling by CTNNB1 phospho-site mutants |
| setSize | 15 |
| pANOVA | 1.53e-07 |
| s.dist | -0.783 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Signaling by GSK3beta mutants
| 1202 | |
|---|---|
| set | Signaling by GSK3beta mutants |
| setSize | 15 |
| pANOVA | 1.53e-07 |
| s.dist | -0.783 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
T41 mutants of beta-catenin aren’t phosphorylated
| 1293 | |
|---|---|
| set | T41 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.53e-07 |
| s.dist | -0.783 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Signaling by Hippo
| 1204 | |
|---|---|
| set | Signaling by Hippo |
| setSize | 20 |
| pANOVA | 1.64e-09 |
| s.dist | -0.779 |
| p.adjustANOVA | 1.78e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AMOTL1 | -11249 |
| YAP1 | -11062 |
| TJP1 | -10967 |
| WWTR1 | -10838 |
| AMOT | -10567 |
| LATS1 | -10224 |
| TJP2 | -10124 |
| SAV1 | -9569 |
| LATS2 | -9336 |
| MOB1A | -9309 |
| STK4 | -9279 |
| AMOTL2 | -9241 |
| MOB1B | -8267 |
| CASP3 | -8212 |
| STK3 | -7927 |
| DVL2 | -7004 |
| YWHAB | -6645 |
| NPHP4 | -6309 |
| WWC1 | -5132 |
| YWHAE | 1543 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AMOTL1 | -11249 |
| YAP1 | -11062 |
| TJP1 | -10967 |
| WWTR1 | -10838 |
| AMOT | -10567 |
| LATS1 | -10224 |
| TJP2 | -10124 |
| SAV1 | -9569 |
| LATS2 | -9336 |
| MOB1A | -9309 |
| STK4 | -9279 |
| AMOTL2 | -9241 |
| MOB1B | -8267 |
| CASP3 | -8212 |
| STK3 | -7927 |
| DVL2 | -7004 |
| YWHAB | -6645 |
| NPHP4 | -6309 |
| WWC1 | -5132 |
| YWHAE | 1543 |
Syndecan interactions
| 1268 | |
|---|---|
| set | Syndecan interactions |
| setSize | 20 |
| pANOVA | 1.76e-09 |
| s.dist | -0.777 |
| p.adjustANOVA | 1.88e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITGB3 | -11388 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| ITGA6 | -11286 |
| ITGAV | -11113 |
| TNC | -10940 |
| ACTN1 | -10918 |
| SDC4 | -10735 |
| PRKCA | -10498 |
| ITGB5 | -10206 |
| TGFB1 | -8918 |
| CASK | -8743 |
| ITGB4 | -8554 |
| THBS1 | -7620 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| SDC2 | -5839 |
| FGF2 | -5307 |
| TRAPPC4 | -4762 |
| VTN | 4190 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITGB3 | -11388 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| ITGA6 | -11286 |
| ITGAV | -11113 |
| TNC | -10940 |
| ACTN1 | -10918 |
| SDC4 | -10735 |
| PRKCA | -10498 |
| ITGB5 | -10206 |
| TGFB1 | -8918 |
| CASK | -8743 |
| ITGB4 | -8554 |
| THBS1 | -7620 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| SDC2 | -5839 |
| FGF2 | -5307 |
| TRAPPC4 | -4762 |
| VTN | 4190 |
MET activates RAP1 and RAC1
| 658 | |
|---|---|
| set | MET activates RAP1 and RAC1 |
| setSize | 11 |
| pANOVA | 8.89e-06 |
| s.dist | -0.773 |
| p.adjustANOVA | 4.31e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MET | -11149 |
| DOCK7 | -10847 |
| GRB2 | -10626 |
| CRKL | -10083 |
| RAPGEF1 | -9150 |
| RAP1B | -9004 |
| CRK | -8881 |
| GAB1 | -8325 |
| RAP1A | -6474 |
| HGF | -4279 |
| RAC1 | -3826 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MET | -11149 |
| DOCK7 | -10847 |
| GRB2 | -10626 |
| CRKL | -10083 |
| RAPGEF1 | -9150 |
| RAP1B | -9004 |
| CRK | -8881 |
| GAB1 | -8325 |
| RAP1A | -6474 |
| HGF | -4279 |
| RAC1 | -3826 |
APC truncation mutants have impaired AXIN binding
| 11 | |
|---|---|
| set | APC truncation mutants have impaired AXIN binding |
| setSize | 14 |
| pANOVA | 6.48e-07 |
| s.dist | -0.768 |
| p.adjustANOVA | 4.24e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
AXIN missense mutants destabilize the destruction complex
| 24 | |
|---|---|
| set | AXIN missense mutants destabilize the destruction complex |
| setSize | 14 |
| pANOVA | 6.48e-07 |
| s.dist | -0.768 |
| p.adjustANOVA | 4.24e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Signaling by AMER1 mutants
| 1168 | |
|---|---|
| set | Signaling by AMER1 mutants |
| setSize | 14 |
| pANOVA | 6.48e-07 |
| s.dist | -0.768 |
| p.adjustANOVA | 4.24e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Signaling by APC mutants
| 1169 | |
|---|---|
| set | Signaling by APC mutants |
| setSize | 14 |
| pANOVA | 6.48e-07 |
| s.dist | -0.768 |
| p.adjustANOVA | 4.24e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Signaling by AXIN mutants
| 1170 | |
|---|---|
| set | Signaling by AXIN mutants |
| setSize | 14 |
| pANOVA | 6.48e-07 |
| s.dist | -0.768 |
| p.adjustANOVA | 4.24e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Truncations of AMER1 destabilize the destruction complex
| 1410 | |
|---|---|
| set | Truncations of AMER1 destabilize the destruction complex |
| setSize | 14 |
| pANOVA | 6.48e-07 |
| s.dist | -0.768 |
| p.adjustANOVA | 4.24e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
ERKs are inactivated
| 357 | |
|---|---|
| set | ERKs are inactivated |
| setSize | 13 |
| pANOVA | 1.68e-06 |
| s.dist | -0.767 |
| p.adjustANOVA | 9.67e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DUSP4 | -11285 |
| PPP2R5D | -11215 |
| MAPK1 | -11008 |
| DUSP7 | -10143 |
| PPP2CB | -10130 |
| DUSP3 | -9469 |
| MAPK3 | -9373 |
| PPP2CA | -7327 |
| VRK3 | -7235 |
| DUSP6 | -6006 |
| PPP2R1B | -5567 |
| PPP2R1A | -4930 |
| MAPK7 | -4670 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DUSP4 | -11285 |
| PPP2R5D | -11215 |
| MAPK1 | -11008 |
| DUSP7 | -10143 |
| PPP2CB | -10130 |
| DUSP3 | -9469 |
| MAPK3 | -9373 |
| PPP2CA | -7327 |
| VRK3 | -7235 |
| DUSP6 | -6006 |
| PPP2R1B | -5567 |
| PPP2R1A | -4930 |
| MAPK7 | -4670 |
MET activates PTK2 signaling
| 657 | |
|---|---|
| set | MET activates PTK2 signaling |
| setSize | 18 |
| pANOVA | 2.19e-08 |
| s.dist | -0.762 |
| p.adjustANOVA | 2.01e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| MET | -11149 |
| LAMB2 | -10934 |
| LAMA5 | -10549 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| PTK2 | -10250 |
| LAMA1 | -10193 |
| ITGA3 | -9698 |
| SRC | -7386 |
| LAMC2 | -6635 |
| HGF | -4279 |
| LAMA2 | -4267 |
| LAMC3 | -2462 |
| LAMA3 | 5212 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| MET | -11149 |
| LAMB2 | -10934 |
| LAMA5 | -10549 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| PTK2 | -10250 |
| LAMA1 | -10193 |
| ITGA3 | -9698 |
| SRC | -7386 |
| LAMC2 | -6635 |
| HGF | -4279 |
| LAMA2 | -4267 |
| LAMC3 | -2462 |
| LAMA3 | 5212 |
Establishment of Sister Chromatid Cohesion
| 372 | |
|---|---|
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 11 |
| pANOVA | 1.5e-05 |
| s.dist | -0.754 |
| p.adjustANOVA | 6.74e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| WAPL | -10914 |
| RAD21 | -10290 |
| PDS5A | -10246 |
| STAG2 | -10214 |
| ESCO1 | -9347 |
| SMC1A | -9265 |
| PDS5B | -9064 |
| STAG1 | -8365 |
| SMC3 | -7530 |
| ESCO2 | -3964 |
| CDCA5 | -597 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| WAPL | -10914 |
| RAD21 | -10290 |
| PDS5A | -10246 |
| STAG2 | -10214 |
| ESCO1 | -9347 |
| SMC1A | -9265 |
| PDS5B | -9064 |
| STAG1 | -8365 |
| SMC3 | -7530 |
| ESCO2 | -3964 |
| CDCA5 | -597 |
MET promotes cell motility
| 660 | |
|---|---|
| set | MET promotes cell motility |
| setSize | 29 |
| pANOVA | 5.6e-12 |
| s.dist | -0.739 |
| p.adjustANOVA | 8.81e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| MET | -11149 |
| LAMB2 | -10934 |
| DOCK7 | -10847 |
| GRB2 | -10626 |
| LAMA5 | -10549 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| PTK2 | -10250 |
| LAMA1 | -10193 |
| CRKL | -10083 |
| ITGA3 | -9698 |
| RAPGEF1 | -9150 |
| RAP1B | -9004 |
| TNS3 | -8959 |
| CRK | -8881 |
| GAB1 | -8325 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| MET | -11149 |
| LAMB2 | -10934 |
| DOCK7 | -10847 |
| GRB2 | -10626 |
| LAMA5 | -10549 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| PTK2 | -10250 |
| LAMA1 | -10193 |
| CRKL | -10083 |
| ITGA3 | -9698 |
| RAPGEF1 | -9150 |
| RAP1B | -9004 |
| TNS3 | -8959 |
| CRK | -8881 |
| GAB1 | -8325 |
| SRC | -7386 |
| LAMC2 | -6635 |
| RAP1A | -6474 |
| HGF | -4279 |
| LAMA2 | -4267 |
| RAC1 | -3826 |
| LAMC3 | -2462 |
| TNS4 | 4061 |
| LAMA3 | 5212 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS
| 270 | |
|---|---|
| set | Defective EXT1 causes exostoses 1, TRPS2 and CHDS |
| setSize | 13 |
| pANOVA | 4.77e-06 |
| s.dist | -0.733 |
| p.adjustANOVA | 2.44e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GPC6 | -11331 |
| AGRN | -11307 |
| SDC4 | -10735 |
| HSPG2 | -9870 |
| EXT2 | -9326 |
| GPC4 | -9044 |
| GPC1 | -8024 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| EXT1 | -6377 |
| SDC2 | -5839 |
| GPC2 | -3380 |
| GPC5 | -3235 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GPC6 | -11331 |
| AGRN | -11307 |
| SDC4 | -10735 |
| HSPG2 | -9870 |
| EXT2 | -9326 |
| GPC4 | -9044 |
| GPC1 | -8024 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| EXT1 | -6377 |
| SDC2 | -5839 |
| GPC2 | -3380 |
| GPC5 | -3235 |
Defective EXT2 causes exostoses 2
| 271 | |
|---|---|
| set | Defective EXT2 causes exostoses 2 |
| setSize | 13 |
| pANOVA | 4.77e-06 |
| s.dist | -0.733 |
| p.adjustANOVA | 2.44e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GPC6 | -11331 |
| AGRN | -11307 |
| SDC4 | -10735 |
| HSPG2 | -9870 |
| EXT2 | -9326 |
| GPC4 | -9044 |
| GPC1 | -8024 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| EXT1 | -6377 |
| SDC2 | -5839 |
| GPC2 | -3380 |
| GPC5 | -3235 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GPC6 | -11331 |
| AGRN | -11307 |
| SDC4 | -10735 |
| HSPG2 | -9870 |
| EXT2 | -9326 |
| GPC4 | -9044 |
| GPC1 | -8024 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| EXT1 | -6377 |
| SDC2 | -5839 |
| GPC2 | -3380 |
| GPC5 | -3235 |
tRNA processing in the mitochondrion
| 1477 | |
|---|---|
| set | tRNA processing in the mitochondrion |
| setSize | 20 |
| pANOVA | 1.43e-08 |
| s.dist | 0.732 |
| p.adjustANOVA | 1.35e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-CYB | 14772 |
| MT-ND2 | 14771 |
| MT-ND3 | 14769 |
| MT-CO2 | 14768 |
| MT-CO1 | 14766 |
| MT-ND1 | 14765 |
| MT-CO3 | 14764 |
| MT-ND4 | 14762 |
| MT-ND4L | 14760 |
| MT-RNR1 | 14757 |
| MT-RNR2 | 14756 |
| MT-ND6 | 14633 |
| MT-ATP6 | 14606 |
| MT-ND5 | 14600 |
| MT-ATP8 | 14192 |
| HSD17B10 | 13513 |
| TRMT10C | 4645 |
| ELAC2 | -1278 |
| TRNT1 | -3642 |
| PRORP | -8469 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-CYB | 14772 |
| MT-ND2 | 14771 |
| MT-ND3 | 14769 |
| MT-CO2 | 14768 |
| MT-CO1 | 14766 |
| MT-ND1 | 14765 |
| MT-CO3 | 14764 |
| MT-ND4 | 14762 |
| MT-ND4L | 14760 |
| MT-RNR1 | 14757 |
| MT-RNR2 | 14756 |
| MT-ND6 | 14633 |
| MT-ATP6 | 14606 |
| MT-ND5 | 14600 |
| MT-ATP8 | 14192 |
| HSD17B10 | 13513 |
| TRMT10C | 4645 |
| ELAC2 | -1278 |
| TRNT1 | -3642 |
| PRORP | -8469 |
Synthesis of PIPs at the early endosome membrane
| 1278 | |
|---|---|
| set | Synthesis of PIPs at the early endosome membrane |
| setSize | 16 |
| pANOVA | 4.19e-07 |
| s.dist | -0.73 |
| p.adjustANOVA | 2.92e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MTMR12 | -11240 |
| PIKFYVE | -10408 |
| PIK3C2A | -9621 |
| PIK3R4 | -9524 |
| MTMR2 | -9438 |
| INPP4A | -8999 |
| MTMR4 | -8979 |
| INPP5F | -8487 |
| PIK3C3 | -7967 |
| MTM1 | -7910 |
| VAC14 | -7876 |
| PI4K2B | -7570 |
| PI4K2A | -6857 |
| MTMR10 | -6497 |
| FIG4 | -5627 |
| INPP4B | 1266 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MTMR12 | -11240 |
| PIKFYVE | -10408 |
| PIK3C2A | -9621 |
| PIK3R4 | -9524 |
| MTMR2 | -9438 |
| INPP4A | -8999 |
| MTMR4 | -8979 |
| INPP5F | -8487 |
| PIK3C3 | -7967 |
| MTM1 | -7910 |
| VAC14 | -7876 |
| PI4K2B | -7570 |
| PI4K2A | -6857 |
| MTMR10 | -6497 |
| FIG4 | -5627 |
| INPP4B | 1266 |
Complex I biogenesis
| 211 | |
|---|---|
| set | Complex I biogenesis |
| setSize | 57 |
| pANOVA | 1.31e-21 |
| s.dist | 0.73 |
| p.adjustANOVA | 5.88e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-ND2 | 14771 |
| MT-ND3 | 14769 |
| MT-ND1 | 14765 |
| MT-ND4 | 14762 |
| NDUFB1 | 14751 |
| NDUFV2 | 14736 |
| NDUFS5 | 14733 |
| NDUFA7 | 14731 |
| NDUFA1 | 14715 |
| NDUFA2 | 14713 |
| NDUFAF3 | 14700 |
| NDUFA3 | 14672 |
| NDUFA12 | 14636 |
| MT-ND6 | 14633 |
| NDUFB8 | 14627 |
| MT-ND5 | 14600 |
| NDUFB4 | 14596 |
| NDUFA13 | 14559 |
| NDUFA6 | 14489 |
| NDUFA8 | 14488 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-ND2 | 14771 |
| MT-ND3 | 14769 |
| MT-ND1 | 14765 |
| MT-ND4 | 14762 |
| NDUFB1 | 14751 |
| NDUFV2 | 14736 |
| NDUFS5 | 14733 |
| NDUFA7 | 14731 |
| NDUFA1 | 14715 |
| NDUFA2 | 14713 |
| NDUFAF3 | 14700 |
| NDUFA3 | 14672 |
| NDUFA12 | 14636 |
| MT-ND6 | 14633 |
| NDUFB8 | 14627 |
| MT-ND5 | 14600 |
| NDUFB4 | 14596 |
| NDUFA13 | 14559 |
| NDUFA6 | 14489 |
| NDUFA8 | 14488 |
| NDUFA11 | 14439 |
| NDUFB9 | 14393 |
| NDUFS8 | 14361 |
| NDUFS3 | 14313 |
| NDUFB10 | 14169 |
| NDUFAF2 | 14161 |
| NDUFB2 | 14098 |
| NDUFB7 | 14030 |
| NDUFC1 | 14023 |
| NDUFS7 | 13997 |
| NDUFV3 | 13890 |
| COA1 | 13884 |
| NDUFB6 | 13749 |
| NDUFS6 | 13691 |
| NDUFB3 | 13629 |
| NDUFB11 | 13161 |
| NDUFC2 | 12983 |
| ACAD9 | 12951 |
| NDUFA5 | 12663 |
| NDUFAF6 | 12067 |
| NDUFA9 | 11918 |
| ECSIT | 11668 |
| TMEM126B | 11368 |
| NDUFAF5 | 11271 |
| NDUFAF4 | 11158 |
| NDUFAF1 | 11010 |
| NDUFV1 | 10505 |
| NDUFAF7 | 10405 |
| NDUFAB1 | 10262 |
| TMEM186 | 6002 |
| NDUFS4 | 4585 |
| TIMMDC1 | -3430 |
| NDUFA10 | -4387 |
| NDUFB5 | -5177 |
| NDUFS1 | -7143 |
| NUBPL | -8112 |
| NDUFS2 | -10170 |
Beta-catenin phosphorylation cascade
| 111 | |
|---|---|
| set | Beta-catenin phosphorylation cascade |
| setSize | 17 |
| pANOVA | 1.86e-07 |
| s.dist | -0.73 |
| p.adjustANOVA | 1.37e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
| FRAT2 | -2944 |
| FRAT1 | -2426 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTNNB1 | -11218 |
| PPP2R5D | -11215 |
| CSNK1A1 | -10939 |
| GSK3B | -10857 |
| PPP2R5E | -10593 |
| APC | -10339 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| AMER1 | -8228 |
| AXIN1 | -7360 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
| FRAT2 | -2944 |
| FRAT1 | -2426 |
Signaling by PDGFRA extracellular domain mutants
| 1229 | |
|---|---|
| set | Signaling by PDGFRA extracellular domain mutants |
| setSize | 12 |
| pANOVA | 1.41e-05 |
| s.dist | -0.724 |
| p.adjustANOVA | 6.37e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDGFRA | -11184 |
| STAT3 | -10772 |
| GRB2 | -10626 |
| PIK3CB | -10352 |
| STAT1 | -10345 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| KRAS | -8721 |
| PIK3R2 | -5950 |
| HRAS | 13906 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDGFRA | -11184 |
| STAT3 | -10772 |
| GRB2 | -10626 |
| PIK3CB | -10352 |
| STAT1 | -10345 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| KRAS | -8721 |
| PIK3R2 | -5950 |
| HRAS | 13906 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
| 1230 | |
|---|---|
| set | Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants |
| setSize | 12 |
| pANOVA | 1.41e-05 |
| s.dist | -0.724 |
| p.adjustANOVA | 6.37e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDGFRA | -11184 |
| STAT3 | -10772 |
| GRB2 | -10626 |
| PIK3CB | -10352 |
| STAT1 | -10345 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| KRAS | -8721 |
| PIK3R2 | -5950 |
| HRAS | 13906 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDGFRA | -11184 |
| STAT3 | -10772 |
| GRB2 | -10626 |
| PIK3CB | -10352 |
| STAT1 | -10345 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| KRAS | -8721 |
| PIK3R2 | -5950 |
| HRAS | 13906 |
Non-integrin membrane-ECM interactions
| 782 | |
|---|---|
| set | Non-integrin membrane-ECM interactions |
| setSize | 42 |
| pANOVA | 8.65e-16 |
| s.dist | -0.717 |
| p.adjustANOVA | 2e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITGB3 | -11388 |
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| AGRN | -11307 |
| ITGA6 | -11286 |
| PDGFB | -11280 |
| ITGAV | -11113 |
| TNC | -10940 |
| LAMB2 | -10934 |
| ACTN1 | -10918 |
| SDC4 | -10735 |
| LAMA5 | -10549 |
| PRKCA | -10498 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| ITGB5 | -10206 |
| LAMA1 | -10193 |
| HSPG2 | -9870 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITGB3 | -11388 |
| LAMB3 | -11357 |
| LAMC1 | -11329 |
| ITGB1 | -11317 |
| ITGA2 | -11315 |
| AGRN | -11307 |
| ITGA6 | -11286 |
| PDGFB | -11280 |
| ITGAV | -11113 |
| TNC | -10940 |
| LAMB2 | -10934 |
| ACTN1 | -10918 |
| SDC4 | -10735 |
| LAMA5 | -10549 |
| PRKCA | -10498 |
| LAMA4 | -10450 |
| LAMB1 | -10431 |
| ITGB5 | -10206 |
| LAMA1 | -10193 |
| HSPG2 | -9870 |
| TGFB1 | -8918 |
| CASK | -8743 |
| DAG1 | -8675 |
| ITGB4 | -8554 |
| DDR1 | -8308 |
| DDR2 | -8017 |
| NTN4 | -7805 |
| THBS1 | -7620 |
| PDGFA | -7510 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| LAMC2 | -6635 |
| SDC2 | -5839 |
| FGF2 | -5307 |
| TRAPPC4 | -4762 |
| LAMA2 | -4267 |
| LAMC3 | -2462 |
| NRXN1 | 150 |
| DMD | 994 |
| TTR | 2169 |
| VTN | 4190 |
| LAMA3 | 5212 |
Viral mRNA Translation
| 1429 | |
|---|---|
| set | Viral mRNA Translation |
| setSize | 87 |
| pANOVA | 6.88e-31 |
| s.dist | 0.716 |
| p.adjustANOVA | 8.48e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
| RPL28 | 14550 |
| RPS16 | 14529 |
| RPS11 | 14523 |
| RPL23 | 14510 |
| RPL29 | 14503 |
| RPL19 | 14499 |
| RPL17 | 14497 |
| RPS15 | 14496 |
| RPS19 | 14476 |
| RPL36 | 14456 |
| RPL9 | 14394 |
| RPL18 | 14388 |
| RPL35A | 14377 |
| RPL26L1 | 14358 |
| RPS27L | 14338 |
| RPS8 | 14333 |
| RPLP1 | 14319 |
| RPL6 | 14318 |
| RPL36AL | 14290 |
| RPS25 | 14278 |
| RPL37A | 14263 |
| RPL26 | 14246 |
| RPS13 | 14240 |
| RPL13 | 14186 |
| RPL4 | 14145 |
| RPS28 | 14071 |
| RPS14 | 14014 |
| RPS6 | 13991 |
| RPL11 | 13968 |
| RPS4X | 13824 |
| RPL22L1 | 13806 |
| RPL15 | 13737 |
| RPS3 | 13719 |
| RPL5 | 13658 |
| RPL39 | 13544 |
| RPL18A | 13507 |
| RPS23 | 13488 |
| RPL7A | 13286 |
| UBA52 | 13217 |
| RPS17 | 13209 |
| RPL27 | 13203 |
| RPS12 | 13178 |
| RPSA | 13154 |
| RPS27 | 12843 |
| RPL30 | 12665 |
| RPS10 | 12226 |
| RPL8 | 11881 |
| RPS9 | 11743 |
| RPL22 | 11069 |
| RPS29 | 10608 |
| RPS2 | 10438 |
| RPL3L | 9364 |
| RPL13A | 8281 |
| RPS27A | 7697 |
| RPS3A | 6205 |
| RPL21 | 6069 |
| RPL10 | 1774 |
| RPL3 | -4637 |
| RPL23A | -5359 |
| RPL41 | -6176 |
| RPL39L | -6371 |
| RPLP0 | -7433 |
| DNAJC3 | -7651 |
| GRSF1 | -7945 |
| RPS5 | -8067 |
| RPL10A | -8314 |
| RPL7 | -8891 |
Peptide chain elongation
| 852 | |
|---|---|
| set | Peptide chain elongation |
| setSize | 87 |
| pANOVA | 7.93e-31 |
| s.dist | 0.715 |
| p.adjustANOVA | 9.02e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
| RPL28 | 14550 |
| RPS16 | 14529 |
| RPS11 | 14523 |
| RPL23 | 14510 |
| RPL29 | 14503 |
| RPL19 | 14499 |
| RPL17 | 14497 |
| RPS15 | 14496 |
| RPS19 | 14476 |
| RPL36 | 14456 |
| RPL9 | 14394 |
| RPL18 | 14388 |
| RPL35A | 14377 |
| RPL26L1 | 14358 |
| RPS27L | 14338 |
| RPS8 | 14333 |
| RPLP1 | 14319 |
| RPL6 | 14318 |
| RPL36AL | 14290 |
| RPS25 | 14278 |
| RPL37A | 14263 |
| RPL26 | 14246 |
| RPS13 | 14240 |
| RPL13 | 14186 |
| RPL4 | 14145 |
| RPS28 | 14071 |
| RPS14 | 14014 |
| RPS6 | 13991 |
| RPL11 | 13968 |
| RPS4X | 13824 |
| RPL22L1 | 13806 |
| RPL15 | 13737 |
| RPS3 | 13719 |
| RPL5 | 13658 |
| RPL39 | 13544 |
| RPL18A | 13507 |
| RPS23 | 13488 |
| RPL7A | 13286 |
| UBA52 | 13217 |
| RPS17 | 13209 |
| RPL27 | 13203 |
| RPS12 | 13178 |
| RPSA | 13154 |
| RPS27 | 12843 |
| RPL30 | 12665 |
| RPS10 | 12226 |
| RPL8 | 11881 |
| RPS9 | 11743 |
| RPL22 | 11069 |
| RPS29 | 10608 |
| RPS2 | 10438 |
| RPL3L | 9364 |
| RPL13A | 8281 |
| RPS27A | 7697 |
| RPS3A | 6205 |
| RPL21 | 6069 |
| RPL10 | 1774 |
| RPL3 | -4637 |
| RPL23A | -5359 |
| RPL41 | -6176 |
| RPL39L | -6371 |
| RPLP0 | -7433 |
| EEF1A1 | -7541 |
| RPS5 | -8067 |
| RPL10A | -8314 |
| RPL7 | -8891 |
| EEF2 | -8912 |
Signaling by PDGFR in disease
| 1228 | |
|---|---|
| set | Signaling by PDGFR in disease |
| setSize | 19 |
| pANOVA | 8.02e-08 |
| s.dist | -0.711 |
| p.adjustANOVA | 6.49e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDGFRA | -11184 |
| STAT3 | -10772 |
| GRB2 | -10626 |
| GOLGA4 | -10363 |
| PIK3CB | -10352 |
| STAT1 | -10345 |
| STRN | -10181 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| KRAS | -8721 |
| KANK1 | -8588 |
| WDR48 | -7167 |
| PIK3R2 | -5950 |
| ETV6 | -5676 |
| KDR | -4602 |
| FIP1L1 | -4599 |
| HRAS | 13906 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDGFRA | -11184 |
| STAT3 | -10772 |
| GRB2 | -10626 |
| GOLGA4 | -10363 |
| PIK3CB | -10352 |
| STAT1 | -10345 |
| STRN | -10181 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| KRAS | -8721 |
| KANK1 | -8588 |
| WDR48 | -7167 |
| PIK3R2 | -5950 |
| ETV6 | -5676 |
| KDR | -4602 |
| FIP1L1 | -4599 |
| HRAS | 13906 |
DCC mediated attractive signaling
| 245 | |
|---|---|
| set | DCC mediated attractive signaling |
| setSize | 14 |
| pANOVA | 4.24e-06 |
| s.dist | -0.71 |
| p.adjustANOVA | 2.22e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DOCK1 | -10879 |
| PTK2 | -10250 |
| NCK1 | -10095 |
| NTN1 | -9908 |
| ABLIM3 | -9474 |
| DCC | -9461 |
| WASL | -8689 |
| CDC42 | -8552 |
| SRC | -7386 |
| TRIO | -6874 |
| ABLIM1 | -5575 |
| RAC1 | -3826 |
| FYN | -3672 |
| ABLIM2 | -1605 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DOCK1 | -10879 |
| PTK2 | -10250 |
| NCK1 | -10095 |
| NTN1 | -9908 |
| ABLIM3 | -9474 |
| DCC | -9461 |
| WASL | -8689 |
| CDC42 | -8552 |
| SRC | -7386 |
| TRIO | -6874 |
| ABLIM1 | -5575 |
| RAC1 | -3826 |
| FYN | -3672 |
| ABLIM2 | -1605 |
Activation of RAC1
| 46 | |
|---|---|
| set | Activation of RAC1 |
| setSize | 13 |
| pANOVA | 9.42e-06 |
| s.dist | -0.709 |
| p.adjustANOVA | 4.53e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ROBO1 | -10780 |
| PAK2 | -10387 |
| NCK1 | -10095 |
| SOS1 | -10023 |
| PAK1 | -9837 |
| SOS2 | -9419 |
| SLIT2 | -9320 |
| PAK3 | -7519 |
| PAK4 | -6964 |
| NCK2 | -6728 |
| PAK5 | -4128 |
| RAC1 | -3826 |
| PAK6 | 418 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ROBO1 | -10780 |
| PAK2 | -10387 |
| NCK1 | -10095 |
| SOS1 | -10023 |
| PAK1 | -9837 |
| SOS2 | -9419 |
| SLIT2 | -9320 |
| PAK3 | -7519 |
| PAK4 | -6964 |
| NCK2 | -6728 |
| PAK5 | -4128 |
| RAC1 | -3826 |
| PAK6 | 418 |
FOXO-mediated transcription of cell cycle genes
| 402 | |
|---|---|
| set | FOXO-mediated transcription of cell cycle genes |
| setSize | 15 |
| pANOVA | 2.13e-06 |
| s.dist | -0.707 |
| p.adjustANOVA | 1.19e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CAV1 | -11260 |
| CDKN1A | -11157 |
| RBL2 | -11019 |
| FOXO3 | -10708 |
| SMAD4 | -10684 |
| FOXO1 | -10285 |
| CDKN1B | -9434 |
| SMAD2 | -9233 |
| BTG1 | -8909 |
| CCNG2 | -8722 |
| SMAD3 | -8597 |
| FOXO4 | -7483 |
| KLF4 | -7151 |
| GADD45A | -1324 |
| PCBP4 | 12731 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CAV1 | -11260 |
| CDKN1A | -11157 |
| RBL2 | -11019 |
| FOXO3 | -10708 |
| SMAD4 | -10684 |
| FOXO1 | -10285 |
| CDKN1B | -9434 |
| SMAD2 | -9233 |
| BTG1 | -8909 |
| CCNG2 | -8722 |
| SMAD3 | -8597 |
| FOXO4 | -7483 |
| KLF4 | -7151 |
| GADD45A | -1324 |
| PCBP4 | 12731 |
HDMs demethylate histones
| 509 | |
|---|---|
| set | HDMs demethylate histones |
| setSize | 22 |
| pANOVA | 1.56e-08 |
| s.dist | -0.696 |
| p.adjustANOVA | 1.46e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KDM5B | -11193 |
| KDM1B | -10910 |
| KDM4C | -10902 |
| KDM5A | -10282 |
| KDM7A | -10275 |
| KDM4B | -10185 |
| KDM3B | -10032 |
| KDM5C | -9480 |
| KDM1A | -9433 |
| KDM6A | -9040 |
| KDM4A | -8582 |
| JMJD6 | -8560 |
| KDM6B | -8163 |
| KDM2B | -8140 |
| KDM2A | -7781 |
| PHF8 | -7730 |
| KDM3A | -7043 |
| ARID5B | -6158 |
| PHF2 | -5878 |
| KDM4D | -5486 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KDM5B | -11193.0 |
| KDM1B | -10910.0 |
| KDM4C | -10902.0 |
| KDM5A | -10282.0 |
| KDM7A | -10275.0 |
| KDM4B | -10185.0 |
| KDM3B | -10032.0 |
| KDM5C | -9480.0 |
| KDM1A | -9433.0 |
| KDM6A | -9040.0 |
| KDM4A | -8582.0 |
| JMJD6 | -8560.0 |
| KDM6B | -8163.0 |
| KDM2B | -8140.0 |
| KDM2A | -7781.0 |
| PHF8 | -7730.0 |
| KDM3A | -7043.0 |
| ARID5B | -6158.0 |
| PHF2 | -5878.0 |
| KDM4D | -5486.0 |
| H3C1 | 3171.0 |
| H3C15 | 9115.5 |
Adenylate cyclase inhibitory pathway
| 61 | |
|---|---|
| set | Adenylate cyclase inhibitory pathway |
| setSize | 12 |
| pANOVA | 3.89e-05 |
| s.dist | -0.686 |
| p.adjustANOVA | 0.000158 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ADCY1 | -11110 |
| GNAI3 | -10973 |
| ADCY6 | -10943 |
| ADCY7 | -10524 |
| ADCY9 | -9337 |
| GNAI1 | -9293 |
| ADCY3 | -7605 |
| ADCY5 | -6394 |
| GNAL | -3771 |
| GNAI2 | -3728 |
| ADCY2 | -3004 |
| ADCY4 | -619 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ADCY1 | -11110 |
| GNAI3 | -10973 |
| ADCY6 | -10943 |
| ADCY7 | -10524 |
| ADCY9 | -9337 |
| GNAI1 | -9293 |
| ADCY3 | -7605 |
| ADCY5 | -6394 |
| GNAL | -3771 |
| GNAI2 | -3728 |
| ADCY2 | -3004 |
| ADCY4 | -619 |
Eukaryotic Translation Termination
| 377 | |
|---|---|
| set | Eukaryotic Translation Termination |
| setSize | 91 |
| pANOVA | 1.29e-29 |
| s.dist | 0.684 |
| p.adjustANOVA | 1.27e-27 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| TRMT112 | 14645 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| TRMT112 | 14645 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
| RPL28 | 14550 |
| RPS16 | 14529 |
| RPS11 | 14523 |
| RPL23 | 14510 |
| RPL29 | 14503 |
| RPL19 | 14499 |
| RPL17 | 14497 |
| RPS15 | 14496 |
| RPS19 | 14476 |
| RPL36 | 14456 |
| RPL9 | 14394 |
| RPL18 | 14388 |
| RPL35A | 14377 |
| RPL26L1 | 14358 |
| RPS27L | 14338 |
| RPS8 | 14333 |
| RPLP1 | 14319 |
| RPL6 | 14318 |
| RPL36AL | 14290 |
| RPS25 | 14278 |
| RPL37A | 14263 |
| RPL26 | 14246 |
| RPS13 | 14240 |
| RPL13 | 14186 |
| RPL4 | 14145 |
| RPS28 | 14071 |
| RPS14 | 14014 |
| RPS6 | 13991 |
| RPL11 | 13968 |
| RPS4X | 13824 |
| RPL22L1 | 13806 |
| RPL15 | 13737 |
| RPS3 | 13719 |
| RPL5 | 13658 |
| RPL39 | 13544 |
| RPL18A | 13507 |
| RPS23 | 13488 |
| RPL7A | 13286 |
| UBA52 | 13217 |
| RPS17 | 13209 |
| RPL27 | 13203 |
| RPS12 | 13178 |
| RPSA | 13154 |
| RPS27 | 12843 |
| RPL30 | 12665 |
| RPS10 | 12226 |
| N6AMT1 | 12141 |
| RPL8 | 11881 |
| RPS9 | 11743 |
| RPL22 | 11069 |
| RPS29 | 10608 |
| RPS2 | 10438 |
| RPL3L | 9364 |
| RPL13A | 8281 |
| RPS27A | 7697 |
| RPS3A | 6205 |
| RPL21 | 6069 |
| RPL10 | 1774 |
| RPL3 | -4637 |
| RPL23A | -5359 |
| RPL41 | -6176 |
| RPL39L | -6371 |
| GSPT2 | -6829 |
| RPLP0 | -7433 |
| RPS5 | -8067 |
| RPL10A | -8314 |
| APEH | -8673 |
| RPL7 | -8891 |
| ETF1 | -9598 |
| GSPT1 | -10362 |
Synthesis of PIPs at the late endosome membrane
| 1279 | |
|---|---|
| set | Synthesis of PIPs at the late endosome membrane |
| setSize | 11 |
| pANOVA | 8.49e-05 |
| s.dist | -0.684 |
| p.adjustANOVA | 0.000319 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -10408 |
| PIK3C2A | -9621 |
| PIK3R4 | -9524 |
| MTMR2 | -9438 |
| MTMR4 | -8979 |
| MTMR9 | -8214 |
| PIK3C3 | -7967 |
| MTM1 | -7910 |
| VAC14 | -7876 |
| FIG4 | -5627 |
| MTMR7 | 5748 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -10408 |
| PIK3C2A | -9621 |
| PIK3R4 | -9524 |
| MTMR2 | -9438 |
| MTMR4 | -8979 |
| MTMR9 | -8214 |
| PIK3C3 | -7967 |
| MTM1 | -7910 |
| VAC14 | -7876 |
| FIG4 | -5627 |
| MTMR7 | 5748 |
ERK/MAPK targets
| 356 | |
|---|---|
| set | ERK/MAPK targets |
| setSize | 22 |
| pANOVA | 2.97e-08 |
| s.dist | -0.682 |
| p.adjustANOVA | 2.66e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DUSP4 | -11285 |
| PPP2R5D | -11215 |
| MAPK1 | -11008 |
| DUSP7 | -10143 |
| PPP2CB | -10130 |
| RPS6KA3 | -9604 |
| DUSP3 | -9469 |
| MAPK3 | -9373 |
| RPS6KA2 | -9203 |
| RPS6KA1 | -7863 |
| MAPK14 | -7640 |
| PPP2CA | -7327 |
| VRK3 | -7235 |
| RPS6KA5 | -7165 |
| DUSP6 | -6006 |
| MEF2A | -5794 |
| PPP2R1B | -5567 |
| PPP2R1A | -4930 |
| MAPK7 | -4670 |
| MEF2C | -4363 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DUSP4 | -11285 |
| PPP2R5D | -11215 |
| MAPK1 | -11008 |
| DUSP7 | -10143 |
| PPP2CB | -10130 |
| RPS6KA3 | -9604 |
| DUSP3 | -9469 |
| MAPK3 | -9373 |
| RPS6KA2 | -9203 |
| RPS6KA1 | -7863 |
| MAPK14 | -7640 |
| PPP2CA | -7327 |
| VRK3 | -7235 |
| RPS6KA5 | -7165 |
| DUSP6 | -6006 |
| MEF2A | -5794 |
| PPP2R1B | -5567 |
| PPP2R1A | -4930 |
| MAPK7 | -4670 |
| MEF2C | -4363 |
| ELK1 | -3995 |
| MAPK11 | 4949 |
Selenocysteine synthesis
| 1146 | |
|---|---|
| set | Selenocysteine synthesis |
| setSize | 91 |
| pANOVA | 3.21e-29 |
| s.dist | 0.68 |
| p.adjustANOVA | 2.97e-27 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
| RPL28 | 14550 |
| RPS16 | 14529 |
| RPS11 | 14523 |
| RPL23 | 14510 |
| RPL29 | 14503 |
| RPL19 | 14499 |
| RPL17 | 14497 |
| RPS15 | 14496 |
| RPS19 | 14476 |
| RPL36 | 14456 |
| RPL9 | 14394 |
| RPL18 | 14388 |
| RPL35A | 14377 |
| RPL26L1 | 14358 |
| RPS27L | 14338 |
| RPS8 | 14333 |
| RPLP1 | 14319 |
| RPL6 | 14318 |
| RPL36AL | 14290 |
| RPS25 | 14278 |
| RPL37A | 14263 |
| RPL26 | 14246 |
| RPS13 | 14240 |
| RPL13 | 14186 |
| RPL4 | 14145 |
| RPS28 | 14071 |
| RPS14 | 14014 |
| RPS6 | 13991 |
| RPL11 | 13968 |
| RPS4X | 13824 |
| RPL22L1 | 13806 |
| RPL15 | 13737 |
| RPS3 | 13719 |
| RPL5 | 13658 |
| RPL39 | 13544 |
| RPL18A | 13507 |
| RPS23 | 13488 |
| RPL7A | 13286 |
| UBA52 | 13217 |
| RPS17 | 13209 |
| RPL27 | 13203 |
| RPS12 | 13178 |
| RPSA | 13154 |
| RPS27 | 12843 |
| RPL30 | 12665 |
| RPS10 | 12226 |
| RPL8 | 11881 |
| RPS9 | 11743 |
| RPL22 | 11069 |
| PSTK | 10855 |
| RPS29 | 10608 |
| RPS2 | 10438 |
| RPL3L | 9364 |
| RPL13A | 8281 |
| RPS27A | 7697 |
| RPS3A | 6205 |
| RPL21 | 6069 |
| RPL10 | 1774 |
| SEPHS2 | -372 |
| EEFSEC | -3593 |
| RPL3 | -4637 |
| SEPSECS | -5198 |
| RPL23A | -5359 |
| RPL41 | -6176 |
| RPL39L | -6371 |
| SECISBP2 | -6619 |
| RPLP0 | -7433 |
| RPS5 | -8067 |
| RPL10A | -8314 |
| RPL7 | -8891 |
| SARS1 | -9523 |
Eukaryotic Translation Elongation
| 375 | |
|---|---|
| set | Eukaryotic Translation Elongation |
| setSize | 92 |
| pANOVA | 5.39e-29 |
| s.dist | 0.673 |
| p.adjustANOVA | 4.43e-27 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL38 | 14728 |
| RPL14 | 14725 |
| RPL37 | 14722 |
| RPL31 | 14719 |
| RPS26 | 14702 |
| FAU | 14690 |
| RPL35 | 14685 |
| RPS20 | 14683 |
| RPL27A | 14639 |
| RPS24 | 14622 |
| RPS21 | 14610 |
| RPL36A | 14597 |
| RPLP2 | 14587 |
| RPL34 | 14584 |
| RPL24 | 14583 |
| RPL12 | 14580 |
| RPS15A | 14577 |
| RPS18 | 14572 |
| RPL32 | 14571 |
| RPS7 | 14564 |
| RPL28 | 14550 |
| RPS16 | 14529 |
| RPS11 | 14523 |
| RPL23 | 14510 |
| RPL29 | 14503 |
| RPL19 | 14499 |
| RPL17 | 14497 |
| RPS15 | 14496 |
| RPS19 | 14476 |
| RPL36 | 14456 |
| RPL9 | 14394 |
| RPL18 | 14388 |
| RPL35A | 14377 |
| RPL26L1 | 14358 |
| RPS27L | 14338 |
| RPS8 | 14333 |
| RPLP1 | 14319 |
| RPL6 | 14318 |
| RPL36AL | 14290 |
| RPS25 | 14278 |
| RPL37A | 14263 |
| RPL26 | 14246 |
| RPS13 | 14240 |
| RPL13 | 14186 |
| RPL4 | 14145 |
| RPS28 | 14071 |
| RPS14 | 14014 |
| RPS6 | 13991 |
| RPL11 | 13968 |
| RPS4X | 13824 |
| RPL22L1 | 13806 |
| RPL15 | 13737 |
| RPS3 | 13719 |
| RPL5 | 13658 |
| RPL39 | 13544 |
| RPL18A | 13507 |
| RPS23 | 13488 |
| RPL7A | 13286 |
| UBA52 | 13217 |
| RPS17 | 13209 |
| RPL27 | 13203 |
| RPS12 | 13178 |
| RPSA | 13154 |
| RPS27 | 12843 |
| RPL30 | 12665 |
| EEF1D | 12604 |
| RPS10 | 12226 |
| RPL8 | 11881 |
| RPS9 | 11743 |
| RPL22 | 11069 |
| RPS29 | 10608 |
| RPS2 | 10438 |
| EEF1B2 | 9965 |
| RPL3L | 9364 |
| RPL13A | 8281 |
| RPS27A | 7697 |
| RPS3A | 6205 |
| RPL21 | 6069 |
| RPL10 | 1774 |
| EEF1A2 | -3549 |
| RPL3 | -4637 |
| RPL23A | -5359 |
| EEF1G | -5887 |
| RPL41 | -6176 |
| RPL39L | -6371 |
| RPLP0 | -7433 |
| EEF1A1 | -7541 |
| RPS5 | -8067 |
| RPL10A | -8314 |
| EEF1A1P5 | -8339 |
| RPL7 | -8891 |
| EEF2 | -8912 |
Platelet sensitization by LDL
| 883 | |
|---|---|
| set | Platelet sensitization by LDL |
| setSize | 15 |
| pANOVA | 6.79e-06 |
| s.dist | -0.671 |
| p.adjustANOVA | 3.36e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| PPP2R5E | -10593 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| PTPN11 | -9492 |
| PLA2G4A | -9352 |
| LRP8 | -9305 |
| PECAM1 | -7865 |
| MAPK14 | -7640 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
| PTPN6 | 6610 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11215 |
| PPP2R5E | -10593 |
| PPP2CB | -10130 |
| PPP2R5A | -9682 |
| PTPN11 | -9492 |
| PLA2G4A | -9352 |
| LRP8 | -9305 |
| PECAM1 | -7865 |
| MAPK14 | -7640 |
| PPP2CA | -7327 |
| PPP2R1B | -5567 |
| PPP2R5C | -5404 |
| PPP2R1A | -4930 |
| PPP2R5B | -4321 |
| PTPN6 | 6610 |
rRNA processing in the mitochondrion
| 1471 | |
|---|---|
| set | rRNA processing in the mitochondrion |
| setSize | 24 |
| pANOVA | 1.27e-08 |
| s.dist | 0.671 |
| p.adjustANOVA | 1.21e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-CYB | 14772 |
| MT-ND2 | 14771 |
| MT-ND3 | 14769 |
| MT-CO2 | 14768 |
| MT-CO1 | 14766 |
| MT-ND1 | 14765 |
| MT-CO3 | 14764 |
| MT-ND4 | 14762 |
| MT-ND4L | 14760 |
| MT-RNR1 | 14757 |
| MT-RNR2 | 14756 |
| MT-ATP6 | 14606 |
| MT-ND5 | 14600 |
| MT-ATP8 | 14192 |
| HSD17B10 | 13513 |
| MRM2 | 12429 |
| MTERF4 | 11344 |
| MRM3 | 8243 |
| MRM1 | 8199 |
| TFB1M | 5669 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-CYB | 14772 |
| MT-ND2 | 14771 |
| MT-ND3 | 14769 |
| MT-CO2 | 14768 |
| MT-CO1 | 14766 |
| MT-ND1 | 14765 |
| MT-CO3 | 14764 |
| MT-ND4 | 14762 |
| MT-ND4L | 14760 |
| MT-RNR1 | 14757 |
| MT-RNR2 | 14756 |
| MT-ATP6 | 14606 |
| MT-ND5 | 14600 |
| MT-ATP8 | 14192 |
| HSD17B10 | 13513 |
| MRM2 | 12429 |
| MTERF4 | 11344 |
| MRM3 | 8243 |
| MRM1 | 8199 |
| TFB1M | 5669 |
| TRMT10C | 4645 |
| ELAC2 | -1278 |
| PRORP | -8469 |
| NSUN4 | -9122 |
Signaling by FLT3 fusion proteins
| 1200 | |
|---|---|
| set | Signaling by FLT3 fusion proteins |
| setSize | 19 |
| pANOVA | 4.21e-07 |
| s.dist | -0.67 |
| p.adjustANOVA | 2.92e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -11157 |
| SPTBN1 | -11088 |
| GRB2 | -10626 |
| TRIP11 | -10478 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| STAT5B | -9035 |
| GOLGB1 | -8910 |
| GAB2 | -8835 |
| KRAS | -8721 |
| ZMYM2 | -6904 |
| PIM1 | -6662 |
| ETV6 | -5676 |
| MYO18A | -4059 |
| NOX4 | -3988 |
| STAT5A | -2885 |
| HRAS | 13906 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -11157 |
| SPTBN1 | -11088 |
| GRB2 | -10626 |
| TRIP11 | -10478 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| STAT5B | -9035 |
| GOLGB1 | -8910 |
| GAB2 | -8835 |
| KRAS | -8721 |
| ZMYM2 | -6904 |
| PIM1 | -6662 |
| ETV6 | -5676 |
| MYO18A | -4059 |
| NOX4 | -3988 |
| STAT5A | -2885 |
| HRAS | 13906 |
Signaling by FGFR3 fusions in cancer
| 1194 | |
|---|---|
| set | Signaling by FGFR3 fusions in cancer |
| setSize | 10 |
| pANOVA | 0.000258 |
| s.dist | -0.667 |
| p.adjustANOVA | 0.000889 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | -10626 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| FRS2 | -9420 |
| KRAS | -8721 |
| GAB1 | -8325 |
| FGFR3 | -7938 |
| HRAS | 13906 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | -10626 |
| SOS1 | -10023 |
| NRAS | -9826 |
| PIK3CA | -9701 |
| PIK3R1 | -9670 |
| FRS2 | -9420 |
| KRAS | -8721 |
| GAB1 | -8325 |
| FGFR3 | -7938 |
| HRAS | 13906 |
Defective B4GALT7 causes EDS, progeroid type
| 267 | |
|---|---|
| set | Defective B4GALT7 causes EDS, progeroid type |
| setSize | 18 |
| pANOVA | 1.16e-06 |
| s.dist | -0.662 |
| p.adjustANOVA | 7.07e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CSPG4 | -11375 |
| VCAN | -11365 |
| GPC6 | -11331 |
| AGRN | -11307 |
| SDC4 | -10735 |
| HSPG2 | -9870 |
| GPC4 | -9044 |
| GPC1 | -8024 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| SDC2 | -5839 |
| B4GALT7 | -5082 |
| BCAN | -4115 |
| GPC2 | -3380 |
| CSPG5 | -3264 |
| GPC5 | -3235 |
| NCAN | -1857 |
| BGN | -1384 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CSPG4 | -11375 |
| VCAN | -11365 |
| GPC6 | -11331 |
| AGRN | -11307 |
| SDC4 | -10735 |
| HSPG2 | -9870 |
| GPC4 | -9044 |
| GPC1 | -8024 |
| SDC1 | -7206 |
| SDC3 | -6862 |
| SDC2 | -5839 |
| B4GALT7 | -5082 |
| BCAN | -4115 |
| GPC2 | -3380 |
| CSPG5 | -3264 |
| GPC5 | -3235 |
| NCAN | -1857 |
| BGN | -1384 |
ALK mutants bind TKIs
| 10 | |
|---|---|
| set | ALK mutants bind TKIs |
| setSize | 12 |
| pANOVA | 7.86e-05 |
| s.dist | -0.658 |
| p.adjustANOVA | 0.000299 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | -11303 |
| EIF2AK3 | -11053 |
| BIRC6 | -10900 |
| PRKAR1A | -10732 |
| STRN | -10181 |
| FN1 | -9930 |
| PPM1B | -8702 |
| HIP1 | -8158 |
| ALK | -6779 |
| EML4 | -5902 |
| BCL11A | -2682 |
| NPM1 | 13339 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CLTC | -11303 |
| EIF2AK3 | -11053 |
| BIRC6 | -10900 |
| PRKAR1A | -10732 |
| STRN | -10181 |
| FN1 | -9930 |
| PPM1B | -8702 |
| HIP1 | -8158 |
| ALK | -6779 |
| EML4 | -5902 |
| BCL11A | -2682 |
| NPM1 | 13339 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.2.4 GGally_2.1.2
## [3] gtools_3.9.2 echarts4r_0.4.3
## [5] beeswarm_0.4.0 vioplot_0.3.7
## [7] sm_2.2-5.7 kableExtra_1.3.4
## [9] topconfects_1.8.0 limma_3.48.3
## [11] eulerr_6.1.1 mitch_1.4.1
## [13] MASS_7.3-56 fgsea_1.18.0
## [15] gplots_3.1.1 DESeq2_1.32.0
## [17] SummarizedExperiment_1.22.0 Biobase_2.52.0
## [19] MatrixGenerics_1.4.3 matrixStats_0.61.0
## [21] GenomicRanges_1.44.0 GenomeInfoDb_1.28.4
## [23] IRanges_2.26.0 S4Vectors_0.30.2
## [25] BiocGenerics_0.38.0 reshape2_1.4.4
## [27] forcats_0.5.1 stringr_1.4.0
## [29] dplyr_1.0.8 purrr_0.3.4
## [31] readr_2.1.2 tidyr_1.2.0
## [33] tibble_3.1.6 ggplot2_3.3.5
## [35] tidyverse_1.3.1 zoo_1.8-9
##
## loaded via a namespace (and not attached):
## [1] readxl_1.3.1 backports_1.4.1 fastmatch_1.1-3
## [4] systemfonts_1.0.4 plyr_1.8.6 polylabelr_0.2.0
## [7] splines_4.2.0 BiocParallel_1.26.2 digest_0.6.29
## [10] htmltools_0.5.2 fansi_1.0.2 magrittr_2.0.2
## [13] memoise_2.0.1 tzdb_0.2.0 Biostrings_2.60.2
## [16] annotate_1.70.0 modelr_0.1.8 svglite_2.1.0
## [19] colorspace_2.0-3 blob_1.2.2 rvest_1.0.2
## [22] haven_2.4.3 xfun_0.30 crayon_1.5.0
## [25] RCurl_1.98-1.6 jsonlite_1.8.0 genefilter_1.74.1
## [28] survival_3.3-1 glue_1.6.2 polyclip_1.10-0
## [31] gtable_0.3.0 zlibbioc_1.38.0 XVector_0.32.0
## [34] webshot_0.5.2 DelayedArray_0.18.0 scales_1.1.1
## [37] DBI_1.1.2 Rcpp_1.0.8.2 viridisLite_0.4.0
## [40] xtable_1.8-4 bit_4.0.4 htmlwidgets_1.5.4
## [43] httr_1.4.2 RColorBrewer_1.1-2 ellipsis_0.3.2
## [46] pkgconfig_2.0.3 reshape_0.8.8 XML_3.99-0.9
## [49] sass_0.4.0 dbplyr_2.1.1 locfit_1.5-9.5
## [52] utf8_1.2.2 tidyselect_1.1.2 rlang_1.0.2
## [55] later_1.3.0 AnnotationDbi_1.54.1 munsell_0.5.0
## [58] cellranger_1.1.0 tools_4.2.0 cachem_1.0.6
## [61] cli_3.2.0 generics_0.1.2 RSQLite_2.2.10
## [64] broom_0.7.12 evaluate_0.15 fastmap_1.1.0
## [67] yaml_2.3.5 knitr_1.37 bit64_4.0.5
## [70] fs_1.5.2 caTools_1.18.2 KEGGREST_1.32.0
## [73] mime_0.12 xml2_1.3.3 compiler_4.2.0
## [76] rstudioapi_0.13 png_0.1-7 reprex_2.0.1
## [79] geneplotter_1.70.0 bslib_0.3.1 stringi_1.7.6
## [82] highr_0.9 desc_1.4.1 lattice_0.20-45
## [85] Matrix_1.4-1 vctrs_0.3.8 pillar_1.7.0
## [88] lifecycle_1.0.1 jquerylib_0.1.4 data.table_1.14.2
## [91] bitops_1.0-7 httpuv_1.6.5 R6_2.5.1
## [94] promises_1.2.0.1 KernSmooth_2.23-20 gridExtra_2.3
## [97] assertthat_0.2.1 rprojroot_2.0.2 withr_2.5.0
## [100] GenomeInfoDbData_1.2.6 hms_1.1.1 grid_4.2.0
## [103] rmarkdown_2.13 shiny_1.7.1 lubridate_1.8.0END of report